Synthesis of small molecule inhibitors targeting signal transduction pathways by Ramamoorthy, Divya
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
2009
Synthesis of small molecule inhibitors targeting
signal transduction pathways
Divya Ramamoorthy
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu.
Scholar Commons Citation
Ramamoorthy, Divya, "Synthesis of small molecule inhibitors targeting signal transduction pathways" (2009). Graduate Theses and
Dissertations.
http://scholarcommons.usf.edu/etd/2160
  
 
Synthesis of Small Molecule Inhibitors Targeting Signal Transduction Pathways 
 
 
 
 
by 
 
 
 
 
Divya Ramamoorthy 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science 
Department of Chemistry 
College of Arts and Sciences 
University of South Florida 
 
 
 
 
Major Professor: Nicholas J Lawrence, Ph.D. 
Wayne C. Guida, Ph.D. 
David Merkler, Ph.D. 
Jerry Wu, Ph.D. 
 
 
 
 
Date of Approval: 
June 10, 2009 
 
 
 
 
Keywords: Bcl-xL, Shp, Ras pathway, EGFR pathway, DiFMUP 
 
© Copyright 2009, Divya Ramamoorthy 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedication 
 
Dedicated to my parents 
  
 
 
 
Acknowledgments 
 
I would like to thank my research advisor, Prof. Nicholas J Lawrence for his 
guidance. For the use of HTS instruments, I would like to thank Dr Harshani Lawrence 
and Yunting Luo. 
For the biological analysis and computational studies, I thank all the members of 
the Drug Discovery Program, Prof. Jerry Wu (Shp-2 phosphatase project), Dr LeiWei 
Chen (Shp-2 phosphatase project), Dr Shen-Shu Sung (modeling for Shp2 phosphatase 
project), and Dr George Sun (Bcl-Xl). 
I would like to thank my committee members, Prof. Wayne C. Guida, Prof. David 
Merkler, Prof. Roman Manetsch and Prof. Jerry Wu for their support and suggestions. 
I would like to thank the crystallographer, Gregory McManus, and Prof. Mike 
Zaworotko’s lab at the University of South Florida, who helped me in obtaining all the 
crystal data. 
I want to thank present and past members of Lawrence lab: Jayan Narayanan, 
Danielle Pernazza, Roberta Pireddu, Jing He, Jon Underwood and Xin Wu for their 
patience, support and help throughout. 
I would like to thank my current advisor, Dr Wayne Guida for his encouragement, 
support and help. I would also like to thank Guida lab members: Daniel Santiago, 
Courtney Duboulay and Sai Lakshman Vankayala for their help and constant support. 
Last but not the least; I want to thank my husband, Arun who has been very 
understanding and supportive. 
 
 i 
 
 
 
Table of Contents 
 
List of Abbreviations ...................................................................................................... iv 
 
List of Tables ....................................................................................................................v 
 
List of Figures ..................................................................................................................vi 
 
Abstract ......................................................................................................................... viii 
 
Chapter 1 Signal Transduction and Cancer .................................................................1 
1.1 Introduction...........................................................................................................1 
1.2 Homeostasis ..........................................................................................................1 
1.3 Apoptosis ..............................................................................................................2 
1.4 Chemotherapy ......................................................................................................3 
1.5 Signal Transduction ..............................................................................................4 
1.6 Protein tyrosine kinase inhibitor: Imatinib ...........................................................6 
1.7 Conclusion ............................................................................................................9 
 
Chapter 2 Design of Bcl-xL inhibitors as therapeutic agents for cancer  
   therapy .......................................................................................................10 
    2.1 Introduction...........................................................................................................10 
    2.2 General characteristics of Bcl family proteins......................................................12 
    2.3 Bcl-xL ...................................................................................................................12 
    2.4 Bcl-xL – Bad Complex ........................................................................................14 
    2.5 Known inhibitors of Bcl-xL .................................................................................15 
    2.6 Conclusion ...........................................................................................................17 
 ii 
Chapter 3 Shp2 Phosphatase as a Target for Cancer Therapy ...................................18 
    3.1 Introduction ..........................................................................................................18 
    3.2 Protein Tyrosine Phosphatases (PTPs) .................................................................19 
    3.3 SHPs .....................................................................................................................20 
  3.3.1 Shp1 PTPase .............................................................................................21 
 3.3.2 Shp2 PTPase .............................................................................................21 
    3.4 Shp2 targets ..........................................................................................................22 
    3.5 Ras/MAPK pathway ............................................................................................23 
    3.6 Epidermal growth factor signaling pathway ........................................................24 
    3.7 Known inhibitors of Shp2 ....................................................................................25 
    3.8 Conclusion ...........................................................................................................27 
 
Chapter 4 Microwaves and Flow reactors in organic synthesis ................................28 
    4.1 Introduction: Microwave-assisted synthesis ........................................................28 
    4.2 Flow reactors: Hydrogenator ...............................................................................31 
    4.3 Conclusion ...........................................................................................................32 
 
Chapter 5 Synthesis and evaluation of small molecules as Bcl-xL  
Inhibitors .................................................................................................33  
    5.1 Introduction ..........................................................................................................33 
    5.2 Biological evaluation of compounds, 12a-z ........................................................39 
    5.3 Conclusion ...........................................................................................................39 
 
Chapter 6 Synthesis and evaluation of small molecules as Shp2  
inhibitors ................................................................................................40 
    6.1 Hit-to-Lead approach based on HTS screening ...................................................40 
 6.1.1 Synthesis of HLM000661 ........................................................................41 
 6.1.2 Synthesis of HLM019544 ........................................................................42 
 6.1.3 Synthesis of HLM002903 .........................................................................48 
 6.1.4 Synthesis of HLM001038 and HLM 001426 ..........................................49 
    6.2 Hit-to-Lead approach based on hits of related phosphatases ...............................51 
 iii 
 6.2.1 HePTP hit evaluated for Shp2 ...................................................................51 
    6.3 Hit-to-Lead approach based on previous hits ......................................................59 
 6.3.1 Synthesis of urea derivatives ....................................................................59 
 6.3.2 Synthesis of Isatin derivatives ..................................................................60 
    6.4 Conclusion ...........................................................................................................63 
 
Chapter 7 Experimental .............................................................................................64 
    7.1 General Methods and Instrumentation .................................................................64 
  7.2 General procedure for the synthesis of 2,2-Diethoxy-N-(2,3,4- 
       substituted benzyl) ethanamines .........................................................................64 
    7.3 General procedure for the synthesis of 4-(4-aryl)-6,7,8 substituted  
 isoquinolines ........................................................................................................67 
    7.4 General procedure for the synthesis of tetrahydro-cyclopentane  
 quinoline-4-carboxylic acids ................................................................................96 
    7.5 General procedure for the synthesis of substituted cyclohexane 
 carboxylic acids .................................................................................................115 
    7.6 General procedure for the synthesis of substituted oxobutanoic acids ..............119 
    7.7 General procedure for the synthesis of urea derivatives ....................................123 
 
References ....................................................................................................................151 
 
Appendices....................................................................................................................161 
 
Appendix 1....................................................................................................................162 
 
 
 
 
 
 
 iv 
 
 
 
List of Abbreviations 
 
DiFMUP 6,8-Difluoro-4-methylumbelliferyl phosphate 
EYA  Eyes absent 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
ERK  Extra-cellular signal-regulated kinase 
FRS  Fibroblast growth factor Receptor Substrate 
IRS  Insulin receptor substrate 
KDa  Kilo dalton 
PDGFR Platelet derived growth factor receptor 
PI3K  Phosphodyl inositol 3-kinase 
PK  Protein kinase 
pNPP  para-nitrophenyl phosphate 
PP  Protein phosphatase 
PTP  Protein tyrosine phosphatase 
Ser  Serine 
SH  Src homology 
Shc  Src homology 2/α-collagen-related 
TK  Tyrosine kinase 
Tyr  Tyrosine 
Thr  Threonine 
 
 
 
 
 
 v 
 
 
 
List of Tables 
 
Table 1 Synthesis of substituted isoquinolinols, 20a-z from 19a-e                      37 
Table 2 Summary of the reaction conditions towards the synthesis of 39a          47 
Table 3 Synthesis of quinolones 39a-h              48 
Table 4 Synthesis of isooxindole derivatives             54 
Table 5 Synthesis of substituted cyclohexane carboxylic acids 63a-h          56 
Table 6 Synthesis of substituted oxobutanoic acids 52a-g            56 
Table 7 Synthesis of urea derivatives 78a-e              60 
Table 8 Synthesis of 82a-x                61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
 
 
List of Figures 
 
Figure 1 Apoptosis by intrinsic and extrinsic pathways             3 
Figure 2 Structures of early chemotherapeutic agents              4 
Figure 3 Structures of Actinomycin and folate antagonists             4 
Figure 4 Representation of signaling cascade at the cell membrane            5 
Figure 5 Structure of Imatinib (Glivec)               7 
Figure 6 Schematic representation of the BCR-Abl kinase pathway            7 
Figure 7 Mechanism of Action of BCR-ABL and of Its Inhibition by  
Imatinib                  8 
Figure 8 Crystal structure of Imatinib with BCR-ABL protein            9 
Figure 9 Bcl-2 family members              11 
Figure 10 Structural features of anti-apoptotic and pro-apoptotic Bcl-2  
proteins                12 
Figure 11 Stucture of Human Bcl-xL in complex with the BH3 binding  
domain of Bak               13 
Figure 12 Crystal structure of Bcl-XL in complex with Bad           15 
Figure 13 Known inhibitors of Bcl-2 family             16 
Figure 14 Structures of ABT-737 and ABT-263            16 
Figure 15 Crystal structure of Bcl-xL in complex with ABT-737          17 
Figure 16 Protein kinases and protein phosphatases            18 
Figure 17 Mechanism of dephosphorylation by PTP            20 
Figure 18 SHP proteins domain structures             20 
Figure 19 Crystal structure of Shp1 SH2 domain complexed with a  
tyrosine-phosphorylated              21 
Figure 20 Crystal structure of the human tyrosine phosphatase Shp2          22 
Figure 21 Schematic representation of basal and active states of Shp2          22 
 vii 
Figure 22 Role of Shp2 in Ras-Raf Pathway             24 
Figure 23 Schematic representation of the EGFR pathway           25 
Figure 24 Known Shp2 inhibitors              25 
Figure 25 PHPS1 and Isatin derivatives and their activity against Shp2         26 
Figure 26 A Active site of Shp2 showing the catalytic cleft           26 
B Ligand interaction of PHPS1 in Shp2 active site            26 
Figure 27 Structure of Isatin (6) and (7) docked to Shp2           27 
Figure 28 dipole moments align parallel in an electric field           29 
Figure 29 Biginelli reaction               30 
Figure 30 Biotage microwave reactor and H-cube hydrogenator          31 
Figure 31 Structures of HL2-100 and HL2-100-2            33 
Figure 32 Pomeranz-Fritsch reaction              34 
Figure 33 Mechanism of Pomeranz-Fritsch reaction            35 
Figure 34 Modifications to Pomeranz-Fritsch reaction            35 
Figure 35 Synthesis of substituted isoquinolinols, 20a-z             36 
Figure 36 Mechanism of synthesis of isoquinolinols            38 
Figure 37 FP assay                39 
Figure 38 Shp2 hits derived from a high throughput screen at the  
Moffitt Cancer Center               40 
Figure 39 X-ray crystal structure of 41              44 
Figure 40 X-ray Crystal structure of 44              49 
Figure 41 X-ray Crystal Structure of 46a             50 
Figure 42 pNPP Assay: Dephosphorylation by Shp2            51 
Figure 43 DiFMUP Assay: Dephosphorylation by Shp2           51 
Figure 44 Docking structure of 52a with the Shp2 PTPase domain          53 
Figure 45 Interactions of 52a amino acid residues of the Shp2 protein,  
in the docking structure              53 
Figure 46 Isatin hits for Shp2               59 
 
 
 
 viii 
 
 
 
Synthesis of Small Molecule Inhibitors Targeting Signal Transduction Pathways 
 
Divya Ramamoorthy 
ABSTRACT 
 
 The main aim of the study described in this thesis is the development of small 
molecules as inhibitors targeting signal transduction pathways, thereby treating cancer. 
We attempted to synthesize compounds based on the hits obtained from high throughput 
screening of the Chemdiv diversity set compounds.  
 Chapter One is a general introduction to cancer, history of chemotherapeutic 
drugs and an introduction to signal transduction pathways. The following two chapters 
briefly introduce the biological targets in the authors study.  
Chapter Two describes the role of B-cell lymphoma type xL (Bcl-xL), in 
apoptosis and the development of drugs targeting Bcl-xL. Examples of Bcl-xL drugs 
relevant to this study have been provided. Chapter Three introduces Src homology 2 
(SH2) domain containing tyrosine phosphatase Shp2, a protein tyrosine phosphatase, as 
an oncogene, its role in signal transduction pathways and the recent developments in drug 
development towards the inhibition of this oncogene. Chapter Four gives a general 
introduction to microwave-assisted organic synthesis and its advantages. This chapter 
also describes the use of flow reactors in organic synthesis and its advantages. 
The following two chapters describe the author’s own findings. 
Chapter Five focuses on the design, synthesis and 
biological evaluation of small molecules as inhibitors of Bcl-xL. 
Isoquinolinols, NSC-131734 and HL2-100 emerged as lead 
compounds from high throughput screening for Bcl-xL. Our 
strategy focused on identifying an isoquinolinol lead with 
increased potency. We focused on improving the synthetic 
N
O
OH
NSC-131734,
R =
HL2-100,
R =
R
 ix 
procedure using microwave-assisted heating, thereby reducing the reaction time and 
facilitating a combinatorial approach for the synthesis of these isoquinolinols. 
Isoquinolinols with different aryl groups (R) were synthesized to study the structure 
activity relationship. A series of isoquinolinols were synthesized by varying the position 
of the hydroxyl- and methoxy- groups in the isoquinoline core.  
Chapter Six focuses on the development of Shp2 inhibitors. 
Based on the hits obtained from HTS screening, compounds 
were re-synthesized and were evaluated for biological activity 
for Shp2. A series of compounds were synthesized, containing the isooxindole scaffold, 
based on the hematopoetic protein tyrosine phosphatase (HePTP) hits reported earlier in 
literature. Modifications were performed on the 
isooxindole core to study the SAR.   
Based on isatin hits obtained earlier through HTS 
screen and SAR studies in our lab, more isatin 
derivatives were synthesized focusing on developing 
inhibitors with increased cell permeability and 
improved potency.  
N
H
Cl
S
O O
N
H
N
O
RPM744, IC50 : 0.98 µM
N
H
O
OH
N
CO2H O
HePTP hit, IC50 = 1.17 µM
O
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Chapter 1 
 
1.0 Signal transduction and cancer 
 
1.1 Introduction 
 Cancer is characterized by uncontrolled cell growth, invasion, and metastasis 
(spread to other locations in the body).1  
Cancer cells, derived from the normal cells in the body, undergo alterations, 
which distinguish them from the normal cells. The alterations in the cells allow them to 
proliferate. Cancer can be caused by genetic abnormalities in the genetic material of the 
transformed cells. The abnormalities may be caused by carcinogens, errors in DNA 
replication or by inheritance. Genetic abnormalities affect oncogenes (genes that 
contribute to cancer in a gain-of-function manner) and, tumor suppressor genes (genes 
inactivated in cancer cells), resulting in the loss of normal functions in those cells.1 
Apoptosis or programmed cell death plays a very important role to maintain the balance 
of cell growth and cell death, essential for homeostasis.  
1.2 Homeostasis 
 Homeostasis is a property that refers to the regulation of the internal environment 
to maintain a stable, constant condition in any living organism. It is a property of either 
the open-system (system interacting with the environment) or the closed-system (system 
isolated from the environment) and is maintained by a balance of cell-proliferation and 
cell-death in multicellular organisms.2  
 Homeostasis is achieved when the rate of cell division by mitosis is balanced by 
cell death. If the balance is disrupted, it might result in the formation of a tumor, by cells 
dividing much faster than they die, or a disorder of cell loss, by cells dividing much 
slower than they die. Thus it is a very important process in living organisms to maintain 
their internal states within certain limits. Many types of cell signaling are involved in 
homeostasis making it essential to be a tightly controlled process: any impairment in this 
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process might lead to a diseased state.2 
1.3 Apoptosis 
 A balance of cell division and cell death is essential to maintain homeostasis in 
multicellular organisms. Apoptosis is a form of programmed cell death of unwanted or 
damaged cells, which is essential for the development and the maintenance of all multi-
cellular organisms. It is critical for the removal of superfluous cells during diverse 
physiological processes in all organisms.3 As a highly ordered process, apoptosis allows 
cells to degrade themselves as a way of eliminating unwanted or dysfunctional cells from 
the body. Cells die in response to a variety of stimuli and during apoptosis they do so in a 
controlled, regulated fashion.4 Apoptosis is critical for normal development and 
thermostatics (response to temperature changes) and serves as a defense mechanism 
against cellular abnormalities. It is tightly regulated at the transcriptional and post-
transcriptional levels. Any dysregulation in the process, either activation or inhibition, is 
usually associated with degenerative disorders and cancer.5 Thus apoptotic pathways are 
of immense interest in drug discovery and development.  
 Apoptosis can be triggered by internal events or an intrinsic pathway in which the 
disruption of the mitochondria and cytochrome C lead to the downstream activation of 
caspases (Fig. a). Alternatively, extrinsic pathways also lead to apoptosis: specific ligands 
bind to the death surface receptors, such as the receptors of the tumor necrosis factor 
(TNF)/ nerve growth factor (NGF) super family (Fig. 1). The immune cells mediate the 
extrinsic pathway to initiate intracellular signaling and downstream activation of 
caspases.6-9 
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Fig. 1: Apoptosis by intrinsic and extrinsic pathways 
1.4 Chemotherapy 
 Detection of cancer at an early stage is critical, as prevention of metastasis is a 
major cancer-fighting tool. Cancer can be diagnosed by performing a biopsy on the tissue 
sample retrieved from a tumor near the body surface. Staging refers to the extent or 
spread of disease at the time of diagnosis. It is based on the primary tumor's size and 
location and is essential to determine the choice of therapy to treat cancer.  
  Statistics from American Cancer Society reveal that, in 2004, cancer prevalence 
in the US was about 10.3 million.10 In 2007 alone, about 7.6 million people died of 
cancer. Cancer can be treated by surgery, chemotherapy, and radiotherapy or by using 
targeted therapies for specific types of cancer (source: www.cancer.org).  
In the early 20th century, Paul Ehrlich, who had coined the term ‘chemotherapy’ 
also developed some aniline drugs to treat cancer. Later, in 1939, Charles Huggins stated 
that estrogens could be used to treat breast cancer.11  
During World War II, the accidental spillage of sulfur mustards on troops, showed 
a remarkable depletion in the bone marrow and lymph nodes in men exposed to the gas.12, 
13
 In 1946, researches at Yale University published the use of nitrogen mustard (Fig. 2) to 
treat lymphomas; unfortunately the remissions were brief and incomplete.14 
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Fig. 2: Structures of early chemotherapeutic agents 
 Farber and coworkers found that folic acid accelerated leukemia cell growth. 
Based on the above observation, folate antagonists were developed; these include 
aminopterin and amethopterin15 (methotrexate) (Fig. 3). These drugs exhibited 
unquestionable remissions. In 1951, 6-thioquanine and 6-mercaptopurine were developed 
for the treatment of acute leukemia.16, 17 Fluoropyrimidine 5-fluorouracil (5-FU), was 
developed by Charles Heidelberger and co-workers to treat non-hematologic cancers. 
This drug was found to have broad-spectrum activity against a range of solid tumors and 
is currently used in the treatment of colorectal cancer. The drug 5-FU targets thymidylate 
synthase (TS), which is an important chemotherapeutic target since the inhibition of TS 
has a positive effect on patients with colorectal and breast cancers. It has been used in 
combination therapy along with other folates to treat cancer.18  
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Fig 3: Structures of Actinomycin and folate antagonists 
 Targeted cancer therapy focuses on treating cancer by attacking only the cancer 
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cells without damaging the normal cells, thus leading to fewer side effects. Targeted 
therapy varies with the type of cancer. They all interfere with the cell proliferation of the 
cancer cells. Usually targeted therapy involves use of small molecules that enter the cell 
and disrupt their function leading to cell death. Targeted therapy involves molecules 
acting on the signaling transduction pathways, disrupting the signaling cascade. 
1.5 Signal Transduction 
Signal transduction refers to the process by which a cell converts one kind of 
signal to another involving a series of biochemical transformations that are caused by 
either enzymes19
 
or protein-protein interactions. Modular protein-protein interaction 
domains, controlled by the phosphorylation status, convey signals from activated 
receptors using a variety of recognition motifs. In many signal transduction processes, the 
number of proteins and other molecules participating in these events increases as the 
process emanates from the initial stimulus, resulting in “signal cascade” (Fig. 4). Defects 
in signal transduction pathways often lead to uncontrolled cell growth and 
tumorigenesis20 indicating the importance of signal transduction in medicine.  
Receptor Receptor
Membrane
Gene 
expression
Growth
Survival
Differentiation
Metabolism
PP
S S
p
P
PK
Input signals
Signal-
Integrating 
complex
Output
USK
PTP PTP
PP
 
Fig. 4: (Reproduced from lit21) Representation of signaling cascade at the cell membrane; signals 
received at the cell membrane stimulate the activation that incorporates both a protein kinase and 
a protein phosphatase. 
The agent that signals a cell to respond is a molecule that binds to a cell surface 
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receptor or to a cytoplasmic receptor. These signals can activate protein kinases and 
phosphatases in the cell. The activation or inactivation of the protein kinase or 
phosphatase, the affinity of the protein target for these enzymes, the concentration and 
access of the kinase, phosphatase and target protein affect the phosphorylation or 
dephosphorylation state of the protein. Phosphorylation or dephosphorylation produces 
specific changes in the function of a target protein and these changes may increase or 
decrease its activity. It can also modify the interactions between the phosphoprotein and 
other proteins, DNA, phospholipids, or other cellular constituents, which can thereby 
alter the function of the phosphoprotein in a signaling pathway, ultimately leading to 
changes in gene expression.22  
Signaling pathways are vital for cell growth and when some of these become 
aberrant, it leads to an increase in proliferative potential, sustained angiogenesis, tissue 
invasion and metastasis, and apoptosis inhibition.23 The proteins involved in the signaling 
pathways may provide druggable targets for cancer therapy since inhibition of any one of 
these proteins stops the signaling cascade.       
 Signal transduction is a cascade process involving a sequence of steps. The 
receptors in the cell membrane transfer information from the cell exterior to the interior. 
The receptor (primary messengers) has both extracellular and intracellular domains: a 
binding site in the extracellular domain recognizes the chemical signal, forming a 
receptor-ligand complex, and then passes the signal to the interior of the cell. Secondary 
messengers, which include cyclic AMP, cyclic GMP, calcium ion, inositol 1,4,5-
triphosphate and diacylglycerol, relay information from the receptor-ligand complex to 
other components of the cell, where gene expression and other processes could be altered. 
The secondary messengers elicit responses by activating protein kinases. After the 
signaling process is initiated and information transduced to other components of the cell, 
it has to be terminated otherwise cells would lose their responsiveness to new signals or 
might lead to uncontrolled cell growth. Protein phosphatases usually terminate the signal 
transduction processes.24  
1.6 Protein tyrosine kinase inhibitor: Imatinib 
Among the enzymes and the proteins involved in signal transduction, kinases 
remain the most established target for cancer therapy. Imatinib (Glivec)25 (Fig. 5), 
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formerly referred as ST1571, is protein tyrosine kinase inhibitor, which targets platelet 
derived growth factor receptor (PDGFR). This is the first example of target-based drug 
design. The Philadelphia chromosome (Ph) of chronic myelogenous leukemia (CML) and 
c-kit (CD117) combine to form a product, which is over-expressed in gastro-intestinal 
stromal tumors, which is targeted by Imatinib.26 
N
N
N
H
N
HN
O
N
N
 
Fig. 5: Structure of Imatinib (Glivec) 
Protein kinases activate the signal transduction pathways by phosphorylating 
proteins (Fig. 6). Several protein kinases are deregulated and over-expressed in human 
cancers, thus posing as attractive targets for developing selective pharmacologic 
inhibitors. BCR-Abl kinase of CML is an extensively studied kinase and Imatinib 
disrupts BCR-Abl mediated transfer of phosphate to its substrates.27-31 
BCR-abl gene
Chromosome 9-22
translocation
Stat5Stat1
JAK2 CRKLGRB2
SOS1
BCR/ABL BCR/ABL
Nucleus
BCR-abl fusion protein
T3151
 
Fig. 6: (Reproduced from biocarta pathways) Schematic representation of the BCR-Abl kinase 
pathway 
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When ATP is bound to BCR-ABL in the kinase-binding site, the substrate is 
activated by the phosphorylation of one of its tyrosine residues and can activate other 
downstream effector molecules. Imatinib bound to the kinase pocket inhibits the action of 
BCR-ABL, by preventing the phosphorylation on the substrate (Fig. 7).  
BCR-ABL
ATP
Substrate
Phosphate Tyrosine
Substrate
Ef
fe
ct
or
ATP
Phosphate
Tyrosine
Chronic Myelogenous Leukemia
BCR-ABL
Substrate
Tyrosine
Substrate
E
ff
ec
to
r
Tyrosine
Chronic Myelogenous Leukemia
Imatinib
X
A B
 
Fig. 7: (Reproduced from lit32) Mechanism of Action of BCR-ABL and of Its Inhibition by 
Imatinib 
A: Activated BCR-ABL oncoprotein with ATP in the kinase pocket; B: Inhibited BCR-ABL 
oncoprotein with Imatinib in the kinase pocket. 
Although the precise oncogenic mechanism of BCR-ABL is unknown,30, 33-35 its 
tyrosine kinase activity leads to the chronic phase of CML.35 BCR-Abl protein kinase C 
and EGFR were among the first protein kinases to be targeted for selective inhibition 
because of their unregulated activity in various human cancers.29 Tyrphostins were 
reported to be specific for epidermal growth factor receptor (EGFR) in 1988. 2-
Phenylaminopyridine compounds were discovered by chemists at Ciba-Geigy to be 
specific for tyrosine kinases. Based on SAR studies, imatinib was developed as an 
inhibitor of PGDF receptor while EGFR, FLT1 and FLT3 remained unaffected.36, 37 
Druker et al reported that Imatinib inhibited proliferating myeloid cell lines containing 
BCR-ABL, but minimally harming normal cells.38 The crystal structure of Imatinib bound 
to the BCR-ABL kinase is shown in Fig. 8.39 
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Fig. 8: Crystal structure of Imatinib with BCR-ABL protein (PDB ID: 2HYY) 
1.7 Conclusion 
 Cancer is recognized to be a major killer, next to heart disease. Development of 
new drugs to treat cancer is very important, given the fact that the drugs currently used in 
treatment of cancer have numerous side effects. The discovery of anti-cancer drugs is a 
challenging endeavor; in spite of the biochemical mechanisms of many signaling 
pathways being extensively studied. Although immensely challenging, it is not 
impossible to develop drug candidates that target specific molecular targets or signaling 
pathways. Some progress to this end is the subject of this dissertation. 
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Chapter 2
 
 
2.0 Design of Bcl-xL inhibitors as therapeutic agents for cancer therapy 
 
2.1 Introduction 
A balance of cell division and cell death is essential to maintain homeostasis in 
multicellular organisms. Apoptosis is a form of programmed cell death of unwanted or 
damaged cells, which is essential for development and the maintenance of all multi-
cellular organisms. The Bcl-2 (Basal cell lymphoma) family of proteins plays a very 
important role in apoptosis. 
 Numerous proteins are involved in the control of apoptosis. The Bcl-2 family of 
proteins (Fig. 9) are thought to be the key regulators functioning at or near the cell death 
pathway.40 A key component in the process of apoptosis is the activation of the caspase 
family in a cascade, which is in turn responsible for the apoptotic-specific changes, and 
dissembly of the cell.  Bcl-2 proteins, present in the outer mitochondrial membrane, play 
a major role in inhibiting apoptosis by playing a critical role in caspase activation. 
Deactivation of Bcl-2 proteins initiates apoptosis through a well-controlled chain of 
enzymatic reactions.41  
 11 
Bcl superfamily
Proapoptotic Antiapoptotic
BH3-only proteins Multidomain (BH)
Bcl-2
Bcl-xL
Bcl-W
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BAK
BAX
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Fig. 9: (Reproduced from researchapoptosis.com) Bcl-2 family members 
   The Bcl-2 family includes the anti-apoptotic proteins (proteins that inhibit 
apoposis), Bcl-xL, Bcl-2, which are the death antagonists, and the proapoptotic proteins 
(proteins that promote apoptosis), Bak, Bax, Bad,42 which are the death agonists. In 
normal cells, the anti-apoptotic proteins bind to the pro-apoptotic proteins and hence 
block apoptosis, whereas in damaged cells this balance is disrupted, triggering apoptosis. 
The mechanism by which the Bcl-2 proteins regulate apoptosis is not quite clear; 
however these protein-protein interactions are critical for the apoptosis to occur.43 
The ratio of the heterodimerization of the death antagonist Bcl-xL to the agonists 
Bax, Bak, Bad determines whether a cell will respond to an apoptotic signal;40 however, 
the importance of hetero-dimerization is not fully understood. The ability of Bcl-xL to 
regulate cell survival may involve other dimerization partners. Non Bcl-2 family 
members like Raf-1, calcineurin, CED-4, Apaf-1 and other caspases are also shown to 
interact with the anti-apoptotic Bcl-2 family members.44, 45 The contribution of these 
interactions to the regulation of apoptosis is difficult to address due to the extensive 
network of protein-protein interactions between the Bcl-2 and non Bcl-2 family members. 
Cancer cells restrain apoptosis by overproducing anti-apoptotic proteins such as Bcl-2 
and Bcl-xL.46 Over-expression of Bcl-2 or Bcl-xL (or both) has been found in a majority 
of human cancers. 
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2.2 General characteristics of Bcl family proteins     
 Bcl-2 codes for a 25-kDa protein having a hydrophobic C-terminus located in the 
outer mitochondrial membrane, the endoplasmic reticulum and the nuclear membrane, 
and an N-terminus facing the cytosol. Bcl-2 family members possess conserved motifs 
known as Bcl-2 homology motifs (BH1 to BH4) (Fig. 10). They contain at least one of 
the four conserved BH domains.5 The anti-apoptotic members, like Bcl-xL and Bcl-2 
show sequence conservation in all four domains while the pro-apoptotic members, Bax, 
Bak, and Bok do not show conservation in the first helical sequence, BH4, but only 
contain BH1, BH2 and BH3, resembling the Bcl-2 family closely. Almost all BH3-
domain-only members are pro-apoptotic. The Bcl-2 family members form homo- or 
hetero-dimers with their anti-apoptotic counterparts. The Bcl-x member generates two 
proteins through alternate splicing mechanism – Bcl-xL and Bcl-xS.   
 Bcl-2 over-expressed cells seem to be deprived of their ATP by glycolysis, which 
is a reversible process. Bcl-xL blocks cell death by preventing the release of cytochrome 
C from mitochondria. Bcl-2 acts as a checkpoint upstream of caspases and mitochondrial 
dysfunction.
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Fig. 10: (Reproduced from lit47) Structural features of anti-apoptotic and pro-apoptotic Bcl-2 
proteins 
2.3 Bcl-xL 
Bcl-xL (Fig. 11) is a transmembrane molecule in mitochondria that plays a very 
critical role in cancer development by inhibiting apoptosis. It is a 241 amino acid protein, 
which shares 43% sequence similarity with Bcl-2; it appears to function in the same 
apoptotic pathway.48 Bcl-xL has two central hydrophobic α-helices surrounded by 
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amphipathic helices. A flexible 60-residue loop, not essential for the anti-apoptotic 
activity, connects α1 and α2. The Bcl-2 homology domains, BH1, BH2 and BH3 are 
close to each other to form an elongated hydrophobic cleft. This hydrophobic cleft 
represents the binding site for Bcl-2 family proteins.  The X-ray crystal structure of 
human Bcl-xL (PDB ID: 1r2d),49 a close analog of Bcl2, provided the structural basis for 
the design and development of small molecules that bind to Bcl-2.40 The X-ray crystal 
structure of human Bcl-xL reveals a hydrophobic pocket essential for the anti-apoptotic 
activity, formed by the conserved BH1, BH2 and BH3 domains; mutations in this pocket 
might abolish their biological function.50, 51 
 
Fig. 11: Stucture of Human Bcl-xL in complex with the BH3 binding domain of Bak (shown in 
blue) (in the α-helix binding pocket) (PDB ID: 1bxl) 
Bcl-xL is an important contributor to the progression of vascular diseases, being a 
critical determinant of intimal lesion formation.52 Expression of Bcl-xL has been found in 
a range of normal tissues, especially in the central nervous system and thymus.  
 In the Bcl-2 family proteins, such as Bcl-xL, Bax, BID and Bcl-2, proteolytic 
cleavage follows a cell-death stimulus which enhances the pro-apoptotic activity in these 
molecules. In Bcl-xL, a C-terminal fragment exhibiting Bax-like properties is produced 
after the endogeneous cleavage by caspases or caplins.53-55 The N- Bcl-xL protein which 
results from the cleavage, lacks the BH4 domain which confers protection against 
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apoptosis.54, 56 Conformational rearrangements at the N terminus might contribute to its 
pro-apoptotic activity, especially in the brain, where Bcl-xL is highly expressed.57 A 
conductance ion channel is produced by N- Bcl-xL which may induce cell death by 
increasing the conductance of this membrane and releasing cytochrome c from 
mitochondria following a cell-death stimulus.54, 56 
 Bcl-xL proteolytic cleavage causes a change of function from anti- to pro-
apoptotic. Both the pro- and anti-apoptotic forms contribute to cell death and some 
nervous system activities. Therefore long term inhibition of Bcl-xL could result in the 
disruption of neuron response to cell death and synaptic function impairment in the 
absence of a death stimulus.56, 58 
 Bcl-xL is over-expressed in most human cancer types, thus it is a very attractive 
target for the development of anticancer agents.11 High expression of Bcl-2 or Bcl-xL in 
human cancer contributes to neoplastic cell expansion and interferes with the therapeutic 
effect of the chemotherapeutic agents used in cancer treatment, by blocking apoptosis. 
Inhibiting the function of Bcl-xL could restore apoptosis or sensitize the tumors for 
therapeutic agents. Interaction between the pro-apoptotic and anti-apoptotic proteins 
involves the hydrophobic groove, essential for the anti-apoptotic activity, on the surface 
of the anti-apoptotic members and the BH3 dimerization domain of the pro-apoptotic 
counterparts.59 Therefore, the BH3 domains of the pro-apoptotic Bcl2 family members, 
provide natural templates for the development of small molecule BH3 mimics that can 
serve as surrogates for designing inhibitors of anti-apoptotic Bcl-2 family proteins.43 
2.4 Bcl-xL - Bad Complex 
 The three dimensional structure of human Bcl-xL in complex with the pro-apoptic 
partner Bad has been determined and published (PDB ID: 2bzw) (Fig. 12). This provides 
a structural basis for the design of Bcl-xL inhibitors. The Bcl-2 family of proteins 
contains conserved Bcl-2 homology regions which mediate the formation of homo- or 
heterodimers, critical for enhancing or suppressing apoptosis. Bad (Bcl-xL/Bcl-2 
associated death promoter) is a new member of the BH3-only family, a subfamily of the 
Bcl-2 family of proteins.3 However, Bad shares the conserved Bcl-2 homology BH1 and 
BH2 domains with other Bcl-2 family members. It counters the anti-apoptotic effects of 
Bcl-xL in an interleukin 3-dependent cell line. Bad has no C-terminal trans membrane 
 15 
domain for targeting to the outer mitochondrial membrane and nuclear envelope. Hsu et. 
al. reported that Bad might regulate apoptosis in a different manner from the Bcl-2 family 
members and interact with cellular proteins outside the Bcl-2 family.3 The pro-apoptotic 
protein Bad is known to promote apoptosis by dimerization with Bcl-xL and displace the 
apoptosis promoter Bax.3  
 
Fig. 12: Crystal structure of Bcl-XL in complex with Bad (shown in yellow) (PDB ID: 2bzw) 
2.5 Known inhibitors of Bcl-xL 
 Chelerythrine (Fig. 13) was found to be a Bcl-xL inhibitor by high throughput 
screening based on Fluorescence Polarization. Chelerythrine was found to disrupt the 
interaction between Bcl-xL and Bax with an IC50 of 1.5 µM.60 Abbott laboratories 
recently published their discovery of a novel inhibitor of Bcl-xL/Bcl-2, ABT 73761 (IC50 
of 35+1 nM). HA14-1 was identified to inhibit BAK BH3/Bcl-2 interaction with an IC50 
of 9 µM.62 Gossypol and Theaflavanin were found to inhibit Bad BH3/Bcl-xL
 
interactions 
with an IC50 of 0.5 µM63, 64 and 120-1230 nM respectively.65 
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Fig. 13: Known inhibitors of Bcl-2 family 
 ABT-73766 (Fig. 14) is a Bcl-xL inhibitor currently in clinical trials. It exhibits an 
IC50 of 35 nM. However, the lack of oral bioavailability of ABT-737 represents an 
obstacle for chronic agent therapy and limits the flexibility to dose in combination 
regimens.67 Fig. 15 shows the docking x-ray crystal structure of ABT-737 with the 
protein, Bcl-xL (PDB ID: 2yxj).68 
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Fig. 14: Structures of ABT-737 and ABT-263 
ABT-26369 (Fig. 14) is another drug launched by Abbott laboraties, which is in 
clinical trials and is a potent, and orally bioavailable Bad-like BH3 mimetic (Ki's of <1 
nmol/L for Bcl-2, Bcl-xL, and Bcl-w). The oral bioavailability of ABT-263 in preclinical 
animal models is 20% to 50%, depending on formulation. ABT-263 disrupts Bcl-2/Bcl-
xL interactions with pro-death proteins leading to the initiation of apoptosis within two 
hours post-treatment. ABT-263 exhibits modest or no single agent activity and yet it 
significantly enhances the efficacy of clinically relevant therapeutic regimens.70 
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Fig. 15: Crystal structure of Bcl-xL in complex with ABT-737 (PDB ID: 2yxj) 
2.6 Conclusion 
 Bcl-xL, being an anti-apoptotic protein, plays a very important role in cancer. 
Since the over-expression of Bcl-xL in cancer cells, render resistance to 
chemotherapeutic agents or radiation therapy, there is an urgent need for molecules that 
specifically target the anti-apoptotic activity of Bcl-xL. Small molecule BH3 surrogates 
can serve as the starting point to develop new molecules that could validate the use of 
Bcl-xL in cancer therapy. Compounds developed by Abbott laboratories currently in 
clinical trials could provide an in-depth knowledge of the biological function of Bcl-xL 
and help in developing new molecules as inhibitors for targeted therapy.  
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Chapter 3 
 
3.0 Shp2 Phosphatase as a Target for Cancer Therapy 
 
3.1 Introduction  
Signal transduction refers to the process by which a cell converts one kind of 
signal to another involving a series of biochemical transformations that are caused by 
either enzymes19
 
or protein-protein interactions. In the signaling pathways, the secondary 
messengers elicit responses by activating protein kinases. Protein phosphatases are the 
terminators of the signal transduction process. 
Kinases and phosphatases regulate all aspects of cellular function. Kinases are 
enzymes that phosphorylate molecules within the cell using ATP.71 Phosphatases are 
enzymes, which dephosphorylate through hydrolysis (Fig. 16). If the phosphorylated 
proteins are not dephosphorylated by phosphatases, then the protein would be in a 
constant state of being activated or inhibited.  
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Fig. 16: Protein kinases and protein phosphatases 
About 518 protein kinases are known in humans.71 Tyrosine phosphorylation is 
catalyzed by protein tyrosine kinases, which are represented by 90 genes in the human 
genome.72 Some of these proteins have a common 100 amino acid domain, called SH, 
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(Src homology) and are phosphorylated by the receptor tyrosine kinase.  The intracellular 
receptor kinase, Src, is activated when it binds through it’s SH domain(s) to the 
autophosphorylated receptor Tyr kinase.  
There are two main kinds of protein phosphatases: phospho-tyrosine phosphatases 
and phospho-serine/threonine phosphatases. Most of the active phosphatases consist of a 
phosphatase catalytic subunit and a regulatory subunit. Regulatory subunits for tyrosine 
phosphatases may contain SH2 domain allowing binding of the binary complex to 
autophosphorylated membrane receptor tyrosine kinases. 
3.2 Protein Tyrosine Phosphatases (PTPases) 
 The 107 PTPs can further be divided into Class-I cysteine-based PTPs, which are 
99 in number and contain the 38-well known tyrosine-specific PTPs.73 These cysteine-
based PTPs can be further subdivided into trans-membrane receptor-like enzymes 
(RPTPs) and intracellular non-receptor PTPs (NRPTPs). Class-II cysteine-based PTPs 
family is represented by a single gene, ACP1 which encodes the low Mr phosphatase 
(LMPTP). Class-III cysteine-based PTPs comprise the three cell cycle regulators, 
CDC25A, CDC25B, CDC25C, in humans. The CDCs dephosphorylate the Cdks at their 
dually phosphorylated N-terminal Thr-Tyr motifs, which is critical for the activation of 
these kinases to drive cell cycle.74 The fourth class of PTP is the Asp-based PTPs, which 
has only 4 EYA genes that have recently shown Tyr/Ser phosphatase activity.75, 76 
 Protein tyrosine phosphatases dephosphorylate many cell surface receptors such 
as EGF and PDGF that have been phosphorylated on tyrosine residues.77 They are 
increasingly viewed as integral components of signal transduction cascades and have 
been implicated in regulation of many cellular processes, including cell growth, cellular 
differentiation, mitotic cycles and oncogenic transformation. Phospho tyrosine kinases 
(PTKs) and PTPs work together to regulate protein function in response to a variety of 
signals, including hormones, mitogens and oncogenes. PTPs utilize a common 
mechanism for catalysis going through a covalent thiophosphate intermediate (Fig. 17) 
that involves the nucleophilic Cys residue in the PTPase signature motif 
(HCXXGXXRS/T).78 
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Fig. 17: Mechanism of dephosphorylation by PTP 
Most of the PTP family members contain at least one domain outside the PTP catalaytic 
domain.  
 Although molecular and cellular biology studies have suggested that PTPs are 
potential therapeutic targets for diabetes, cancer, and immunologic diseases, PTP 
inhibitor design is a new area in the field of drug development.  For the majority of PTPs, 
chemical genetic studies are not yet possible because of the lack of specific inhibitors.   
3.3 SHPs 
 The SHP family consists of Shp1, Shp2 and Csw (from Drosophila) that form the 
subfamily of the intracellular PTPs.79 They contain two SH2 domains, a PTP catalytic 
domain and an inhibitory C terminus (Fig. 18). These enzymes remain inactive within 
resting cells which is attributed to the insertion of the D’-E loop of the N-terminal SH2 
somain into the susbtrate binding pocket. They translocate to the plasma membrane from 
the cytoplasm after the cell stimulation and become activated by binding to the tyrosine-
phosphorylated receptors through their SH2 domains.79 
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Fig. 18: (Reproduced from lit80) SHP proteins domain structures 
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3.3.1 Shp1 PTPase 
 Shp1 (Fig. 19) is a cytostolic PTP, 65 KDa protein, and is highly expressed in 
hematopoietic cells that is found to cause profound abnormalities in the immune system. 
It functions as a negative regulator in eukaryotic cellular signaling pathways81 and 
terminates the signal transduction pathway by dephosphorylation of appropriate 
substrates. 
 The catalytic site of Shp1 has a core region and the extended N and C termini. 
Shp1 shows 38% sequence identity with PTP1B and 60% with Shp2. Shp1 and Shp2 
share extremely high similarity in both the secondary and tertiary structures, the major 
difference in the catalytic site being that the N- and C-termini in Shp1 are extended away 
from the molecule. Shp1 and Shp2 have different substrate specificities explained by the 
electrostatic potentials being more positive in Shp2 than in Shp1.81 
 
Fig. 19: Crystal structure of Shp1 SH2 domain complexed with a tyrosine-phosphorylated (PDB 
ID: 2yu7)81 
3.3.2 Shp2 PTPase 
Shp2 is a ubiquitously expressed, non-receptor Src homology protein containing 
tyrosine phosphatase (PTPase), also known as PTP1D, PTP2C, SHPTP2 or Syp. It is 
ubiquitously expressed in mammalian tissues82 and is essential for embryonic 
development. It is a signal-enhancing component of growth factor, cytokine, and extra-
cellular matrix receptor signaling, and plays an important role in regulating cell 
proliferation, differentiation and migration.  
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Fig. 20: Crystal structure of the human tyrosine phosphatase Shp2 (PTPN11) showing N-SH2 
(Yellow), C-SH2 (Green) and PTP catalytic domains (Blue) (PDB ID: 3b7o)83 
Shp2 is a 68-kDa protein82 (Fig. 20) and is composed of a single phosphotyrosine 
phosphatase (PTP) domain and two Src homology 2 (SH2) domains at its NH2 terminus 
(N-SH2 and C-SH2, respectively, where N-SH2 is closest to the N-terminus). The C-
terminal region of Shp2 contains sites of tyrosine phosphorylation and a proline-rich 
region (Fig. 20).84 In the basal state, the PTP domain is inhibited by intramolecular 
interaction with N-SH2. Phosphotyrosyl peptide binding to the N-SH2 domain induces a 
conformational change that reverses this inhibition and activates Shp2 (Fig. 21).85, 86 
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Fig. 21: (Reproduced frim lit87) Schematic representation of basal and active states of Shp2 
Mutations in PTPN11, the human Shp2 gene, have known to cause Leopard syndrome, 
Noonan syndrome,88 juvenile myelomonocytic leukemia89 and other malignancies. Most 
PTPN11 mutations affect N-SH2 or PTP domain residues involved in the basal inhibition 
of Shp2.90 Gain-of-function mutations in Shp291 may lead to an increased activation of 
the Ras/MAPK pathway and increased cell proliferation.  
3.4 Shp2 targets  
There has been a great deal of efforts to identify Shp2 substrates. It has been 
found that Shp2 dephosphorylates Gab1 and partially dephosphorylates EGFR indicating 
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that Gab1 and EGFR can be the substrates for Shp2.  RasGAP has been found to be a 
downstream target of Shp288 since Shp2 dephosphorylates RasGAP to facilitate Ras 
activation.88 
Shp2 is an important downstream signaling molecule of Met/Gab1 for the 
activation of Mitogen activated protein kinase (MAPK) pathway, which may lead to cell 
transformation, a pre-requisite for cancer. Shp2 activates a signaling step downstream of 
Gab1 and upstream of Src and Ras in the MAPK pathway. Dephosphorylation of a 
RasGAP binding site on Gab1 by shp2 negatively regulates the association of Gab1 with 
RasGAP.91 Shp2 gets phosphorylated at its C-terminal end after stimulation, which then 
binds to Grb2 with the C-terminal end and to other receptors as EGFR, PDGFR and IRS-
1 via its sh2 domains. Grb2 functioning as an adapter molecule facilitates MSOS binding 
to Shp2. This complex activates Ras/MAPK pathway and thus Shp2 acts as a positive 
regulator of cell proliferation.92  
These suggest that Shp2 is a great target for cancer therapy since, inhibition of 
Gab1 dephosphorylation by Shp293 may ultimately stop the MAPK/ERK signaling 
cascade, thereby preventing the alteration of gene expression. Being a positive mediator 
of GF signaling, especially in the Ras pathway, Shp2 inhibition by small molecules 
would be of great therapeutic interest in drug discovery. Therefore, the search for small 
molecules, which can restore the basal state of Shp2, by interacting with the PTP catalytic 
domain, represents an exciting and novel area for anti-cancer drug development. 
3.5 Ras/MAPK pathway 
 Shp2 plays a critical role in cell development by promoting the Ras/MAPK 
activation in response to various agonists. Ras/MAPK is a major signaling cascade 
modulating the cell cycle. Shp2 functions as a positive regulator/signal-enhancer in this 
pathway. Although studies indicate that Shp2 plays a signal-enhancing action in this 
pathway, the mechanism by which it functions is not quite clear.94  
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Fig. 22: (Reproduced from lit95) Role of Shp2 in Ras-Raf Pathway 
Shp2 participates in Ras/MAPK activation under EGF stimulation. Gab1 is one of 
the substrates of Shp2. Shp2 down-regulates the recruitment of RasGAP by 
dephosphorylating RasGAP binding sites on Gab1 (Fig. 22). Thus this Ras inhibitor is 
excluded out of the signaling complex, promoting sustained Ras/MAPK activation in 
response to EGF.  
3.6 Epidermal growth factor receptor signaling pathway 
Epidermal growth factors (EGFs) are critical for cell cycle, cell differentiation and 
growth. Epidermal growth factor receptors (EGFRs) are present on the cell surface, and 
their mutations could lead to uncontrolled cell division and thereby other malignancies. 
In normal cells, EGFR exists in equilibrium between its inactive monomeric and its 
active homodimeric form. Dimerization stimulates its intrinsic intracellular protein-
tyrosine kinase activity.96 The protein tyrosine phosphatase, Shp2, plays a vital role in the 
EGFR transduction pathway leading to src activation; Gab1 phosphorylation; Grb2 
binding to Sos1 (and thereby stimulation of the MAPK/ERK cascade); PI3K cascade; and 
the JNK cascade (Fig. 23).91 This implies that Gab1 is a substrate for Shp297 since Shp2 
dephosphorylation of Gab1 leads to the PI3K cascade. 
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Fig. 23: (Reproduced from biocarta pathways) Schematic representation of the EGFR pathway 
3.7 Known inhibitors of Shp2 
There are several compounds known to inhibit Shp2 without selectivity. They                       
include CDL 4340-0580 (from ChemDiv Inc.)91 and NAT6-297775 (Fig. 24), discovered 
from a screen of a natural product-like library.98  
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Fig. 24: Known Shp2 inhibitors 
Recently, Birchmeier reported a new class of Shp2 selective inhibitor, PHPS1 (5) 
(Fig. 25) which exhibited a Ki of 0.73±0.34 µM. This compound was identified via in 
silico screening of ~2.7 million compounds, out of which 843 compounds showed 
potency and 235 were specific to Shp2. Out of these compounds, 5, exhibited good 
predicted ADME properties and the compound synthesized showed an IC50 less than 1 
µM. Compound 5 is a potential phosphotyrosine mimetic because of the presence of a 
sulfonic acid group and is reported to penetrate into the substrate-binding pocket of Shp2.  
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Fig. 25: PHPS1 and Isatin derivatives and their activity against Shp2 
According to the high-throughput docking studies,99 the pyrazolone core of 5 and 
its substituents make contacts to residues at the periphery of this cleft. The amino acid 
residues Lys-280, Asn 281, Arg-362, and His-426 of Shp2 are the only residues of the 
catalytic cleft that are not conserved between Shp2 and PTP1B. These residues (Fig. 26) 
may be of particular importance for inhibitor specificity, because they are all involved in 
binding to 5.99  
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Fig. 26: (Reproduced from lit100) A. Active site of Shp2 showing the catalytic cleft, B. Ligand 
interaction of PHPS1 in Shp2 active site. 
Our lab has been actively involved in the investigation of oxindole-based small 
molecules as potential selective inhibitors of Shp2. The isatin derivative 7 (Fig. 25) 
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emerged as a hit of modest potency. This was based on compound NSC-87877101 
obtained from the HTS screening of the NCI Diversity set at the Moffitt Cancer Center. 
Extensive SAR studies around the oxindole scaffold led us to the discovery of novel, 
potent and selective inhibitors 6 and 8. The carboxylic acid group in the isatin 
compounds was found to be critical for the phosphatase activity, as a mimic of the 
phospho-tyrosine. It is reported that the hydrazone aromatic system is pointing into the 
active site PTP signature motif (VHCSAGIGRTG).102 The nitro group in compound 7 
mimics the phosphate group of the tyrosine phosphate and the sulfonic acid group is 
hydrogen-bonded with the basic residues Arg362 and Lys366 (Fig. 27). Compounds with 
an oxindole core have been studied by other groups as potential therapeutic agents.103, 104  
 
 
Fig. 27: (Adapted from lit105) Structure of Isatin (6) and (7) docked to Shp2 
3.8 Conclusion 
Shp2 has been identified as a positive regulator of growth factor signaling. Gain-
of-function mutations in many types of human cancers indicate that Shp2 is an oncogene. 
Over-expression of Shp2 in many types of cancers, including childhood leukemias makes 
it a potential anti-cancer target, suitable for drug development. Recently, Shp2 is in the 
highlight of medicinal chemistry research amongst its related PTPs because of its 
involvement in many signaling pathways. Although, the biological function of Shp2 is 
known, its role in the signaling pathways remains unclear. Inhibiting Shp2 activation 
using small molecules has gained enormous interest lately, in the area of drug discovery. 
To validate Shp2 as a therapeutic target and to get a clear understanding of its underlying 
mechanism in the signaling pathways, there is need for inhibitors that are specific to 
Shp2. 
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Chapter 4 
 
4.0 Microwaves and Flow reactors in organic synthesis 
 
4.1 Introduction: Microwave-assisted synthesis 
High-speed microwave-assisted synthesis has gained substantial interest lately, 
especially in the area of drug discovery where it is important to generate collections of 
compounds rapidly and efficiently. Commercial use of microwave ovens began in 1947.  
High water content and consequent efficient conversion of microwave energy into 
thermal energy by water molecules at microwave frequencies was well recognized in the 
earlier days.106          
 Microwave chemistry involves the use of microwave radiation to conduct 
chemical reactions. Microwaves are electromagnetic waves consisting of an oscillating 
magnetic field with a perpendicular oscillating electric field and lie between the infrared 
and the radio waves in the electromagnetic spectrum. They have wavelengths between 
0.01 and 1m and frequencies ranging from 30GHz to 300 MHz respectively. The 
microwave frequency most commonly used is 2.45 GHz, which is ideal for the 
interaction with water molecules and aqueous solutions.  
Microwaves heat up the sample by utilizing the ability of the solid or liquid to 
convert the electromagnetic radiation into heat. The charged particles or dipoles present 
in the sample tend to align with the incident radiation, when it interacts with an electric 
field (Fig. 28). The alternating nature of the radiation realigns the polarized particles in 
the opposite direction as the field alternates. The time taken for the dipoles to realign with 
the microwave field is the same as that of the alternating oscillation in the microwave 
frequency. Thus the particles are in constant motion, which results in heating.29   
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Fig. 28: dipole moments align parallel in an electric field 
 Ideal solvents for use in the microwave reactors depend on the reaction itself and 
the polarity of the solvent. Usually reactions in the microwaves are conducted using the 
same solvent as the conventional method. Since microwave heating occurs through 
dipolar polarization or conduction mechanism, solvents that are dipolar or ionic can only 
absorb microwave energy. Polar solvents like water, N, N’-dimethyl formamide (DMF), 
N-mehyl pyrrolidine (NMP), Dimethyl sulfoxide (DMSO), acetone, dichloromethane, 
dichloroethane, methanol, ethanol and acetic acid work well in microwaves because of 
their high dielectric constants. Usually non-polar solvents like toluene, benzene, diethyl 
ether, dioxane and THF do not absorb microwave energy well and are considered poor 
solvents for use in microwaves. Ionic liquids are suitable for use in microwaves due to 
their dielectric properties.  
  In the microwave reactor, in the presence of an electric field, the dipole moments 
align parallel to the applied field, they realign if the electrical field is oscillating. The 
molecules become agitated and the molecular collisions give rise to dipolar heating, 
approximately 10 degrees per second.107 In conventional heating, an external heat source 
is employed, which is relatively slow and inefficient to transfer energy into the system, as 
it is dependent on the thermal conductivity of the materials that must be penetrated. In 
this case, the temperature of the reaction vessel is much hotter than the reaction mixture 
itself. In microwave irradiation, direct coupling of microwave energy with the molecules 
present in the reaction mixture produces an efficient internal heating.108 In the 
conventional heating, ‘thermal lag’, the time required to bring the reactants to the 
reaction temperature from the room temperature, is quite long, which is a major 
drawback. In the microwave heating, the desired temperature can be attained in less than 
three minutes. The ‘ramp time’ which is the time required to reach the desired 
temperature can be changed accordingly. 
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Microwave synthesis can be conducted with a modified commercial microwave 
oven. However, there are microwave reactors specifically designed to perform reactions, 
which has controls for pressure and temperature and the microwave energy source is well 
shielded. The microwave reactor used in this work is a bench-top model from Biotage 
Inc. (Fig. 30). It has an infrared sensor, which measures the temperature. It is an 
automated system and has sample containers that can accommodate 4-8 reactions at a 
time. The vessels used for the reactions are made of contaminant free microwave-safe 
glass. They are designed to hold volumes from 0.2 mL to 20 mL and withstand pressures 
of up to 300 psi (20 bars). The caps are made of Teflon lined septum, which can 
withstand high pressure and temperature. The septum allows repeated reactions and in-
situ sampling, since it can be resealed after it has been penetrated. Magnetic stirring 
allows even temperature distribution in the reaction mixture.     
 Advantages of microwave synthesis include higher reaction temperatures, 
significantly reduced reaction times, use of low-boiling solvents under pressure, uniform 
heating of the reaction components, ease of temperature and pressure control, energy 
efficiency and parallel synthesis.107 Microwave assisted synthesis is ideal for synthesizing 
compounds in pharmaceutical drug development. Microwave-assisted heating enhances 
the reaction rates compared to the conventional heating because of the high temperatures 
used. We also observed that there were fewer impurities when we used microwave-
assisted heating. 
For example, the Biginelli reaction (Fig. 29) involves a one-pot condensation of 
an aldehyde, a ketone and either a substituted thiourea, urea or guanidine in ethanol using 
a strong acid catalyst like acetic acid and a Lewis acid at reflux temperature of ethanol for 
2-12 hrs; and the yield obtained varies from 20-60%; the same reaction performed in the 
microwave reactor takes 10-20 minutes at 120 °C, with yields of 30-90%109.  
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Fig. 29: Biginelli reaction 
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Reactions performed in the microwave reactors are usually cleaner and more 
environment friendly than the conventional heating methods; usage of solvent can be 
minimized or even eliminated since microwaves heat the compounds directly. Higher 
temperatures using low boiling solvents could be achieved in the microwave by using the 
autoclave technology. Higher yields and cleaner reactions allow rapid reaction 
optimization and library synthesis. Combinatorial synthesis plays a very critical role in 
the generation of libraries in drug discovery. Combining combinatorial synthesis and 
microwave-assisted heating to generate compounds have recently evolved much interest 
due to its enormous benefits.    
 However, there are limitations to microwave chemistry; the reaction scale is 
usually limited to grams; Solvents that absorb microwave energy can only be used. In 
spite of the adverse effects of the microwave, it still remains an efficient source of 
heating, which results in saving energy and time.108, 110 One of the major drawbacks of 
the microwave technology is the scalability of reactions in the process industry. But 
despite the limitations, microwave chemistry plays a major role in organic synthesis. 
Many reactions, which were not possible previously using conventional methods of 
heating have been effectively performed in the microwave reactors quickly and 
efficiently in a few minutes.107 
  
Fig. 30: Biotage microwave reactor and H-cube hydrogenator 
4.2 Flow reactors: Hydrogenator 
 The competitive nature of pharmaceutical research requires lead optimization and 
library synthesis to be performed easier and faster. A recent development in the field of 
drug discovery is the use of continuous flow reactors.111 The use of flow reactors in 
organic synthesis is highly attractive since it can handle a wide range of scale that can be 
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performed and the ease of use. Reductions of nitro compounds to the corresponding 
amino compounds were performed on a H-cube flow reactor (Fig. 32). It is a bench-top 
hydrogenator, in which the hydrogen is generated by electrolysis of water. A HPLC 
pump flows a continuous stream of solvent into reactor. Hydrogen, generated in-situ, is 
mixed with the sample, heated and passed through a catalyst cartridge (30-70mm), where 
the reaction takes place and the hydrogenated product is collected into the product vial. 
Reductions varying from 10mg-1 g scale can be performed in the flow reactor. The 
maximum temperature and pressure that can be attained in the H-cube flow reactor are 
100 °C and 14.5 psi (100 bars) respectively. The flow of reactant can be controlled by the 
HPLC pump from 1-10 mL. This reactor is relatively safe compared to other 
hydrogenation devices since no cylinders or external hydrogen source is required in the 
H-cube. There is no risk of handling the metal catalyst or filtering it.  
4.3 Conclusion 
 Flow reactors have drastically changed and improved the way in which organic 
reactions are performed. Many reactions that were previously impossible using the 
conventional method can now be performed using microwave technique. 
Hydrogenations, generally considered dangerous can easily be performed in the bench-
top hydrogenator, which not only has cut down the risks involved with the handling of 
catalysts but also enables pressurized reactions to be performed at elevated temperatures. 
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Chapter 5 
 
5.0 Synthesis and evaluation of small molecules as Bcl-xL inhibitors 
 
5.1 Introduction 
Bcl-xL is over-expressed in most human cancer types, making it a very attractive 
target in the area of anti-cancer drug development.11 High expression of Bcl-2 or Bcl-xL 
in human cancer contributes to neoplastic cell expansion and interferes with the 
therapeutic effect of the chemotherapeutic agents used in cancer treatment, by blocking 
apoptosis. Inhibiting the function of Bcl-xL could restore apoptosis or sensitize the 
tumors for therapeutic agents.  
From a high throughput screening of the NCI Diversity Set 
at the Moffitt Cancer Center, the isoquinolinol NSC-131734 was 
identified as an inhibitor of p53-HDM2 binding and Bcl-xL-Bax 
interactions having an IC50 of less than 15 µM in the FP (fluorescent 
polarization) assay.  
Isoquinolinols are very 
important compounds in the field of drug discovery, 
especially as short-acting cardiovascular agents and 
anti-hypertensive agents. The opium alkaloid, 
Papaverine is an 
isoquinolinol,  
which has a relaxant effect on the vascular and visceral smooth 
muscle.112 Based on the screening, two analogs of NSC-
131734, isoquinolinols HL2-100 and HL2-101 (Fig. 31) were 
synthesized and identified as a new starting point in our hit-to-lead process in the search 
of new inhibitor of Bcl-xL-Bax interactions. Molecules bearing a fused anthracene or an 
N
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Fig. 31 Structures of HL2-100 and HL2-100-2 
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anthracycline ring system are known to intercalate the DNA.113 Since NSC-131734 has a 
fused anthracene ring system, it was suspected that it would act as a DNA intercalating 
drug. DNA intercalators are drugs that bind to DNA tightly and reversibly by a 
combination of hydrophobic, electrostatic, hydrogen bonding and dipolar forces causing 
programmed cell-death. DNA intercalation usually gives rise to high toxicity, which is 
undesirable in drug discovery and medicine. We have therefore designed and prepared 
focused libraries of 4-methylarylisoquinolines114 (Table 1) related to these structures, 
which we hoped would retain the Bcl-xL inhibition but without acting as DNA 
intercalators.  
Initially, we focused on synthesizing a library by varying the substituents on the 
aromatic ring (Ring A) attached to the isoquinoline ring. A 
variety of benzaldehydes were chosen to generate the first 
library for the initial screening against Bcl-xL. We then 
focused on the isoquinoline core (Ring B) and synthesized a 
few compounds by varying the groups in ring B. All these 
compounds were tested for Bcl-xL.  
 The isoquinolines, 12a-z (Table 1) were synthesized using the Pomeranz-Fritsch 
reaction115 (Fig. 32). Amongst the other methods to prepare isoquinolines such as the 
Pictet-Spengler116 and Bishler-Napieralski cyclization,117 the Pomeranz-Fritsch reaction 
is widely used to synthesize completely unsaturated isoquinolines.115 The Pomeranz-
Fritsch reaction involves the synthesis of isoquinolines via the acid-mediated cyclization 
of the appropriate aminoacetal intermediate iii (Fig. 33). Benzaldehydes bearing electron-
donating substituents in the 3- or 4- positions are favorable substrates for the Pomeranz-
Fritsch reaction.118  
 
Fig. 32: Pomeranz-Fritsch reaction 
N
Ring A
Ring B
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 The conventional mechanism of this reaction involves the formation of an imine 
11 from the amine 10 and the aldehyde 9, which on cyclization and subsequent 
elimination affords the isoquinoline 14 (Fig. 33)115.  
 
Fig. 33: Mechanism of Pomeranz-Fritsch reaction 
Modified Pomeranz-Fritsch reactions were performed, employing milder reaction 
conditions (Fig. 34). The Bobbitt modification forms the 4-hydroxy isoquinolines by 
employing mild acidic conditions for cyclization. The Jackson modification involves the 
cyclization of the N-tosylated aminoacetal intermediate.119 The Schlittler-Mueller 
modification120 involves the formation of imine from a benzyl amine and 2,2-
diethoxyacetaldehyde, which on cyclization yields the corresponding isoquinoline.121  
 
Fig. 34: Modifications to Pomeranz-Fritsch reaction 
 The Pomeranz-Fritsch reaction has also been carried out in the presence of Lewis-
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acid catalysts like BF3-trifluoroacetic anhydride or polyphosphoric acid.122, 123 In such 
cases, only the activated imines, bearing electron donating groups in the 3- or 4- 
positions, cyclize to give the isoquinolines, whereas the inactivated benzaldehydes fail to 
cyclize.  
 We synthesized the isoquinolinols 20a-b following the literature reported method 
described by Bobbitt and Dyke.114 The aniline 9a was treated with aminoacetal diethyl 
amine at 80 °C to afford the imines 10a. Reduction of 10a with sodium borohydride 
afforded the amines 19a. Compound 19a was then treated with the corresponding 
benzaldehydes at reflux temperatures to afford the isoquinolinols, 20a-b. To facilitate 
parallel synthesis of compounds for our initial library and reduce the reaction time, we 
carried out reactions under microwave conditions. High-speed microwave-assisted 
synthesis has gained substantial interest lately, especially in the area of drug discovery 
where it is important to generate collection of compounds rapidly and efficiently.  
 Compounds 20c-z were synthesized using the microwave-assisted Pomeranz-
Fritsch reaction (Fig. 35). Compounds 10c-e were synthesized by treatment of the 
appropriate benzaldehydes with aminoacetaldehyde diethylacetal in EtOH at 130 °C for 
15 min in the Biotage microwave reactor afforded the imines 10c-e. Sodium borohydride 
was directly added to the reaction mixture to afford amines 19c-e. The amines 19c-e were 
then reacted with a wide range of commercially available aldehydes in the presence of 
concentrated hydrochloric acid to provide the desired 4-aryl isoquinolinols 20c-z (Table 
1). 
 
Fig. 35: Synthesis of substituted isoquinolinols, 20a-z 
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Reagents and conditions: a. EtOH, reflux, 30 min; b. EtOH, µw, 130 °C, 15 min; c. NaBH4, MeOH, 30 
min, rt; d. ArCHO, HCl, H2O, reflux, 40 min or e. ArCHO, HCl, H2O, µw, 140 °C, 15 min  
Table 1: Synthesis of substituted isoquinolinols, 20a-z from 19a-e 
Entry R1 R2 R3 Ar Yield (%) 
(from 19) 
20a OH OMe H 2-Cl 70a 
20b OH OMe H 4-Br 69a 
20c OH OMe H 2,4-Cl2 82b 
20d OH OMe H 3,5-(CH3)2 71b 
20e OH OMe H 4-Biphenyl 90b 
20f OH OMe H 3-Pyridyl 99b 
20g OH OMe H 4-Et 61b 
20h OH OMe H 3-Cl,4-F 99b 
20i OH OMe H 4-CH(CH3)2 23b 
20j OH OMe H 2,4-(CH3)2 50b 
20k OH OMe H 4-(4-Pyridin-2-yl)benzyl 99b 
20l OH OMe H 2-CF3 55b 
20m OH OMe H 3,5-Br2 99b 
20n OH OMe H 2,3-Cl2 80b 
20o OH OMe H 4-Pyridyl 65b 
20p OH OMe H 2,6-Cl2 64b 
20q OH OMe H 3-F 64b 
20r OH OMe H 4-F 95b 
20s H OMe OH 4-Br 89b 
20t H OMe OH 3-Cl,4-F 82b 
20u H OMe OH 4-F quantitativeb 
20v H OMe OH 3-F 64b 
20w H OMe OH 2,3-Cl2 99b 
20x H OMe OH 2,4-Cl2 quantitativeb 
20y H OMe OMe 4-NH2 73b 
20z H OMe OMe 3-Cl,4-F 94b 
 
a reflux, 40 min; b µw, 130 °C, 15 min. 
The reaction is believed to take place by the mechanism shown (Fig. 36). The 
formation of intermediate 23 is similar to that shown in Fig. 33. Intermediate 23, being an 
enamine is highly reactive and hence it reacts further with the aryl aldehyde to form the 
hemi-acetal 21, which on elimination of water, rearranges to give the isoquinolinol 20. 
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Fig. 36: Mechanism of synthesis of isoquinolinols 
All the compounds synthesized were analyzed by 1H NMR, 13C NMR, IR and 
HRMS. The structures of these compounds were established from their unique NMR 
spectra. 
Compound 12a showed a singlet at δ 3.7 ppm in the 1H 
NMR spectrum, indicative of the methoxy group. The singlet for 
two protons at δ 4.4 ppm indicates the benzylic protons. In the 13C 
NMR spectrum, the signals for the methoxy and methylene 
carbons appeared at 37 ppm and 57 ppm respectively. A series of peaks between 6.84 and 
7.44 ppm in the 1H NMR spectrum indicates the protons on the benzyl group containing 
the chlorine and the protons on the ring containing the methoxy group (Ha and Hb). Two 
sharp singlets at δ 8.22 and δ 9.56 ppm indicate the protons on the isoquinoline ring 
containing the nitrogen, Hc and Hd respectively. Mass spectrometry of the compound 
(MS (m/z) 300.1 (M+H)+) further confirmed the structure of this compound. 
The first library of compounds (Table 1) was tested in the fluorescence 
N
O
OH
Cl
Ha
Hb
HdHc
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polarization (FP) assay.124 FP is a technique amply used to analyze protein-protein 
interactions in solution. The measurements are based on the assessment of the rotational 
motions of species. The theory of FP was established by Perrin, in 1926.125 Fluorescent 
molecules when excited with plane-polarized light rotate and tumble during the 
fluorophore's excitation. When a protein binds to a fluorophore-labeled peptide, it leads 
to a decrease in peptide rotation and an increase in polarization upon excitation with 
polarized light (Fig. 37). The fluorescence of the small molecule bound to the Bcl-xL 
protein is measured, which is proportional to the polarization value.124, 126  
InteractionPeptide
Fluorophore
Fast tumbling
Depolarized emission
Slow tumbling
Polarized emission
Protein Protein
 
Fig. 37: FP assay 
5.2 Biological evaluation of compounds, 12a-z 
Initial screening of the NCI diversity set compounds in the FP assay led to the 
discovery of the hit, NSC-131734. Although initial screening of the commercially 
available compounds did show substantial activity for Bcl-xL using the in-house FP 
assay, later screening of the NCI diversity set hits and the in-house synthesized 
compounds in the same assay did not exhibit any inhibitory activity. This, in part, might 
be due to some impurities present in the commercially purchased compounds, which 
were undetectable using NMR or high-resolution MS. The impurities could have been 
responsible for the detection of the compounds as false positives. Compounds 12a-z 
exhibited IC50 greater than 300 µM for Bcl-xL in the FP assay. 
5.3 Conclusion 
 In the search for novel small molecules as disruptors of Bcl-xL activity, an 
efficient microwave-assisted synthesis of isoquinolinols has been developed. 
Isoquinolinols, being one of the most important pharmacophores in drug discovery, the 
applicability of this reaction to a broad range of substrates and the ease of synthesis 
makes it valuable in combinatorial chemistry and drug discovery.  
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Chapter 6 
 
6.0 Synthesis and evaluation of small molecules as Shp2 inhibitors 
 
6.1 Hit-to-Lead approach based on HTS screening 
From a high throughput screen of the NCI Diversity Set and the Moffitt ChemDiv 
20000 compound collection, a diverse set of small molecules (Fig. 37) were identified as 
hits, capable of inhibiting Shp2 PTP. The original hits were chosen based on their initial 
Shp1/Shp2 selectivity profile and whether they were amenable to analog synthesis. The 
initial step in our hit-to-lead approach is re-synthesis of the original hits to confirm the 
biological activity. The second step involves the design and synthesis of new analogs to 
improve the potency of the initial hits. The lead optimization is also directed towards the 
design and synthesis of new inhibitors showing potency and selectivity for Shp2 rather 
than the related phosphatase Shp1.   
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Fig. 38: Shp2 hits derived from a high throughput screen at the Moffitt Cancer Center 
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6.1.1 Synthesis of HLM000661 
From the screening of the Moffitt ChemDiv library by HTS for Shp2 inhibitory 
action, HLM000661 (34) was identified as a hit of remarkable potency with an IC50 of 
0.67 µM. Hence, re-synthesis of the compound HLM000661 (34) was undertaken using 
the synthetic route as depicted scheme 1.127, 128 The oxime 28 was synthesized by reacting 
6,7-dihydrobenzo[b]thiophen-4(5H)-one 27 with hydroxylamine hydrochloride under 
microwave assisted heating at 120 °C for 15 min. The tosylated oxime 29 was obtained 
by reaction of 28 with p-toluenesulfonyl chloride in presence of pyridine. Treatment of 
29 with KOH and ethanol under the Beckman conditions gave the 7-membered lactams 
30 and 30a.128 This reaction provided both regio-isomers 30 and 30a in equal yield. The 
two isomers were separated by column chromatography and analyzed using 1H NMR and 
13C NMR. The protons on the thiophene ring displayed signals at 6.51 ppm and 7.06 ppm 
in the 1H NMR for the desired product compared to the peaks at 7.23 and 7.83 ppm for 
the regioisomer respectively. The melting points of the samples were taken which further 
confirmed the desired product. Compound 30a had a melting point of 85-87 °C while the 
desired isomer had a melting point of 133-134 °C, which was comparable to the reported 
data (30a: lit. m.p. 92-93 °C; 30: lit. m.p. 134-135 °C).129 Acylation of 30 under the 
Friedel-Crafts conditions (AlCl3, 0 °C) proved unsuccessful. The desired isomer 30 was 
acylated with methyl 4-chloro-4-oxobutyrate in presence of SnCl4 at 0 °C to give 31. The 
reduction of the carbonyl group to the corresponding alcohol was performed using 
NaBH4. Treatment of 32 with Et3SiH/BF3.Et2O yielded compound 33. Prior attempts to 
perform direct reduction of 31 under Wolf-Kishner (hydrazine hydrate KOH, Diethylene 
glycol, 150 °C, 4hrs) or Clemmenson (potassium acetate, ethanol-water, reflux, 22hrs) 
conditions, failed to provide the target product 33. Saponification (1M NaOH) of the 
methyl ester 33 afforded the desired product 34. Compound 34 was analyzed by 1H 
NMR, 13C NMR and mass spectrometry. A singlet at 6.41 ppm (proton on the thiophene 
ring), seven –CH2 peaks at 1.59-2.89 ppm in the 1H NMR and the signals for 2 carbonyl 
groups and four aromatic carbon peaks in the 13C NMR confirmed the structure of 34. 
The mass spectrometry of compound 34 (MS m/z 268 (M+H)+) further confirmed the 
structure of 34. The analytical data were comparable to the literature reported data129 and 
the analytical data of the HLM000661 sample purchased from ChemDiv.  
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Scheme 1: Synthesis of HLM000661 (34) 
Reagents & Conditions: a. NH2OH.HCl, NaHCO3, µw, 120 °C, 10 min; b. p-TsCl, Pyridine, 0 °C, 1 hr; c. 
K2CO3, EtOH, H2O, reflux, 22 hrs; d. Methyl 5-chloro-5-oxo-pentanoate, SnCl4, DCM, 0 °C - rt, 30 min, 
Ar; e. NaBH4, MeOH, 30 min, rt; f. BF3. Et2O, Et3SiH, DCM, rt, 30 min; g. 1M NaOH, rt, 1 hr. 
 
6.1.2 Synthesis of HLM019544 
The quinolone 41, (initially purchased from ChemDiv) was found to inhibit Shp2 
activity with an IC50 of 3.59 µM. Synthesis of HLM019544 (41) was performed as 
shown (scheme 4).130-132 Amide coupling, followed by Pd-catalyzed hydrogenation of the 
nitro group, performed in a Thales H-cube Flow Reactor, 
provided the key intermediates 37a-h. The nitro group in 
36i, bearing chlorine at the ortho-position of the 
sulfonamide terminus, was reduced to the corresponding 
amine 37i by treatment with NiCl2 and NaBH4 (Table 2, note a). In fact, the cleavage of 
the C (aromatic)-Cl bond under Pd-catalyzed hydrogenation has been amply described 
and documented in the literature.133 The aminomethylenemalonates 38a-i were prepared 
by reacting compounds 37a-i with diethyl ethoxymethylenemalonate under solvent free 
heating (180 ºC, 1h) (Scheme 2).  
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Scheme 2: Synthesis of quinolone, 41 
Reagents and Conditions: a. p-Nitrosulfonyl chloride, DCE, Pyridine, µw, 150 °C, 10 min; b. 
NiCl2⋅6H2O, NaBH4, 0 °C, 30 min; c. H2, 10% Pd/C, Methanol, H-cube; d. Diethylethoxymethylene 
malonate, 180 °C, 1 hr; e. o-Dichlorobenzne, 250 °C, µw, 15 min; f. 10% KOH, EtOH, reflux, 1.5 hrs; g. 
SOCl2, refux, 1 hr; h. CH3NH2, Pyridine, DCM, rt, 1 hr. 
Ring closure to form the quinolone
 
was a key step in this synthesis. The synthesis 
of 39 is discussed later. Base-catalyzed hydrolysis of the ester 39 afforded acid 40. 
Reaction of 40 with thionyl chloride afforded the acid chloride, which was treated with 
methylamine in presence of pyridine gave 41. Compound 41 was analyzed using 1H 
NMR, 13C NMR, MS and single crystal X-ray diffraction analysis (Fig. 39, for data, see 
Appendix). The presence of two peaks (for the two methyl groups) in the upfield region 
of 1H NMR, a multiplet  (four protons of the aromatic ring 
attached to the sulfonamide unit), a doublet with a coupling 
constant of 2 Hz (meta coupling, Ha), a doublet of doublet 
showing meta and ortho coupling (Hd) and a doublet 
showing ortho coupling (Hc), a singlet at 8.78 ppm (proton 
in the quinolone ring, Hb) confirmed the structure of 41. The 1H NMR and MS obtained 
for compound 41 were comparable with the data obtained for the HLM019544 sample 
purchased from ChemDiv.  
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Fig. 39: X-ray crystal structure of 41 
Quinolones are a family of broad-spectrum antibiotics representing an area of 
great interest in medicinal chemistry. In fact, they are widely used for the treatment of 
many infectious diseases as antimicrobial as well as anti-bacterial agents. Discovered in 
the 1960s, Nalidixic acid was the first quinolone used as a clinical agent in the treatment 
of urinary tract infections caused by gram-negative organisms.134, 135 Due to its 
pharmacological relevance, medicinal chemistry efforts have been directed towards the 
search and the synthesis of Nalidixic acid 
derivatives of increased potency and 
improved pharmacokinetic and 
pharmacodynamic properties. 
Ciprofloxacin belonging to the 
fluoroquinolones group was introduced as a synthetic antibiotic in the 1980s effective 
against gram-positive and gram-negative bacteria. Ciprofloxacin possesses a remarkably 
improved profile in terms of potency, spectrum and pharmacodynamic properties 
compared to the first generation quinolones and the parent compound, Nalidixic acid.136, 
137
 Quinolones have been found to show their antibacterial properties through the 
stabilization of the bacterial type II topoisomerases-DNA complex.134, 135 DNA 
topoisomerases are essential for DNA replication, 
transcription, chromosome segregation, and DNA 
recombination. Quinolone antibacterials display a remarkable 
selectivity between the bacterial and mammalian II 
topoisomerase and, therefore, a good toxicity profile.134, 135 
Quinolones like 42 show both topoisomerase II mediated DNA cleavage and anti-tumor 
activity.138 Many of the quinolones show their cytotoxicity through the stabilization of 
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the topoisomerase-DNA complex (also referred to as cleavage complex), forming ternary 
complexes.139 The mechanistic similarities of the antibacterial quinolones and anti-tumor 
agents have stimulated a new interest in the quinolone class of compounds in an effort to 
change their biological profile from antibacterial to cytotoxic agent.140  
Due to their therapeutical potential, there is always the need for new and 
optimized synthetic routes to access novel quinolones in a combinatorial fashion. In the 
synthesis of quinolones 41, we investigated the optimization of a microwave assisted 
Gould-Jacob cyclization for the synthesis of ethyl 6-sulfamoyl-4-oxoquinoline-3-
carboxylates 39 employing o-dichlorobenzene (ODCB) as solvent. 
The synthesis of a small library of ethyl 6-sulfamoyl-4-oxoquinoline-3-
carboxylates 39 as precursors for the synthesis of cystic 
fibrosis transmembrane conductance ‘potentiators’ has 
been recently published by Kurth and coworkers.141 
Kurth’s protocol involves the microwave irradiation of a 
diphenylether solution of diethyl 2-[(4-phenylsulfamoyl-phenylamino)-methylene]-
malonates containing catalytic p-chlorobenzoic acid (250 ºC, 2h, µw). We initially 
attempted to build our library upon Kurth’s protocols (Scheme 3).  
Literature reported protocols for the synthesis of quinolones involve the 
condensation between anilines and diethyl ethoxymethylenemalonate followed by 
thermal cyclization (Gould-Jacob reaction). The cylclization is usually performed very 
high temperatures (180-250 °C) under solvent free classical or microwave heating, or 
employing diphenyl ether or biphenyl or Dowtherm (an eutectic mixture of biphenyl and 
diphenylether) as solvents. 
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Scheme 3: Synthesis of quinolones  
Reagents and Conditions: a. Diphenyl ether, 250 °C, 2hrs; b. Diphenyl ether, p-chlorobenzoic acid, 250 
°C, µw, 2 hrs; c.  Dowtherm, 250 °C, 2 hrs.
  
 As a simple model, we initially studied the reaction of 38a (Table 2). Our initial 
experiment was carried out in the Biotage microwave reactor under the following 
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conditions: Ph2O, cat. p-chlorobenzoic acid, 250 ºC, 2 h (Table 2, entry 1). However, a 
maximum temperature of 150 ºC could be achieved using diphenyl ether as solvent in the 
microwave reactor. A mixture of starting material and aniline 37a was recovered and no 
product formation was observed. A series of experiments were performed in the CEM 
microwave reactor under different conditions (Table 2, entries 2, 3), which proved 
unsuccessful. Classical heating diphenyl ether as solvent (cat. p-chlorobenzoic acid, 
reflux, 15 min), afforded a complex reaction mixture (analyzed by 1H NMR 
spectroscopy). No starting material was recovered.  
In an effort to optimize the synthesis of ethyl 6-sulfamoyl-4-oxoquinoline-3-
carboxilates 39, we addressed the possibility of performing the Gould-Jacob reaction in 
different solvents under microwave heating. Employing ethanol or dioxane as solvents, 
allowed us to reach the maximum temperature of 180 ºC but no reaction was observed 
and a mixture of starting material and the corresponding amine 37a was recovered (Table 
2, entry 4, 5). o-Dichlorobenzene has a high boiling point (250 °C) and also a high dipole 
moment (2.14 debye units at 20 °C),142 a feature of solvents that absorb microwave 
radiation efficiently. Since high temperatures are required to promote thermal cyclization, 
the reaction was performed using o-dichlorobenzene as solvent. The quinolones formed 
could be easily isolated by washing the reaction mass with hexane to remove ODCB.  
Thus, ODCB was found to be the best choice of solvent to reach high temperature under 
microwave heating (250 ºC) and effective to promote the quantitative thermal cyclization 
of 38a (as determined by analysis of the crude 1H NMR spectrum), shortening 
significantly the reaction time to 15 min compared to Kurth’s protocol)141 (Table 2, entry 
6).  
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Table 2: Summary of the reaction conditions towards the synthesis of 39a 
N
H
38a 39a
N
H
S
OO
CO2Et
CO2Et
N
H
S
OO
N
H
O O
CO2Et
 
Entry Microwave 
reactor 
Solvent p-chloro 
benzoic acid 
Max. T 
(ºC) 
Power 
(W) 
Time 
(min) 
Reaction outcomea 
 
1 Biotage Ph2O Catalytic 150 N.A. 15 Starting material & 37a 
2 CEM Ph2O Catalytic 250 275 30 Decomposition 
3 CEM Ph2O Catalytic 212 250 30 Complex mixture 
4 Biotage Ethanol Catalytic 180 N.A 15 Starting material & 
37a 
5 Biotage Dioxane Catalytic 180 N.A 15 Starting material & 37a 
6 Biotage ODCB Catalytic 250 N.A 15 39a, quantitative 
7 Biotage ODCB None 250 N.A 15 39a, 84%b 
 
aDetermined by NMR spectroscopy, bIsolated yield 
The reaction also proved to be successful in absence of cat. p-chlorobenzoic acid 
(39a, 84%, Table 2, entry 7). Moreover, the pure product could be easily precipitated 
from the reaction mixture by addition of hexane. No further purification was required. 
Meeting our need of a straightforward and robust protocol to synthesize the target 
molecules, the optimized conditions (Table 2, entry 7) proved to be reproducible, 
reliable, and applicable to a variety of substrates in good to excellent yields (Table 2, 
39b-i)139. The structures of the compounds 39a-i were determined by NMR and Mass 
spectroscopy.           
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Table 3: Synthesis of quinolones (39a-h) 
N
H
ODCB
MW, 250 oC, 15 min
38b-h 39b-h
N
H
S
OO
CO2Et
CO2Et
N
H
S
OO
N
H
O O
O
R R
 
Entry R R1 Yield (%) 
39b 2-Cl H 90 
39c 4-OMe H 95 
39d H Me 70 
39e 2-Et H 81 
39f 3-Me H 57 
39g 2-OMe H 90 
39h H H 89 
39i 4-Me H 88 
 
6.1.3 Synthesis of HLM002903 
HLM002903, 44 (purchased from ChemDiv library) exhibited Shp2 activity with 
an IC50 of 6.41 µM. Compound 44 (HLM002903) was synthesized as shown in Scheme 
4. Pseudothiohydantoin was treated with formaldehyde to give compound 43.143 
Compound 43 was further treated with formaldehyde and ethylamine in the presence of 
potassium carbonate to give 44. DEPT spectral analysis showed five negative signals at 
135 ° pulse (5 -CH2 groups), which had the appropriate splitting pattern  in the 1H NMR, 
and one positive signal (CH3 group) confirmed the presence of 44. 
Although, the 2 -CH2 groups (a & b) appear to be equivalent, they 
have different chemical shifts on the 13C NMR as well as the 1H 
NMR due to the presence of the ethyl group on the nitrogen atom (in the triazine ring), 
which makes the carbon (C1), a diastereotopic center. The mass spectrometry and single 
crystal X-ray diffraction analysis further confirmed the structure of compound 44 (Fig. 
40, for data see Appendix). The 1H NMR and MS obtained for compound 44 were 
comparable with the analytical data obtained for the HLM002903 sample purchased from 
ChemDiv.  
N
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Scheme 4: Synthesis of HLM002903 (44) 
Reagents & Conditions: a. HCHO, triethylamine, ammonium carbonate, rt, 1 day; b. HCHO, 0.2M 
ethylamine in THF, K2CO3, rt, 30 min. 
 
Fig. 40: X-ray crystal structure of 44 
6.1.4 Synthesis of HLM001038 and HLM001426 
HLM001038, 46a and HLM001426, 46b exhibited an IC50 of 12.2 µM and 2.45 
µM respectively in the HTS screening. Compounds 46a-b were synthesized by Ytterbium 
triflate catalysed intermolecular imino Diels-Alder reaction of 45a-b with freshly cracked 
cyclopentadiene and glyoxylic acid as shown in Scheme 5.144 Compounds 46a and 46b 
were analyzed by 1H NMR, 13C NMR, and mass spectrometry, which confirmed their 
structures. DEPT spectral analysis showed one negative signal at 135 ° pulse (-CH2 
group) and six positive signals (-CH3 and –CH groups) for compound 46a and one 
negative signal and five positive signals (-CH groups) for Compound 46b respectively. 
The 1H NMR and MS obtained for Compound 46a and 46b were comparable with the 
analytical data obtained for the HLM001038 and HLM001426 samples purchased from 
ChemDiv. The structure of compound 46a was further confirmed by single crystal X-ray 
diffraction analysis (Fig. 41, for data see Appendix). 
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Scheme 5: Synthesis of HLM001038 and HLM001426 (46a and 46b) 
Reagents & Conditions: a. cyclopentadiene, glyoxalic acid, ytterbium triflate (10 mol%), magnesium 
sulfate, DCM, 14 hrs. 
 
Fig. 41: X-ray crystal Structure of 46a 
 All the synthesized compounds were evaluated in the fluorogenic DiFMUP91 
assay for their ability to inhibit Shp2 phosphatase activity. The enzyme activity of Shp2 
can be assessed by a number of known methods. They include the pNPP assay,91 in which 
the activity is measured by the absorption generated by the dephosphorylation of p-
nitrophenyl phosphate yielding the fluorescent 4-nitrophenolate (Fig. 42) and the 
DiFMUP assay, in which the activity is measured by the absorption generated by the 
dephosphorylation of the fluorogenic 6,8-difluoro-4-methylumbelliferyl phosphate 
(DiFMUP) yielding the fluorescent 6,8-difluoro-7-hydroxy-4-methyl-2H-chromen-2-one 
as the substrate (Fig. 43). 
For the screening of our compounds, we have used the DiFMUP assay to test the 
enzyme activity of Shp2. 
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Fig. 42: pNPP Assay: Dephosphorylation by Shp2 
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Fig. 43: DiFMUP Assay: Dephosphorylation by Shp2 
The biological results showed that the IC50 of the re-synthesized compounds were 
greater than 300 µM. From the results obtained, we concluded that not all compounds 
obtained from commercial sources contain the structure that is claimed. Since all the 
analytical data obtained for the re-synthesized compounds matched the analytical data of 
the outsourced compounds, we hypothesized that the initial activity observed in the HTS 
screen must have resulted from some minor impurity present in the sample.  
 According to Hubbard,145 it is not unusual for 5-10% of compounds purchased 
from commercial suppliers to either be not what they claim to be, or to contain major 
contaminants that can give false positive (or false negative) results.145 It is also known 
that the phosphatase assay is particularly sensitive to oxidants, because of the catalytic 
cysteine residue Cys459.146 
6.2 Hit-to-Lead approach based on hits of related phosphatases 
 Since the above approach towards the development of Shp2 inhibitors was not 
successful, we focused our attention towards an alternative approach involving the 
synthesis of compounds known to inhibit related PTPs. We focused on synthesizing 
compounds, which were previously reported as hits for HePTP, hematopoietic protein 
tyrosine phosphatase.  
6.2.1 HePTP hit evaluated for Shp2 
 HePTP, a protein tyrosine phosphatase found in the 
hematopoetic cells in the myeloid and lymphatic tissues. It is a 38 
KDa protein having a C-terminus, a short N-terminus and a PTP 
N
CO2H O
52a
O
 52 
catalytic domain. Homology modeling shows 38% identity in the conserved region of the 
PTP catalytic domains of Shp2 and HePTP.11 The results from San Diego Center for 
Chemical Genomics compound collection screening for HePTP inhibitors, obtained via 
Pubchem, showed that 52a is active as a HePTP inhibitor with an IC50 of 1.17 µM in 
DiFMUP assay. The isooxindole 52a was chosen for hit-to-lead optimization since it is a 
low molecular weight compound, which may bind in the PTPase catalytic site of Shp2.  
 The synthesis of the isooxindole 52a was performed modifying a literature 
procedure (Scheme 6).147, 148 The imine 49a were synthesized from 2-furaldehyde and p-
anisidine using microwave assisted heating at 130 °C for 15 minutes. The imine 49a was 
reduced to the corresponding amine 50a using NaBH4 in MeOH. The amine 50a was then 
treated with maleic anhydride to give the Diels-Alder adduct 51a. The compound 51a 
was aromatized using H3PO4 to give the isooxindole 7-carboxylic acid, 52a.The 1H NMR 
analysis showed 2 singlets at δ 3.78 ppm and δ 5.17 ppm respectively which denotes the 
methoxy protons in the phenyl ring and the methylene protons present on the isoosindole 
ring. Two doublets with a coupling constant of 8.8 Hz at δ 7.04 and δ 7.71 ppm 
respectively showed the presence of the protons in the phenyl ring (AB pattern). A triplet 
and 2 doublets above δ 7.8 ppm showed the presence of the 3 protons on the isooxindole 
ring. The carbons of the carbonyl group in the isooxindole ring and that of the carboxylic 
acid showed at δ 165.69 and δ 168.40 ppm respectively in the 13C NMR spectrum. An 
m/z of 284 (M+H)+ on the mass spectral analysis further confirmed the structure. 
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Scheme 6: Synthesis of isooxindole derivative (52a) 
Reagents & Conditions: a. EtOH, MW, 130 ºC, 15 min; b. NaBH4, MeOH, 20 min, rt; c. maleic 
anhydride, toluene, rt, 3 days; d. H3PO4, reflux, 1 hr. 
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Compound 52a was found to have IC50 of 3.89 ± 1 µM in the DiFMUP assay for 
Shp2. The docking structure of compound 52a with the Shp2 PTPase domain (PDB ID: 
3b7o) is illustrated in Fig. 44.  
Fig. 44: Docking structure of 52a with the Shp2 PTPase domain (PDB ID: 3b7o) 
Fig. 5 shows that the compound 52a binds relatively well into the PTP binding pocket of 
the Shp2 protein. The docking structure below (Fig. 45) shows the interactions of the 
compound 52a with the amino acid residues LYS366, SER460, GLY427, GLN510, and 
CYS459. 
 
Fig. 45: Interactions of 52a amino acid residues of the Shp2 protein, in the docking structure 
We hoped to build upon the isooxindole scaffold to achieve selectivity for Shp2 
by capturing interactions outside the catalytic site. The synthesis of a series of 
GLN510
LYS366 
SER460 
CYS459 
GLY427
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isooxindoles was performed using the procedure outlined (Table 4).  
Table 4: Synthesis of isooxindole derivatives 
O H
N
O
N
N
CO2H O
O
O
H
H2N
O
CO2H
N
O
+
a b c
d
50a-o 51a-o
52a-o
R
R
R
R
R47b-o
48
49a-o
 
Entry R Yield (%) IC50 (µM) 
52b 4-CH(CH3)2 39 >300 
52c 2,4-F2 61 Not tested 
52d 4-Cl 44 95 
52e 4-Br 41 12.3 
52f 4-OEt 47 8.9 
52g 2-OMe 19 3.6 
52h 3,4-Methylenedioxy 30 0.7 
 
To probe the molecular features of 52a, responsible for Shp2 activity, we also 
synthesized compound 55 (Scheme 7) from phthaldialdehyde 55 and p-anisidine in acetic 
acid, under microwave assisted heating (130 °C for 15 min).149 These compounds lacked 
the carboxylic acid group at position 7 but retained all rings. These were synthesized to 
probe the function of the carboxylic acid group for Shp2 activity.  
H
H
O
O
N O
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Scheme 7: Synthesis of Isooxindole derivative 55 
Reagents & Conditions: a. p-anisidine, acetic acid, µw, 130 °C, 10 min. 
Compound 59 (Scheme 8), was synthesized by treating p-anisidine 57a with 2-
chloroethyl isocyanate 56 and closing the ring to form the imidazolidinone using NaH in 
THF. In compound 59, the imidazolidinone ring was introduced to replace the 
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pyrrolidinone ring and probe the function of the pyrrolidinone ring for Shp2 activity.  
O
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Scheme 8: Synthesis of imidazolidinone derivative 
Reagents & Conditions: a. 1-chloro-2-isocyanatoethane, THF, µw, 100 °C, 35 min; b. NaH, THF, 0 °C - 
rt, 30 min.
 
Compounds 61a-b (Scheme 9), were synthesized to provide analogs that have the 
pyrolidonone ring attached to the aryl group, but lack the phenyl group with the 
carboxylic acid.  
R
N O
R
NH2
61a, R = OMe, 47%
61b, R = Me, 47%
R
HN O
Cl
a b
57a, R = OMe
57b, R = Me 60
 
Scheme 9: Synthesis of pyrrolidinone derivatives 60a-b 
Reagents & Conditions: a. 4-chlorobutanoyl chloride, Na2HPO4, CHCl3, rt, 22 hrs; b. NaH, THF, 0 °C - rt, 
30 min. 
To probe the function of the isooxindole ring (ring B), 
compounds 63a-h (Table 5) were synthesized by the ring-
opening of cyclohexane dicarboxylic acid anhydride by an 
aniline. These were synthesized based on compounds 52. 
These were synthesized to introduce more flexibility to the 
molecule by removing ring B while keeping the other rings intact. The aromatic ring in 
39 was replaced by the cyclohexyl ring in compounds 63a-h.  
 
 
 
 
N
O
OHO
Ring B
Ring A
Ring C
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Table 5: Synthesis of substituted cyclohexane carboxylic acids (63a-h) 
N
H
O
O OH
R
(+) -63a-h
O
O
O
62
 
Reagents & Conditions: a. RC5H5NH2, CHCl3, rt, 2 hrs 
Entry R Yield (%) 
63a 4-OCH3 85 
63b 2,4-F2 69 
63c 4-Cl 93 
63d 4-Br 74 
63e 4-CH3 87 
63f 4-CH(CH3)2 83 
63g 4-CF3 98 
63h 4-CO2Et 84 
 
Compounds 65a-g, (Table 6), were synthesized by ring opening of succinic 
anhydride with an aniline. In these cases, the indole carboxylic acid has been replaced in 
part by a more conformationally flexible succinamide group while keeping the carbon 
backbone intact. 
Table 6: Synthesis of substituted oxobutanoic acids (52a-g) 
65a-g
HN
O
COOH
R
O
O
O
64
 
Reagents & Conditions: a. RC5H5NH2, CHCl3, rt, 2 hrs. 
 
Entry R Yield (%) 
65a 4-OCH3 81 
65b 2,4-F2 99 
65c 4-Cl 92 
65d 4-Br 97 
65e 4-CH3 91 
65f 4-CH(CH3)2 98 
65g 4-CO2Et 82 
 
Compounds 56-65 exhibited no significant activity for Shp2. The above results 
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proved that the isooxindole ring and the carboxylic acid group were critical for Shp2 
activity.  
It was found that the compound 52a lost its activity completely when the 
carboxylic acid is removed. This showed that the carboxylic acid was very important for 
the activity as it possibly mimics the phosphate group of phospho-tyrosine. Having 
proved that the isooxindole ring with the carboxylic acid is important for Shp2 activity, 
other isooxindole compounds (Table 6), were synthesized using the synthetic route 
shown in Scheme 5 and were tested using DiFMUP assay for Shp2 activity. 
As shown in table 6, compounds 52f, 52g and 52h were found to have IC50’s 8.9 
µM, 3.6 µM and 0.7 µM respectively. Compound 52h was found to be the most potent 
amongst these compounds with an IC50 of 700 nM.  
The sodium salt 54 of the parent compound, 52a was found to be equally potent 
as compound 54h with an IC50 of 700 nM. The free carboxylic acid was converted into 
the corresponding methyl ester (53a) and ethyl ester (53b) using thionyl chloride and the 
corresponding alcohol (Scheme 10). Unfortunately, the compounds 53a and 53b showed 
no activity for Shp2.  
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Scheme 10: Synthesis of esters of 53a and 54b 
Reagents & Conditions: a. SOCl2, ROH, µw, 60 °C, 15 min. 
The carboxylic acid group in 53a and 53b were also replaced with the nitro group. 
This compound was synthesized with the objective of replacing the carboxylic acid with 
a tetrazole ring, a non-classical bioisostere of carboxylic acid. The 7-nitro isooxindole 69 
was synthesized as shown in Scheme 11,150 starting from 2-methyl-6-nitrobenzoic acid 
66. The carboxylic acid was converted into the corresponding methyl ester 67 under basic 
conditions using methyl iodide and potassium carbonate. Bromination of 67 using NBS 
in CCl4 afforded methyl 2-(bromomethyl)-6-nitrobenzoate 68. Compound 68 on 
treatment with p-anisidine in the microwave reactor afforded 7-nitro isooxindole 69. 
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Compound 69 was tested for Shp2 inhibition in the DiFMUP assay and was found to 
exhibit no activity for Shp2. 
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Scheme 11: Synthesis of 7-nitro isooxindole (56) 
Reagents and conditions: a. Methyl iodide, Potassium carbonate, acetone, reflux, 18 hrs; b. NBS, CCl4, 
reflux, 38 hrs, c. p-anisidine, DMF; 150 °C, 15 min;  
Using the synthetic route shown in scheme 6 for compounds 52a-h, the point of 
diversity could be introduced only in the initial stage of the reaction. To facilitate parallel 
synthesis and vary the substituents at a later stage, an alternate route was followed in our 
lab and the isooxindole hit 52a, was synthesized using the new route (Scheme 12).  
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Scheme 12: Synthesis of isoindoline hits 52a, 52g and 52h 
Reagents and conditions: a. maleic anhydride, toluene, rt, 16 hrs; b. tetramethylene sulfone, Con. H2SO4,  
-55 °C – rt, 6 hrs; c. H2SO4, MeOH, reflux, 16 hrs; d. NBS, DCM, rt, 16 hrs; e. substituted aniline, µw, 150 
°C, 15 min; f. 
 
1M LiOH, MeOH, µw, 150 °C, 15 min, 1M HCl. 
The analytical data (1H NMR, 13C NMR, LCMS) obtained for compound 52 
(from Scheme 12) was similar when compared to the analytical data of the compound 
prepared using the route outlined in Scheme 6. However, compound 52a synthesized 
through the new synthetic route (scheme 12) exhibited no inhibitory activity for Shp2. 
Compounds 52g and 52h were also synthesized using scheme 12 because of this 
abnormal change in activity of 52a and they had similar analytical data to the compounds 
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prepared using the earlier route. The compounds 52g and 52h synthesized by the new 
route also turned out to be inactive. This unusual behavior made us re-confirm the 
activity of the original hit 52a, using the approach illustrated in scheme 6. While the 
compounds re-synthesized by the initial route (scheme 6) showed activity in the same 
scale as before, the compounds synthesized using the alternate route (Scheme 12) failed 
to exhibit any inhibitory activity for Shp2 in the DifMUP assay. Hence we concluded that 
the activity of the compounds would have been due to some minor impurity produced 
during the course of the synthesis, which was not detectable either by NMR or by LCMS. 
Since all the above compounds proved unsuccessful as Shp2 inhibitors, we 
decided to turn our attention towards the synthesis of isatin derivatives (Fig. 46) based on 
the hits obtained previously.  
6.3 Hit-to-Lead approach based on previous hits, NSC117199 and RPM744 
Isatin derivatives 6 and 7 were found to exhibit Shp2 activity with an IC50 of a 
few micromolar. These compounds were based on the compounds NSC-87877 and NSC-
127199101 (Fig. 46) obtained from the screen of the NCI Diversity set at the Moffitt 
Cancer Center.  
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Fig. 46: Isatin hits for Shp2 
6.3.1 Synthesis of urea derivatives 
 Substituted ureas were synthesized based on the results of isatin compounds 
previously screened for Shp2 inhibition. Ureas are 
considered non-classical bioisosteres of amides; 
the amide group in isatin was replaced with the 
much flexible urea linker. The urea linker can 
orientate the two-aryl groups, in a similar manner 
to the isatin, NSC-87877. Diarylureas 78a-e were synthesized using an efficient 
microwave synthesis of methyl 2-isocyanatobenzoate and the corresponding aniline by 
6, IC50 : 0.8 ± 0.22 mM
N
H
N
O
HO2C
NH
HO2C
N
H
HO2C
O
N
H
R
78 a-e
 60 
heating at at 100 °C for 10 min to give 77a-e. Then a microwave-assisted saponification 
of the esters 77a-e gave the desired compounds 78a-e (Table 7). 
Table 7: Synthesis of urea derivatives (78a-e) 
NH2
77a-e 78a-e
a bN
H
NO H
O
O
N
H
NO H
O
OH
R
R1
R2
R3
R
R1
R2
R3
R
R1
R2
R3
76
 
Reagents & Conditions: a. Methyl 2-isocyanatobenzoate, THF, µw, 100 °C, 10 min; b. 1M NaOH, 
MeOH, µw, 60 °C, 10 min. 
Entry R R1 R2 R3 
Yield 
(%) 
78a H COOH H H 73 
78b COOH H H H 73 
78c H H COOH H 79 
78d H OH COOH H 88 
78e H H OH COOH 60 
 
6.3.2 Synthesis of isatin derivatives 
Compound RPM744 was found to have an IC50 of 0.98 µM for Shp2. Although 
RPM744 exhibited good inhibitory activity, it 
lacked cell permeability. Therefore we decided to 
synthesize isatin derivatives introducing 
hydrophilic groups at the sulfonamide terminus of 
RPM744 aiming at improving the cell 
permeability. Compounds 82a-x were 
synthesized as illustrated (Table 8). Isatin-5-sulfonic acid 79 was treated with POCl3 at 
60 °C to give the Isatin-5-sulfonyl chloride 80. Compound 80 was then treated with the 
corresponding amines in a microwave-assisted reaction using diisopropyl ethylamine as 
base to afford the sulfonamides 81a-m. The sulfonamides 81a-m were treated with the 
corresponding hydrazine benzoic acids to afford compounds 82 a-x.  
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Table 8: Synthesis of 82a-x 
80, 56%
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Reagents and Conditions: a. POCl3, Tetramethylene sulfone, 60 °C, 3 hrs; b. DIPEA, 4-fluorophenyl 
hydrazine, µw, 60 °C, 10 min; c. 4-hydrazinobenzoic acid, EtOH, 1M HCl, µw, 120 °C, 15 min. 
 
Entry R R1 Yield (%) IC50 (µM) 
82a 4-fluorophenylpiperazine 4-COOH 34 15.1 
82b 4-morpholinoaniline 4-COOH 29 3.2 
82c 2-morpholinoethanamine 4-COOH 17 >300 
82d 1-((1,3-dihydroisobenzofuran-5-yl)methyl)piperazine 4-COOH 46 >300 
82e isoxazol-3-amine 4-COOH 22 >300 
82f 2H-tetrazol-5-amine 4-COOH 10 >300 
82g 1-(3-chlorophenyl)piperazine 4-COOH 25 >300 
82h 1-(3-(trifluoromethyl)phenyl)piperazine 4-COOH 65 >300 
82i 1-(3,4-dichlorophenyl)piperazine 4-COOH 40 16.7 
82j 1-(2,3-dichlorophenyl)piperazine 4-COOH 13 39.8 
82k 1-(3-methoxyphenyl)piperazine 4-COOH 60 57.5 
82l 1-(3-chlorobenzyl)piperazine 4-COOH 25 39.8 
82m 1-cyclohexylpiperazine 4-COOH 62 >300 
82n 4-fluorophenylpiperazine 3-COOH Quantitative >300 
82o 4-morpholinoaniline 3-COOH 37 >300 
82p 2-morpholinoethanamine 3-COOH 43 >300 
82q isoxazol-3-amine 3-COOH 47 17.8 
82r 1-(3-chlorophenyl)piperazine 3-COOH 22 >300 
82s 1-(3-(trifluoromethyl)phenyl)piperazine 3-COOH 39 42.7 
82t 1-(3,4-dichlorophenyl)piperazine 3-COOH 35 29.5 
82u 1-(2,3-dichlorophenyl)piperazine 3-COOH 11 52.5 
82v 1-(3-methoxyphenyl)piperazine 3-COOH 51 >300 
82w 1-(3-chlorobenzyl)piperazine 3-COOH 49 22.1 
82x 1-cyclohexylpiperazine 3-COOH 49 >300 
 
The piperazine substituents, ‘R’ were chosen based on other hits for Shp2. The 
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piperazine ring structure is also found in some antibiotics (piperacillin) and anti-psycotic 
drugs (clozapine). The morpholino, isoxazol and tetrazol substituents were chosen to 
introduce more diversity in the sulfonamide terminus of the molecule. 
The compounds 82a-x were analyzed by 1H NMR, 13C NMR and LCMS. All the 
compounds except 82e, 82f and 82q displayed multiplets in the upfield region of the 1H 
NMR indicating the piperazine/morpholine protons. Compound 82b showed two triplets 
at 2.95 and 3.63 ppm in the 1H NMR spectrum indicative of the morpholine protons. The 
protons in the phenyl ring, attached to the morpholine group 
showed as two doublets in the 1H NMR spectrum and so do the 
phenyl group attached to the hydrazine group. The latter is 
shifted downfield indicative of the electron withdrawing 
groups present. A singlet at 9.71 ppm indicated the –NH group 
of the isatin ring, while a sharp singlet at 11.44 ppm indicates 
the –NH group of the hydrazine. The sharp peak of the 
hydrazone proton confirmed the Z configuration of the 
compound, since the NH of the hydrazone is involved in 
intramolecular hydrogen bonding with the carbonyl group of the oxindole. Another sharp 
singlet at 12.74 ppm indicates the proton of the carboxylic acid. 
The isatin compounds 82a-x synthesized, were tested for Shp2 inhibitory activity 
using the DifMUP assay (Table 8). Some piperazine substituents also exhibited moderate 
inhibitory activity for Shp2. Compound 82a showed an IC50 of 15.1 µM, the 3-chloro 
phenylpiperazine derivative 82w exhibited an IC50 of 22.1 µM, however compound 82g 
exhibited no inhibitory activity for Shp2. The 1-(3,4 dichlorophenyl)piperazine 
derivatives, 82i and 82t had IC50‘s of 16.7 and 29.5 µΜ respectively. The most potent 
compound in this series, 82b exhibited an IC50 of 3.2 ± 1 µM, but less potent than the 
previous hit RPM744 (IC50 0.98 ± 2 µM). Although compound 82b displayed less 
potency than the previous hit RPM744, it opens up further avenues for SAR studies. 
Morpholine group is chemically very stable and has a strong dipole. The morpholine ring 
structure is also found in some drugs: anti-depressent drug minaprine (cantor) and the 
vasodilating drug molsidomine. We anticipate that the hydrophilicity of the morpholine 
ring might improve the water solubility of the compound, and hence its cell permeability. 
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Testing compound 82b in cell-based assay would open-up further avenues for SAR and 
cell permeability studies on these compounds. 
6.4 Conclusion 
 In the search for novel small molecule inhibitors for Shp2, an efficient and fast 
microwave-assisted synthesis of quinolones has been developed. Applicability to a broad 
range of substrate and ease of synthesis makes this reaction valuable for the synthesis of 
various quinolones in a combinatorial fashion. An efficient microwave-assisted synthesis 
of imines has been successfully developed. This reaction was found to be applicable to a 
variety of substrates. Imines are one of the most important intermediates in organic 
synthesis and this makes the microwave-assisted synthesis valuable in the field of organic 
chemistry. 
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Chapter 7 
 
7.0 Experimental Section 
 
7.1 General Methods and Instrumentation  
Infra red spectra were recorded on a Jasco FT-IR 400 spectrometer. NMR spectra were 
recorded on a 400 MHz Varian Mercury plus instrument at 25 °C and chemical shifts are 
referenced to TMS using the residual protio form of the solvent used (e.g. CHCl3, 
MeOH) as internal standard. Data is expressed in parts per million and reported as 
chemical shift (δ
H
), multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, q 
= quartet or m = multiplet) and relative integral. High-resolution mass spectrometry was 
carried out on an ESI-TOF Agilent Technologies LC/MSD instrument. Automated flash 
chromatography was conducted using a Flashmaster II system (Argonaut-Biotage), using 
Biotage silica cartridges. Thin layer chromatography was performed using 250 µm silica 
gel 60 F254 plates (Fisher or Whatman). Compounds were visualized by ultraviolet 
fluorescence or by staining with ceric ammonium molybdate in H2SO4. Anhydrous 
solvents were obtained as follows: dichloromethane (anhydrous, 99.8% contains 50-150 
ppm hydrocarbon as stabilizer from Aldrich), dimethyl formamide (anhydrous, 99.9% 
from Aldrich), tetrahydrofuran (anhydrous, 99.9%, inhibitor free, Aldrich), acetonitrile 
(anhydrous, 99.8%, Aldrich), toluene (anhydrous, 99.8%, Aldrich), methanol (anhydrous, 
99.8%, Aldrich). High performance liquid chromatography was performed on a Jasco 
LC-NetII/ADC instrument. Microwave reactions were performed in a Biotage Initiator I 
microwave reactor. Melting points were measured on a Mel-Temp apparatus. 
 
7.2 General procedure for the synthesis of 2,2-Diethoxy-N-(2,3,4-substituted benzyl) 
ethanamines (19a-e): 
Aminoacetaldehyde diethyl acetal (1 eq) was added to a stirred solution of the aldehyde 
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in EtOH (2 mL/ mmol). The resulting solution was heated at 130 °C for 15 minutes in the 
microwave reactor. After the reaction, EtOH was evaporated and MeOH (1 mL/ mmol) 
was added. To the resulting solution, NaBH4 (2.5 eq) was added in portions and stirred at 
rt for 30 minutes. Methanol was evaporated from the resulting mixture; the aqueous layer 
was extracted with DCM, dried (Na2SO4) and evaporated to afford the product. 
 
2-((2,2-Diethoxyethylamino)methyl)-6-methoxyphenol (19a)114 
H
N OEt
OEt
OH
O
 
This was prepared from o-vanillin (5.00 g, 33.0 mmol) and aminoacetaldehyde 
diethylacetal (4.80 mL, 33.0 mmol) in a similar manner as described above. The product 
was obtained as a yellow solid, (7.40 g, 85%); The crude product was taken as such for 
the next without further purification. 1H NMR (400 MHz, CDCl3) δ 1.22 (t, J = 7.2 Hz, 
6H), 2.78 (d, J = 5.6 Hz, 2H), 3.49 (q, J = 7.2 Hz, 2H), 3.76 (q, J = 7.2 Hz, 2H), 3.88 (s, 
3H), 4.02 (s, 2H), 4.62 (t, J = 5.6 Hz, 1H), 6.63 (dd, J = 1.6, 8.0 Hz, 1H), 6.76 (t, J = 8.0 
Hz, 1H), 6.82 (dd, J = 1.6, 8.0 Hz, 1H). 
 
 
5-((2,2-Diethoxyethylamino)methyl)-2-methoxyphenol (19b) 
H
N OEt
OEt
OH
O
 
This was prepared from 3-hydroxy-4-methoxybenzaldehyde (0.500 g, 3.30 mmol) and 
aminoacetaldehyde diethylacetal (0.480 mL, 3.30 mmol) in a similar manner as described 
above. The product was obtained as a yellow solid, (0.740 g, 85%); The crude product 
was taken as such for the next without further purification. 1H NMR (400 MHz, CDCl3) δ 
1.22 (t, J = 7.2 Hz, 6H), 2.74 (t, J = 5.8 Hz, 2H), 3.48 (q, J = 7.2 Hz, 2H), 3.64 (q, J = 
7.2 Hz, 2H), 3.87 (s, 3H), 4.62 (t, J = 5.8 Hz, 1H), 6.79 (s, 2H), 6.89 (s, 1H). 
 
4-((2,2-Diethoxyethylamino)methyl)-2-methoxyphenol (19c) 
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This was prepared from 4-hydroxy-3-methoxybenzaldehyde (0.500 g, 3.30 mmol) and 
aminoacetaldehyde diethylacetal (0.480 mL, 3.30 mmol) in a similar manner as described 
above. The product was obtained as a yellow solid, (0.730 g, 82%); The crude product 
was taken as such for the next without further purification. 1H NMR (400 MHz, CDCl3) δ 
1.22 (t, J = 7.2 Hz, 6H), 2.75 (d, J = 5.6 Hz, 2H), 3.50 (q, J = 7.2 Hz, 2H), 3.66 (q, J = 
7.2 Hz, 4H), 3.86 (s, 3H), 4.64 (t, J = 5.6 Hz, 1H), 6.88 (s, 1H), 6.78-6.80 (m, 2H). 
 
N-(3,4-Dimethoxybenzyl)-2,2-diethoxyethanamine (19d) 
H
N OEt
OEt
O
O
 
This was prepared from 3,4-dimethoxybenzaldehyde (5.00 g, 31.0 mmol) and 
aminoacetaldehyde diethylacetal (4.40 mL, 31.0 mmol) in a similar manner as described 
above. The product was obtained as a yellow solid, (8.00 g, 87%); The crude product was 
taken as such for the next without further purification.  1H NMR (400 MHz, CDCl3) δ 
1.28 (t, J = 7.2 Hz, 6H), 2.75 (d, J = 5.6 Hz, 2H), 3.49 (q, J = 7.2 Hz, 2H), 3.65 (q, J = 
7.2 Hz, 2H), 3.75 (s, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 4.64 (t, J = 5.6 Hz, 1H), 6.80-6.89 
(m, 3H). 
 
2-((2,2-Diethoxyethylamino)methyl)-4-methoxyphenol (19e) 
H
N OEt
OEt
O
HO
 
This was prepared from 2-hydroxy-5-methoxybenzaldehyde (5.00 g, 32.8 mmol) and 
aminoacetaldehyde diethylacetal (4.78 mL, 32.8 mmol) in a similar manner as described 
above. The product was obtained as a pale yellow solid, (8.83 g, 88%); The crude product 
was taken as such for the next without further purification. 1H NMR (400 MHz, CDCl3) δ 
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1.28 (t, J = 7.2 Hz, 6H), 2.75 (d, J = 5.6 Hz, 2H), 3.49 (q, J = 7.2 Hz, 2H), 3.65 (q, J = 
7.2 Hz, 2H), 3.75 (s, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 4.64 (t, J = 5.6 Hz, 1H), 6.80-6.89 
(m, 3H). 
 
7.3 General procedure for the synthesis of 4-(4-aryl)-6,7,8 substituted isoquinolines 
(20a-z): 
The corresponding benzaldehyde (1.25 eq) was added to a stirred solution of the amine 7-
10 in HCl (8.0 mL/ mmol) and the resulting mixture was heated at 140 °C for 15 minutes 
in the microwave reactor. After the reaction, ammonium hydroxide was added till pH = 8 
and the mixture was filtered. The residue was washed with water and dried to give the 
product. 
 
4-(2-Chlorobenzyl)-7-methoxyisoquinolin-8-ol (20a) 
N
O
OH
Cl
 
This was prepared from 2-chlorobenzaldehyde (0.190 g, 1.40 mmol) and amine 19a 
(0.370 g, 1.40 mmol) in a similar manner as described above. The product was collected 
as a red solid (0.240 g, 83%); m.p 238-240 °C; 1H NMR (400 MHz, CDCl3) δ 3.73-4.04 
(s, 3H), 4.42 (s, 2H), 6.84 (dd, J = 1.2, 8.0 Hz, 1H), 7.04 (dt, J = 1.2, 7.6 Hz, 1H), 7.13 
(dt, J = 1.6, 8.0 Hz, 1H), 7.33 (dd, J = 0.8, 9.2 Hz, 1H), 7.39 (s, 1H), 7.41-7.44 (m, 2H), 
8.22 (s, 1H), 9.56 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 33.79, 57.19, 115.25, 127.09, 
127.97, 129.62, 130.48, 137.83, 142.35; IR (cm-1) ν 2992, 2839, 1735, 1569, 1512, 1074, 
1052; API-ES (m/z) found 300.1 (M+H)+ (100%), calculated for C17H14NO2Cl 300.0785, 
found 300.0792. 
 
4-(4-Bromobenzyl)-7-methoxyisoquinolin-8-ol (20b) 
N
O
OH
Br
 
This was prepared from 4-bromobenzaldehyde (0.260 g, 1.40 mmol) and compound 19a 
(0.370 g, 1.40 mmol) in a similar manner as described above. The product was collected 
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as a red solid (0.170 g, quantitative); m.p 210-211 °C; 1H NMR (400 MHz, CDCl3) δ 
3.96 (s, 3H), 4.32 9s, 2H), 7.17 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 
8.8 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 8.11 (s, 1H), 9.39 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 36.17, 57.17, 115.06, 117.99, 119.69, 120.36, 127.76, 130.40, 139.03, 142.55, 
146.93; IR (cm-1) ν 3009, 2963, 2949, 1739, 1541, 1456, 1371, 1074, 1014; API-ES 
(m/z) 344 (M+H)+ (100%), 346 (M+2)+ (100%), calculated for C17H14NO2Br 344.0281, 
found 344.0285. 
 
4-(2,4-Dichlorobenzyl)-7-methoxyisoquinolin-8-ol (20c) 
N
O
OH
Cl
Cl
 
 
This was prepared from 2,4-dichlorobenzaldehyde (0.240 g, 1.40 mmol) and compound 
19a (0.370 g, 1.40 mmol) in a similar manner as described above. The product was 
collected as a yellow solid (0.170 g, 82%); m.p 208-210 °C; 1H NMR (400 MHz, 
CDCl3) δ 4.00 (s, 3H), 4.37 (s, 2H), 6.74 (d, J = 8.4 Hz, 1H), 7.02 (dd, J = 2.0, 8.4 Hz, 
1H), 7.29 (br s, 1H), 7.39 (d, J = 9.2 Hz, 1H), 7.45 (d, J = 2.0 Hz, 1H), 8.22 (s, 1H), 9.57 
(s, 1H); 13C NMR (101 MHz, CDCl3) δ 33.01, 57.62, 114.35, 120.38, 120.74, 127.79, 
128.19, 129.42, 130.14, 132.47, 132.55, 134.64, 137.15, 141.67, 142.42, 143.85, 147.07; 
IR (cm-1) ν 3013, 2966, 1739, 1559, 1541, 1467, 1361, 1222, 1081, 1031; API-ES (m/z) 
found 334 (M+H)+ (100%), 336 (M+2)+ (70%), calculated for C17H13NO2Cl2 334.0396, 
found 334.0400. 
 
4-(3,5-Dimethylbenzyl)-7-methoxyisoquinolin-8-ol (20d) 
N
O
OH
 
This was prepared from 3,5-dimethylbenzaldehyde (0.110 g, 0.840 mmol) and compound 
19a (0.230 g, 0.840 mmol) in a similar manner as described above. The product was 
collected as a reddish solid (0.140 g, 71%); m.p 196-197 °C; 1H NMR (400 MHz, 
CDCl3) δ 2.20 (s, 6 H), 3.95 (s, 3H), 4.25 (s, 2H), 6.80 (br s, 3H), 7.46 (d, J = 9.2 Hz, 
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1H), 7.54 (d, J = 9.2 Hz, 1H), 8.06 (s, 1H), 9.37 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
21.48, 36.56, 57.51, 115.14, 117.99, 119.97, 126.58, 128.15, 129.51, 130.68, 138.21, 
139.97, 141.53, 142.11, 142.49, 146.73; IR (cm-1) ν 3009, 2970, 2931, 1735, 1555, 1541, 
1456, 1361, 1233, 1219, 1074, 1031; API-ES (m/z) found 294.1 (M+H)+ (100%), 
calculated for C19H19NO2 294.1488 found 294.1491. 
 
4-(Biphenyl-4-ylmethyl)-7-methoxyisoquinolin-8-ol (20e) 
N
O
OH
 
This was prepared from 4-biphenylbenzaldehyde (0.153 g, 0.90 mmol) and compound 
19a (0.240 g, 0.90 mmol) in a similar manner as described above. The product was 
collected as a yellow solid (0.220 g, 90%); m.p 252-254 °C; 1H NMR (400 MHz, 
CDCl3) δ 3.99 (s, 3H), 4.37 (s, 2H), 7.24 (br s, 1H), 7.31 (td, J = 1.6, 7.6 Hz, 1H), 7.38 
(d, J = 3.6 Hz, 1H), 7.40-7.44 (m, 4H), 7.48 (d, J = 8.0 Hz, 2H), 7.53-7.55 (m, 2H), 8.15 
(s, 1H), 10.02 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 36.38, 57.18, 104.98, 115.51, 
127.17, 127.36, 127.48, 129.09, 139.12, 141.00; IR (cm-1) ν 3181, 3150, 3056, 2987, 
2960, 2905, 2833, 1793, 1686, 1590, 1278, 1075; API-ES (m/z) 342 (M+H)+ (100%) 
calculated for C23H19NO2 342.1488, found 342.1492. 
 
7-Methoxy-4-(pyridin-3-ylmethyl)isoquinolin-8-ol (20f) 
N
O
OHN
 
This was prepared from pyridine-3-carboxaldehyde (0.080 mL, 0.90 mmol) and 
compound 19a (0.240 g, 0.90 mmol) in a similar manner as described above. The product 
was collected as a red solid (0.240, quantitative); m.p 215-217 °C; 1H NMR (400 MHz, 
CDCl3) δ 3.98 (s, 3H), 4.33 (s, 2H), 7.14 (dd, J = 4.8, 7.6 Hz, 1H), 7.34-7.41 (m, 3H), 
8.30 (s, 1H), 8.45 (d, J = 4.4 Hz, 1H), 8.58 (s, 1H), 9.57 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 15.77, 28.61, 36.30, 57.18, 115.39, 117.65, 128.19, 128.21, 128.63, 130.56, 
137.24, 141.73, 146.70; IR (cm-1) ν 3019, 2970, 1866, 1739, 1622, 1559, 1279, 1078; 
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API-ES (m/z) 267 (M+H)+ (100%), calculated for C16H14N2O2 267.1128, found 
267.1130. 
 
4-(4-Ethylbenzyl)-7-methoxyisoquinolin-8-ol (20g) 
N
O
OH
 
This was prepared from 4-ethylbenzaldehyde (0.120 mL, 0.90 mmol) and compound 19a 
(0.240 g, 0.90 mmol) in a similar manner as described above. The product was collected 
as a red solid (0.160 g, 61%); m.p 179-180 °C; 1H NMR (400 MHz, CDCl3) δ 1.17 (t, J = 
7.6 Hz, 3H), 2.56 (q, J = 7.6 Hz, 2H), 3.97 (s, 3H), 4.29 (s, 2H), 7.09 (s, 4H), 7.36 (d, J = 
9.2 Hz, 1H), 7.43 (d, J = 9.2 Hz, 1H), 8.29 (s, 1H), 9.53 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 16.28, 28.37, 35.67, 57.63, 115.07, 120.09, 128.42, 128.99, 130.28, 141.75, 
141.80, 142.08, 142.22, 143.57, 146.58; IR (cm-1) ν 3021, 1740, 1563, 1461, 1349, 1267, 
1105; API-ES (m/z) 294 (M+H)+ (100%), calculated for C19H19NO2 294.1489, found 
294.1493. 
 
4-(3-Chloro-4-fluorobenzyl)-7-methoxyisoquinolin-8-ol (20h) 
N
O
OH
F
Cl
 
This was prepared from 3-fluoro-4-chlorobenzaldehyde (0.140 g, 0.90 mmol) and 
compound 19a (0.240 g, 0.90 mmol) in a similar manner as described above. The product 
was collected as a yellow solid (0.290 g, quantitative); m.p 217-219 °C; 1H NMR (400 
MHz, CDCl3) δ 3.99 (s, 3H), 4.27 (s, 2H), 7.01 (br s, 1H), 7.02 (d, J = 1.2 Hz, 1H), 7.19 
(d, J = 7.2 Hz, 1H), 7.31 (d, J = 9.0 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H), 8.28 (s, 1H), 9.56 
(s, 1H); 13C NMR (101 MHz, CDCl3) δ 35.73, 57.18, 115.06, 116.64, 116.84, 117.73, 
128.16, 128.22, 130.57, 141.97, 147.31; IR (cm-1) ν 2991, 2968, 1736, 1590, 1496, 1366, 
1281, 1178, 1115, 1060; API-ES (m/z) 318 (M+2)+ (100%) 320 (M+4)+ (30%), 
calculated for C17H13NO2ClF 318.0692, found 318.0691. 
 
4-(4-Isopropylbenzyl)-7-methoxyisoquinolin-8-ol (20i) 
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This was prepared from 4-isopropylbenzaldehyde (0.130 mL, 0.90 mmol) and compound 
19a (0.240 g, 0.90 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.0640 g, 23%); m.p 200-201 °C; 1H NMR (400 MHz, CDCl3) δ 
1.20 (d, J = 6.8 Hz, 6H), 2.83 (heptet, J = 6.8 Hz, 1H), 3.98 (s, 3H), 4.29 (s, 2H), 7.11 
(br s, 4H), 7.37 (d, J = 9.0 Hz, 1H), 7.44 (d, J = 9.0 Hz, 1H), 8.29 (s, 1H), 9.52 (s, 1H); 
13C NMR (101 MHz, CDCl3) δ 24.22, 33.87, 36.26, 57.16, 115.16, 117.89, 126.77, 
128.65, 130.63, 137.36, 141.60, 142.09, 142.47, 146.78, 147.03; IR (cm-1) ν 3016, 2966, 
1735, 1421, 1364, 1219; API-ES (m/z) 308 (M+H)+ (100%), calculated for C20H21NO2 
308.1645, found 308.1653. 
 
4-(2,4-Dimethylbenzyl)-7-methoxyisoquinolin-8-ol (20j) 
N
O
OH
 
This was prepared from 2,4-dimethylbenzaldehyde (0.120 g, 0.900 mmol) and compound 
19a (0.240 g, 0.90 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.130 g, 50%); m.p 222-224 °C; 1H NMR (400 MHz, 
CDCl3) δ 2.29 (s, 3H), 2.33 (s, 3H), 3.99 (s, 3H), 4.24 (s, 2H), 6.69 (d, J = 7.8 Hz, 1H), 
6.84 (d, J = 7.8 Hz, 1H), 7.04 (br s, 1H), 7.39 (br s, 2H), 8.08 (s, 1H), 9.53 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 24.22, 33.87, 36.26, 57.16, 115.16, 117.89, 126.77, 128.65, 
130.63, 137.36, 141.60, 142.09, 142.47, 146.78, 147.03; IR (cm-1) ν 3019, 2963, 1735, 
1537, 1474, 1446, 1364, 1215, 1092, 1060; API-ES (m/z) 293 (M+H)+ (100%), 
calculated for C19H19NO2 294.1489, found 294.1491. 
 
7-Methoxy-4-(4-(pyridin-2-yl)benzyl)isoquinolin-8-ol (20k) 
N
O
OH
N
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This was prepared from 4-(2-pyridyl)benzaldehyde (0.150 g, 0.900 mmol) and compound 
19a (0.240 g, 0.900 mmol) in a similar manner as described above. The product was 
collected as a yellow solid (0.300 g, 99%); m.p 232-234 °C; 1H NMR (400 MHz, 
CDCl3) δ 3.96 (s, 3H), 4.38 (s, 2H), 7.18 (ddd, J = 1.2, 4.8, 7.2 Hz, 1H), 7.27 (d, J = 8.4 
Hz, 2H), 7.34 (d, J = 9.0 Hz, 1H), 7.39 (d, J = 9.0 Hz, 1H), 7.65 (td, J = 1.0, 8.0 Hz, 
1H), 7.69 (dt, J = 2.0, 7.2 Hz, 1H), 7.87 (d, J = 8.4 Hz, 2H), 8.35 (s, 1H), 8.65 (d, J = 4.8 
Hz, 1H), 9.56 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 36.60, 57.16, 115.37, 117.77, 
120.58, 122.16, 127.30, 127.69, 128.93, 130.47, 136.92, 137.71, 141.15, 141.94, 142.38, 
147.03, 149.80, 157.41;  IR (cm-1) ν 3019, 2966, 2938, 1739, 1541, 1456, 1364, 1215, 
1081; MS API-ES (m/z) 343 (M+H)+, calculated for C22H18N2O2 343.1441, found 
343.1443. 
 
7-Methoxy-4-(2-(trifluoromethyl)benzyl)isoquinolin-8-ol (20l) 
N
O
OH
CF3
 
This was prepared from 2-trifluoromethylbenzaldehyde (0.110 mL, 0.900 mmol) and 
compound 19a (0.240 g, 0.900 mmol) in a similar manner as described above. The 
product was collected as a red solid (0.170 g, 55%); m.p 200-202 °C; 1H NMR (400 
MHz, CDCl3) δ 3.98 (s, 3H), 4.38 (s, 2H), 7.30-7.36 (m, 3H), 7.38 (d, J = 9.2 Hz, 1H), 
7.44-7.49 (m, 2H), 8.29 (s, 1H), 9.58 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 36.50, 
57.17, 115.07, 117.66, 123.47, 129.21, 130.18, 132.00, 141.05, 147.30; IR (cm-1) ν 2960, 
1735, 1565, 1357, 1286, 1156, 1071; API-ES (m/z) 333 (M+H)+ (100%), calculated for 
C18H14NO2F3 334.1049, found 334.1056. 
 
4-(3,5-Dibromobenzyl)-7-methoxyisoquinolin-8-ol (20m) 
N
O
OHBr
Br
 
This was prepared from 3,5-dibromobenzaldehyde (0.110 g, 0.420 mmol) and compound 
19a (0.110 g, 0.420 mmol) in a similar manner as described above. The product was 
 73 
collected as a red solid (0.210 g, quantitative); m.p 244-246 °C; 1H NMR (400 MHz, 
CDCl3) δ 4.00 (s, 3H), 4.26 (s, 2H), 7.25 (br s, 2H), 7.28 (d, J = 9.2 Hz, 1H), 7.40 (d, J = 
9.2 Hz, 1H), 7.49 (t, J = 1.6 Hz, 1H), 8.28 (s, 1H), 9.57 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 36.07, 57.19, 114.93, 117.91, 123.32, 127.47, 130.03, 130.44, 131.41, 132.36, 
142.02, 142.50, 144.17, 147.50; IR (cm-1) ν 3009, 1743, 1364, 1226, 1081; API-ES (m/z) 
422 (M+H)+ (45%), 424 (M+2)+ (100%), 427 (M+4)+ (45%), calculated for 
C17H13Br2NO2 343.1441, found 343.1443. 
 
4-(2,3-Dichlorobenzyl)-7-methoxyisoquinolin-8-ol (20n)  
N
O
OH
Cl
Cl
 
This was prepared from 2,3-dichlorobenzaldehyde (0.0740 g, 0.420 mmol) and 
compound 19a (0.110 g, 0.420 mmol) in a similar manner as described above. The 
product was collected as a yellow solid (0.100 g, 80%); m.p 228-230 °C; 1H NMR (400 
MHz, CDCl3) δ 4.00 (s, 3H), 4.45 (s, 2H), 6.71 (dd, J = 1.6, 7.8 Hz, 1H), 6.98 (t, J = 7.6 
Hz, 1H), 7.27 (d, J = 9.0 Hz, 1H), 7.33 (dd, J = 1.6, 7.6 Hz, 1H), 7.39 (d, J = 9.0 Hz, 
1H), 8.22 (s, 1H), 9.58 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 34.73, 57.18, 115.01, 
117.78, 127.36, 127.48, 128.52, 128.79, 130.28, 142.11, 147.28; API-ES (m/z) 334 
(M+H)+ (100%) 336 (M+2)+ (70%), calculated for C17H13NO2Cl2 334.0396, found 
334.0394. 
 
7-Methoxy-4-(pyridin-4-ylmethyl)isoquinolin-8-ol (20o) 
N
O
OH
N
 
This was prepared form 4-pyridylbenzaldehyde (0.0800 mL, 0.840 mmol) and compound 
19a (0.230 g, 0.840 mmol) in a similar manner as described above. The product was 
collected as a yellow solid (0.150 g, 65%); m.p 221-222 °C; 1H NMR (400 MHz, 
CDCl3) δ 3.99 (s, 3H), 4.32 (s, 2H), 7.08 (d, J = 5.6 Hz, 2H), 7.26 (d, J = 8.8 Hz, 1H), 
7.37 (d, J = 8.8 Hz, 1H), 8.33 (s, 1H), 8.46 (d, J = 5.6 Hz, 2H), 9.58 (s, 1H); IR (cm-1) 
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ν 3026, 2966, 1739, 1555, 1272, 1156, 1084; API-ES (m/z) 267 (100%), calculated for 
C16H14N2O2 267.1128, found 267.1134. 
 
4-(2,6-Dichlorobenzyl)-7-methoxyisoquinolin-8-ol (20p) 
N
O
OH
Cl
Cl
 
This was prepared from 2,6-dichlorobenzaldehyde (0.150 g, 0.840 mmol) and compound 
19a (0.230 g, 0.840 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.180 g, 64%); m.p 219-221 °C; 1H NMR (400 MHz, CDCl3) δ 
4.05 (s, 3H), 4.65 (s, 2H), 7.21 (d, J = 8.8 Hz, 1H), 7.39 (d, J = 8.0 Hz, 2H), 7.53 (d, J =  
8.8 Hz, 1H), 7.62 (br s, 1H), 7.67 (dd, J = 0.8, 8.8 Hz, 1H), 9.50 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 31.68, 57.27, 113.98, 117.70, 119.27, 126.27, 129.03, 134.95, 136.68, 
142.50, 146.52; IR (cm-1) ν 3023, 2970, 1739, 1435, 1226, 1084; API-ES (m/z) 334 
(M+H)+ (100%) 336 (M+2)+ (70%), calculated for C17H13NO2Cl2 334.0396, found 
334.0404. 
 
4-(3-Fluorobenzyl)-7-methoxyisoquinolin-8-ol (20q) 
N
O
F
OH
 
This was prepared from 3-fluorobenzaldehyde (0.200 g, 0.675 mmol) and compound 19a 
(0.104 g, 0.844 mmol) in a similar manner as described above. The product was collected 
as a red solid (0.224 g, 64%); m.p. 189-191 °C; 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 
3H), 4.15 (s, 2H), 6.87-6.96 (m, 2H), 6.98 (d, J = 8.0 Hz, 1H), 7.19 (m, 2H), 7.34 (m, 
1H), 8.30 (s, 1H), 9.57 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 36.43, 51.18, 104.98, 
113.35, 113.56, 115.26, 115.51, 117.67, 124.30, 124.33, 130.12, 130.20, 130.31, 141.95, 
142.30, 147.07; MS API-ES (m/z) 284 (M+H)+ (100%), calculated for C17H14NO2F 
284.1081 found 284.1086. 
 
4-(3-Fluorobenzyl)-7-methoxyisoquinolin-8-ol (20r) 
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N
O
OH
F
 
This was prepared from 4-fluorobenzaldehyde (0.100 g, 0.337 mmol) and compound 19a 
(0.0836 g, 0.422 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.090 g, 95%); m.p. 230-231 °C; 1H NMR (400 MHz, CDCl3) δ 
3.98 (s, 3H), 4.29 (s, 2H), 6.92 (m, 2H), 7.11 (m, 2H), 7.37 (s, 2H), 8.28 (s, 1H), 9.54 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ 32.91, 35.93, 50.28, 56.23, 57.17, 115.19, 115.64, 
116.19, 116.68, 117.66, 117.97, 130.01, 130.36, 132.39, 141.85, 142.32, 147.00, 190.69; 
MS API-ES (m/z) 284 (M+H)+ (100%), calculated for C17H14NO2F 284.1081 found 
284.1087. 
 
4-(4-bromobenzyl)-7-methoxyisoquinolin-6-ol (20s) 
N
OH
O
Br
 
This was prepared form 4-bromobenzaldehyde (0.100 g, 0.337 mmol) and compound 19c 
(0.0780 g, 0.422 mmol) in a similar manner as described above. The product was 
collected as a yellow solid (0.0995 g, 89%); m.p 209-210 °C; 1H NMR (400 MHz, 
CDCl3) δ 4.06 (s, 3H), 4.22 (s, 2H), 7.01-7.04 (m, 2H), 7.15 (d, J = 7.2 Hz, 1H), 7.18 (d, 
J = 0.8 Hz, 1H), 7.24 (s, 1H), 8.22 (s, 1H), 8.96 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
29.92, 35.65, 56.34, 105.54, 106.06, 116.63, 116.84, 121.10, 121.84, 124.83, 127.81, 
128.15, 128.22, 130.52, 132.13, 136.87, 136.91, 142.24, 148.61, 149.71, 150.62, 155.71, 
158.17; API-ES (m/z) 344 (M+H)+ (100%), 346 (M+2)+ (100%), calculated for 
C17H14NO2Br 344.0280, found 344.0285. 
 
4-(3-chloro-4-fluorobenzyl)-7-methoxyisoquinolin-6-ol (20t) 
N
OH
O
F
Cl
 
This was prepared form 3-chloro-4-fluorobenzaldehyde (0.140 g, 0.840 mmol) and 
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compound 19c (0.220 g, 0.840 mmol) in a similar manner as described above. The 
product was collected as a yellow solid (0.0900 g, 82%); m.p 209-210 °C; 1H NMR (400 
MHz, CDCl3) δ 4.06 (s, 3H), 4.22 (s, 2H), 7.01-7.04 (m, 2H), 7.15 (d, J = 7.2 Hz, 1H), 
7.18 (d, J = 0.8 Hz, 1H), 7.24 (s, 1H), 8.22 (s, 1H), 8.96 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 29.92, 35.65, 56.34, 105.54, 106.06, 116.63, 116.84, 121.10, 121.84, 124.83, 
127.81, 128.15, 128.22, 130.52, 132.13, 136.87, 136.91, 142.24, 148.61, 149.71, 150.62, 
155.71, 158.17; API-ES (m/z) 318 (M+H)+ (100%) 320 (M+2)+ (30%), calculated for 
C17H13NO2ClF 318.0692, found 318.0694. 
 
4-(4-fluorobenzyl)-7-methoxyisoquinolin-6-ol (20u) 
N
OH
O
F
 
This was prepared from 4-fluorobenzaldehyde (0.0500 g, 0.420 mmol) and compound 
19c (0.110 g, 0.420 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.170 g, quantitative); m.p. 125-126 °C; 1H NMR (400 MHz, 
CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 4.06 (s, 3H), 4.25 (s, 2H), 6.92 (d, J = 8.8 Hz, 
2H), 7.11 (dd, J = 5.6, 7.4 Hz, 2H), 7.25-7.26 (m, 2H), 8.21 (s, 1H), 8.97 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 35.17, 56.37, 106.11, 107.51, 115.69, 115.90, 130.75, 131.97, 
136.75, 136.78, 140.92, 148.85, 150.40, 152.41, 160.17, 162.57; MS API-ES (m/z) 284 
(M+H)+ (100%), calculated for C17H14NO2F 284.1081, found 284.1088. 
 
4-(3-fluorobenzyl)-7-methoxyisoquinolin-6-ol (20v) 
N
OH
O
F
 
This was prepared from 3-fluorobenzaldehyde (0.150 g, 0.840 mmol) and compound 19c 
(0.230 g, 0.840 mmol) in a similar manner as described above. The product was collected 
as a red solid (0.220 g, 64%); m.p. 132-133 °C; 1H NMR (400 MHz, CDCl3) δ 4.06 (s, 
3H), 4.27 (s, 2H), 6.82-6.90 (m, 2H), 6.96 (d, J = 7.6 Hz, 1H), 7.21-7.24 (m, 3H), 8.24 (s, 
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1H), 8.97 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 35.72, 56.34, 106.00, 107.38, 113.46, 
113.67, 115.67, 115.88, 124.69, 125.12, 125.14, 128.08, 130.91, 130.99, 131.71, 141.84, 
143.77, 149.45, 150.28, 152.09, 161.68, 164.10; MS API-ES (m/z) 284 (M+H)+ (100%), 
calculated for C17H14NO2F 284.1081 found 284.1086. 
 
4-(2,3-dichlorobenzyl)-7-methoxyisoquinolin-6-ol (20w) 
N
OH
O
Cl
Cl
 
This was prepared from 2,3-dichlorobenzaldehyde (0.100 g, 0.337 mmol) and compound 
19c (0.0738 g, 0.422 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.111 g, 99%); m.p. 132-133 °C; 1H NMR (400 MHz, CDCl3) δ 
4.06 (s, 3H), 4.27 (s, 2H), 6.82-6.90 (m, 2H), 6.96 (d, J = 7.6 Hz, 1H), 7.21-7.24 (m, 3H), 
8.24 (s, 1H), 8.97 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 34.49, 56.32, 105.47, 107.35, 
124.57, 126.20, 128.80, 129.31, 129.55, 131.61, 131.81, 132.59, 140.61, 142.29, 149.97, 
150.38, 152.25; MS API-ES (m/z) 334 (M+H)+ (100%) 336 (M+2)+ (30%), calculated for 
C17H13NO2Cl2 334.0396 found 334.0396. 
 
4-(2,4-dichlorobenzyl)-7-methoxyisoquinolin-6-ol (20x) 
N
OH
O
Cl
Cl
 
This was prepared from 3-fluorobenzaldehyde (0.100 g, 0.337 mmol) and compound 19c 
(0.0738 g, 0.422 mmol) in a similar manner as described above. The product was 
collected as a red solid (0.113 g, quantitative%); m.p. 132-133 °C; 1H NMR (400 MHz, 
CDCl3) δ 4.06 (s, 3H), 4.27 (s, 2H), 6.82-6.90 (m, 2H), 6.96 (d, J = 7.6 Hz, 1H), 7.21-
7.24 (m, 3H), 8.24 (s, 1H), 8.97 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 33.07, 56.34, 
105.52, 107.41, 124.61, 126.32, 128.15, 129.40, 131.59, 132.28, 132.44, 134.73, 137.03, 
142.10, 149.85, 150.34, 152.17; MS API-ES (m/z) 334 (M+H)+ (100%) 336 (M+2)+ 
(30%), calculated for C17H13NO2Cl2 334.0396 found 334.0404. 
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4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)aniline (20y) 
N
O
O
H2N
 
This was prepared from p-aminobenzaldehyde (0.240 g, 2.00 mmol) and compound 19d 
(0.500 g, 1.60 mmol) in a similar manner as described above. The product was collected 
as a yellow solid (0.0950 g, 73%); m.p. 160-161 °C (lit151 166-167 °C); 1H NMR (400 
MHz, CDCl3) δ 3.87 (s, 3H), 4.00 (s, 3H), 4.19 (s, 2H), 6.58 (d, J = 8.8 Hz, 2H), 6.98 (d, 
J = 8.8 Hz, 2H), 7.10 (s, 1H), 7.18 (s, 1H), 8.27 (s, 1H), 8.95 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 36.21, 56.20, 102.49, 106.01, 115.57, 125.01, 129.40, 129.55, 129.94, 
131.70, 142.60, 144.88, 149.31, 150.10, 152.86; API-ES (m/z) 296 (M+H)+ (100%), 
calculated for C18H18N2O2 295.1441, found 295.1450. 
 
4-(3-Chloro-4-fluorobenzyl)-6,7-dimethoxyisoquinoline (20z) 
S
H
N
HO
O
 
This was prepared from compound 19d (0.170 g, 0.600 mmol) and 3-chloro-4-fluoro 
benzaldehyde (0.200 g, 0.600 mmol) in a similar manner as described above. The product 
was collected as a red solid (0.170 g, 94%); m.p. 126-127 °C; 1H NMR (400 MHz, 
CDCl3) δ 3.88 (s, 3H), 4.02 (s, 3H), 4.26 (s, 2H), 6.97 (s, 1H), 7.03-7.05 (m, 2H), 7.23-
7.24 (m, 2H), 8.27 (s, 1H), 9.00 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 34.74, 56.33, 
56.43, 102.68, 106.98, 117.35, 119.94, 125.15, 129.77, 130.94, 132.65, 138.89, 142.62, 
150.45, 153.32, 155.16, 157.59, 191.53; MS API-ES (m/z) found 332 (M+H)+ (100%), 
334 (30%), calculated for C18H15NO2ClF 332.0396 found 332.0404. 
 
N-(4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)phenyl)benzamide (26a) 
N
O
O
N
H
O
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4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)aniline (20y) (0.200 g, 0.700 mmol) was 
dissolved in THF (5 mL). To this solution, benzoic acid (0.080 g, 0.700 mmol), HATU 
(0.390 g, 1.00 mmol) and DIPEA (0.450 mL, 2.77 mmol) were added and heated at 100 
°C for 10 min. in the microwave reactor. The resulting mixture was extracted with EtOAc 
(3 × 5 mL), washed with satd. NaHCO3 (5 mL), dried (Na2SO4) and evaporated. The 
crude product was column purified using EtOAc-hexane (1:3, v/v) to give 26a (0.030 g, 
9.2%) as a yellow solid; m.p. 185-186 °C; 1H NMR (400 MHz, CDCl3) δ 3.90 (s, 3H), 
4.02 (s, 3H), 4.32 (s, 2H), 7.09 (s, 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.46-7.49 (m, 2H), 7.53-
7.58 (m, 3H), 7.86 (dd, J = 1.6, 6.8 Hz, 3H), 8.27 (s, 1H), 9.01 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 36.44, 56.24, 102.28, 106.13, 120.65, 127.24, 128.80, 129.29, 131.67, 
132.02, 135.14, 136.12, 136.62, 142.55, 149.45, 150.25, 153.12, 165.98; MS API-ES 
(m/z) found 398 (M+H)+ (100%); calculated for C25H22N2O3 399.1703, found 399.1704.  
 
N-(4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)phenyl)-3,4,5-trimethoxybenzamide 
(26b) 
N
O
O
N
H
O
O
O
O
 
4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)aniline (20y) (0.100 g, 0.340 mmol) was 
dissolved in DCM (2 mL). To this solution, 3,4,5 trimethoxybenzoyl chloride (0.0800 g, 
0.340 mmol) and pyridine (0.0300 mL, 0.400 mmol) were added and heated at 60 °C for 
10 minutes in the microwave reactor.  The resulting solution was evaporated and washed 
with CHCl3 to give 26b (0.0250 g, 15%) as an off-white solid; m.p. 110-112 °C; 1H NMR 
(400 MHz, CDCl3) δ 3.86 (s, 6H), 3.88 (s, 6H), 3.99 (s, 3H), 4.28 (s, 2H), 7.04 (s, 1H), 
7.13-7.18 (m, 5H), 7.52 (d, J = 8.4 Hz, 2H), 8.25 (s, 1H), 8.39 (s, 1H), 8.93 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 36.39, 56.23, 56.55, 61.15, 102.25, 104.82, 106.09, 115.57, 
120.76, 125.05, 128.85, 129.24, 129.54, 130.58, 131.63, 136.04, 136.70, 141.35, 142.60, 
149.47, 150.25, 153.10, 153.46, 165.81; MS API-ES (m/z) 489 (M+H)+ (100%), 
calculated for C28H28N2O6 489.2020, found 489.2026; 
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2,4-Dichloro-N-(4-((6,7-dimethoxyisoquinolin-4-yl)methyl)phenyl)benzamide (26c) 
N
O
O
N
H
Cl
OCl
 
4-((6,7-Dimethoxyisoquinolin-4-yl)methyl)aniline (20y) (0.100 g, 0.340 mmol) was 
dissolved in THf (2 mL). To this solution, 2,4-dichlorobenzoyl chloride (0.070 g, 0.340 
mmol), HATU (0.190 g, 0.510 mmol) and DIPEA (0.170 g, 1.360 mmol) were added and 
heated at 100 °C for 10 min. in the microwave reactor. The resulting mixture was purified 
by flash column chromatography using DCM-MeOH (96-4, v/v) to give 26c (0.0200 g, 
12%); m.p. 219-220 °C; 1H NMR (400 MHz, CDCl3) δ 3.90 (s, 3H), 4.02 (s, 3H), 4.32 (s, 
2H), 7.08 (s, 1H), 7.21-7.24 (m, 3H), 7.37 (dd, J = 1.6, 6.4 Hz, 1H), 7.46 (d, J = 1.6 Hz, 
1H), 7.56 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 1H), 7.90 (s, 1H), 8.27 (s, 1H), 9.00 (s, 
1H); MS API-ES (m/z) 467 (M+H)+ (100%) 469 (M+2)+ (30%), calculated for 467.0924, 
found 467.0922. 
 
4-(3-(4-(3-Chloro-4-fluorobenzyl)-7-methoxyisoquinolin-6-yloxy)propyl)morpholine 
(26d) 
N
O
O
F
Cl
N
O
 
4-(3-Chloro-4-fluorobenzyl)-7-methoxyisoquinolin-6-ol (20t) (0.060 g, 0.180 mmol) was 
dissolved in DMF (2 mL). To this solution, K2CO3 (0.0780 g, 0.560 mmol), TBAI (0.069 
g, 0.190 mmol) and 4-(3-chloropropyl)morpholine (0.0380 g, 0.190 mmol) was added 
and heated at 80 °C for 4 hrs. The resulting solution was diluted with water (5 mL), 
extracted three times with DCM (5 mL), dried (Na2SO4) and evaporated to afford 26d 
(0.0400 g, 38%) as a yellow solid, m.p. 82-84 °C; 1H NMR (400 MHz, CDCl3) δ 1.97-
2.04 (quintet, J = 7.0 Hz, 2H), 2.45 (br s, 4H), 2.50 (t, J = 7.0 Hz, 2H), 3.70 (t, J = 4.6 
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Hz, 4H), 3.99 (s, 3H), 4.04 (t, J = 6.8 Hz, 2H), 4.25 (br s, 2H), 6.96 (s, 1H), 7.02-7.04 
(m, 2H), 7.21-7.27 (m, 2H), 8.26 (s, 1H), 8.98 (s, 1H); 19F NMR  (376 MHz, CDCl3) δ -
119.145 - -119.198 (q); 13C NMR (101 MHz, CDCl3) δ 26.02, 35.96, 53.90, 55.54, 56.22, 
67.16, 67.28, 76.73, 76.91, 77.23, 77.43, 77.55, 102.89, 106.38, 116.74, 121.12, 121.30, 
128.19, 137.12, 142.78, 149.96, 150.59, 152.58, 155.72, 158.18; IR (cm-1) ν 3002, 2956, 
1502, 1463, 1247, 1166, 1116; MS API_ES (m/z) 445 (M+H)+ (100%) 447 (M+2)+ 
(30%), calculated for C24H26N2FCl 445.1689 found 445.1700. 
 
6,7-Dihydrobenzo[b]thiophen-4(5H)-one oxime (28)127 
S
NOH
 
Hydroxylamine hydrochloride (5.10 g, 73.9 mmol) was added to a suspension of 6,7-
dihydrobenzo[b]thiophen-4(5H)-one (5.00 g, 32.8 mmol) and sodium bicarbonate (5.00 
g, 59.1 mmol) in water (75 mL). The mixture was stirred at room temperature until the 
evolution of CO2 ceased. The reaction mixture was heated at 120 °C in the microwave 
reactor for 10 minutes. After cooling to room temperature, the mixture was acidified to 
pH 3.0 (1M HCl), filtered and dried, to give the oxime 28 (4.60 g, 86%) as an off-white 
solid, m.p. 125-127 °C (lit.1, m.p. 125-127 °C) as colorless crystals; 1H NMR (CDCl3) δ 
1.97-2.04 (m, 2H), 2.79 (t, J = 6.8 Hz, 2H), 2.88 (t, J = 6.4 Hz, 2H), 7.08 (d, J = 5.4 Hz, 
1H), 7.35 (d, J  = 5.4 Hz, 1H). 
 
6,7-Dihydrobenzo[b]thiophen-4(5H)-one O-tosyl oxime (29)127 
S
NOTs
 
6,7-Dihydrobenzo[b]thiophen-4(5H)-one oxime (28) (2.00 g, 11.9 mmol) was dissolved 
in dry pyridine (4.20 mL) and cooled to 0 °C. Para-toluenesulfonyl chloride (2.50 g, 13.2 
mmol) was added and the reaction mixture was stirred at 0 °C for 1 hr. The resulting 
mixture was filtered and the residue washed with pyridine and dried to give the O-tosyl 
oxime 29 (3.84 g, 93%) as an off-white crystals, m.p. 130-131 °C (lit.1, m.p. 130-132 °C); 
1H NMR (400 MHz, CDCl3) δ 1.96-1.98 (m, 2H), 2.87 (t, J = 6.4 Hz, 2H), 2.84 (t, J = 
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6.4 Hz, 2H)), 7.05 (d, J = 4.2 Hz, 1H), 7.23 (d, J = 4.2 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 
7.91 (d, J = 8.4 Hz, 2H). 
 
7,8-Dihydro-4H-thieno[3,2-b]azepin-5(6H)-one (30)128 
S
H
N
O
 
6,7-Dihydrobenzo[b]thiophen-4(5H)-one O-tosyl oxime (29) (2.50 g, 7.80 mmol) was 
dissolved in EtOH-H2O mixture (1:1.6, 160 mL). Potassium carbonate (16.00 g, 161.00 
mmol) was added and the reaction mixture was refluxed for 22 hrs. After evaporation of 
EtOH, the aqueous layer was filtered, washed with water and dried to give the lactam 30 
(0.840 g, 42%) as a yellow solid, m.p. 133-134 °C (lit.3, m.p. 134-135 °C); 1H NMR (400 
MHz, CDCl3) δ 2.17-2.23 (m, 2H), 2.61-2.66 (m, 2H), 2. 97 (t, J = 6.8 Hz, 2H), 6.42-
6.50 (m, 1H), 6.61 (d, J = 5.4 Hz, 1H), 7.07 (d, J = 5.4 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 23.70, 27.57, 35.89, 122.59, 122.99, 125.00, 133.01, 175.65; MS m/z (API-
ES): 168  (M+H)+ (100%). 
 
Methyl 5-oxo-5-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl)pentanoate 
(31)  
S
H
N
O
O
O O
 
Methyl 5-chloro-5-oxopentanoate (0.280 mL, 2.02 mmol) was dissolved in dry DCM (2 
mL) and cooled to 0 °C. 7,8-Dihydro-4H-thieno[3,2-b]azepin-5(6H)-one (30) (0.200 g, 
1.20 mmol) was added dropwise to the above solution. To this mixture, SnCl4 (0.200 mL, 
1.80 mmol) was added in such a rate that the temperature of the reaction mixture was 
maintained between 0 °C and 10 °C. The reaction mixture was allowed to come to room 
temperature over a period of 30 min and was quenched with ice. The aqueous layer was 
extracted with DCM (3 × 5 mL), washed with 20% HCl solution (5 mL), brine, dried 
(Na2SO4) and evaporated to give 31 (0.280 g, 82%) as a brown crystalline solid; m.p. 
106-108 °C; 1H NMR (400 MHz, CDCl3) δ 1.98 (t, J = 6.8 Hz, 2H), 2.14-2.21 (m, 2H), 
2.38 (t, J = 6.8 Hz, 2H), 2.56-2.59 (m, 2H), 2.87 (t, J  = 7.0 Hz, 2H), 2.97 (t, J = 7.0 Hz, 
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2H), 3.64 (s, 3H), 7.31 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 20.05, 20.12, 20.17, 
23.95, 27.22, 32.58, 50.91, 127.37, 134.54, 135.89, 139.29, 174.14, 175.51, 192.70; MS 
m/z (API-ES): 296 (M+H)+ (100%), calculated for C14H17NO4S 296.0951, found 
296.0959. 
 
Methyl 5-hydroxy-5-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl) 
pentanoate (32) 
S
H
N
O
O
O OH
 
Methyl 5-oxo-5-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl)pentanoate (31) 
(0.150 g, 0.500 mmol) was dissolved in MeOH (1.5 mL). To this mixture, NaBH4 (0.050 
g, 1.26 mmol) was added in portions such that the temperature was maintained between 
25 °C and 30 °C. The mixture was stirred at rt for 30 min. Methanol was evaporated from 
the reaction mixture, and the aqueous layer was extracted with DCM (3 × 10 mL), dried 
(Na2SO4) and evaporated. The crude product was purified using column chromatography 
to afford pure 32 (0.130 g, 54%) as a brown oil; 1H NMR (400 MHz, CDCl3) δ 1.73-1.76 
(m, 4H), 2.05-2.08 (m, 2H), 2.32 (t, J = 6.8 Hz, 2H), 2.53-2.58 (m, 2H), 2.86 (t, J = 6.8 
Hz, 2H), 3.63 (s, 3H), 4.71-4.72 (m, 1H), 6.52 (s, 1H), 8.81 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 19.67, 20.12, 23.95, 27.22, 32.65, 34.98, 37.19, 50.86, 127.37, 134.54, 135.89, 
139.29, 174.07, 175.51; MS m/z (API-ES): 298 (M+H)+ (100%) 280 (M-H2O)+ (50%), 
calculated for C14H19NO4S 298.1108, found 298.1116. 
 
Methyl 5-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl)pentanoate (33) 
S
H
N
O
O
O
 
Methyl 5-hydroxy-5-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl) pentanoate 
(32) (0.240 g, 0.800 mmol) was dissolved in DCM (2.5 mL) and cooled to 0 °C. To this 
mixture, Et3SiH (0.140 mL, 0.880 mmol) was added. To the resulting mixture, BF3.Et2O 
(0.110 mL, 0.880 mmol) was added dropwise and the reaction mixture was allowed to 
come to rt over a period of 1 hr. The reaction mixture was quenched slowly with water, 
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the aqueous layer was extracted with DCM (3 × 3 mL), dried (Na2SO4) and evaporated to 
afford 33 as a yellow crystalline solid (0.170 g, 77%); m.p. 95-96 °C; 1H NMR (400 
MHz, CDCl3) δ 1.56-1.81 (m, 4H), 2.06-2.51 (m, 4H), 2.60-2.65 (m, 4H), 2.90 (t, J = 6.8 
Hz, 2H), 3.53-3.90 (m, 3H), 6.33 (s, 1H), 8.19 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
23.39, 24.48, 27.78, 28.15, 29.82, 30.95, 33.93, 51.76, 120.01, 122.15, 131.65, 141.99, 
174.08, 175.39; MS m/z (API-ES): 282 (M+H)+ (100%), calculated for C14H19NO3S 
282.1158, found 282.1179. 
 
5-(5-Oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl)pentanoic acid (34) 
S
H
N
O
HO
O
 
Methyl 5-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-2-yl)pentanoate (33) (0.050 
g, 0.170 mmol) was dissolved in MeOH (1 mL). Sodium hydroxide (1M, 0.200 mL) was 
added and the reaction mixture was stirred at rt for 1 hr. The resulting mixture was 
acidified to pH 5.0 (1M HCl), filtered, washed with water and dried to afford the final 
compound 34 (0.040 g, 89%) as an off-white solid, m.p. charred >150 °C; 1H NMR (400 
MHz, CD3OD) δ 1.59-1.71 (m, 4H), 2.10-2.14 (m, 2H), 2.25-2.40 (m, 2H), 2.46-2.56 (m, 
2H), 2.68-2.74 (m, 2H), 2.89 (t, J = 6.8 Hz, 2H), 6.41 (s, 1H); 13C NMR (101 MHz, 
CD3OD) δ 23.72, 25.71, 26.97, 29.47, 31.22, 35.35, 37.21, 119.80, 122.49, 131.85, 
142.14, 174.51, 176.25; MS m/z (API-ES): 268 (M+H)+ (100%), calculated for 
C13H17NO3S 268.0929, found 268.0918. 
 
4-Nitro-N-o-tolylbenzenesulfonamide (36)130 
N
H
S
NO2
OO
 
o-Toluedine (0.640 g, 6.00 mmol) was dissolved in DCE (10 mL). To this solution, p-
nitrosulfonylchloride (1.25 g, 5.40 mmol) in dry pyridine (0.500 mL) was added. The 
above reaction mixture was heated at 150 °C for 10 min in the microwave reactor. The 
resulting mixture was acidified (1M HCl) to pH = 3. The aqueous layer was extracted 
with DCM (3 × 5 mL), dried (Na2SO4) and evaporated to give 36 (1.76 g, quantitative) as 
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a brown solid, m.p. 157-158 °C (lit.i, 157-159 °C) 1H NMR (400 MHz, CD3OD) δ 2.01 
(s, 3H), 7.13-7.14 (m, 3H), 7.14-7.25 (m, 1H), 7.89 (d, J = 8.8 Hz, 2H), 8.26 (d, J = 8.8 
Hz, 2H). 
 
4-Amino-N-o-tolylbenzenesulfonamide (37)131, 132 
N
H
S
NH2
OO
 
4-Nitro-N-o-tolylbenzenesulfonamide (36) (1.70 g, 6.00 mmol) was dissolved in MeOH-
THF (50:50, 20 mL) and cooled to 0 °C. To this solution, NiCl2.6H2O (5.50 g, 23.0 
mmol) was added. To the resulting mixture, NaBH4 (1.80 g, 48.0 mmol) was added in 
portions such that the temperature is maintained between 0-10 °C. The resulting slurry 
was filtered through celite (Sigma-Aldrich, Celite 521). The filtrate was extracted with 
DCM (3 × 15 mL) dried (Na2SO4) and evaporated to give 37 (1.29 g, 85%) as a brown 
solid, m.p. 154-155 °C (lit.ii 154-155°C) 1H NMR (400 MHz, CD3OD) δ 1.23 (d, J = 3.2 
Hz, 2H), 2.01 (s, 3H), 6.56 (d, J = 8.8 Hz, 2H), 7.04-7.07 (m, 2H), 7.10-7.11 (m, 1H), 
7.30 (d, J = 8.8 Hz, 2H), 7.4 (d, J = 8.8 Hz, 2H).  
 
Diethyl 2-((4-(N-o-tolylsulfamoyl)phenylamino)methylene)malonate (38a) 
N
H
S
N
H
OO
O
O
OO
 
Diethyl ethoxymethylenemalonate (0.900 mL, 4.60 mmol) was added to 4-amino-N-o-
tolylbenzenesulfonamide (37) (1.25 g, 4.20 mmol) and heated 180 °C for 1 hr. To the 
resulting solution, Et2O (5 mL) was added, filtered, the residue dried and washed with 
Et2O to give 38a (1.66 g, 80%) as a colorless solid; m.p. 1158-160 °C; 1H NMR (400 
MHz, CDCl3) δ 1.32 (t, J  = 7.2 Hz, 3H), 1.37 (t, J = 7.2 Hz, 3H), 2.00 (s, 3H), 4.26 (q, J 
= 7.2 Hz, 2H), 4.29 (q, J = 7.2 Hz, 2H), 6.31 (d, J = 5.2 Hz, 1H), 7.04-7.36 (m, 5H), 7.70 
(d, J = 8.7 Hz, 2H), 8.46 (d, J  = 13.0 Hz, 1H), 11.09 (d, J = 13.0 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ 14.44, 14.60, 17.84, 60.75, 61.05, 116.75, 124.90, 126.78, 127.26, 
129.53, 131.12, 131.82, 134.39, 135.10, 143.21, 150.32, 165.46, 168.85;  MS m/z (API-
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ES): 433 (M+H)+ (100%), calculated for C21H24N2O6S 433.1428, found 433.1428. 
 
Diethyl 2-((4-(N-(3-ethylphenyl)sulfamoyl)phenylamino)methylene)malonate (38b) 
N
H
S
N
H
OO
O
O
OO
 
This was prepared from diethyl ethoxymethylenemalonate (0.120 mL, 0.600 mmol) and 
4-amino-N-(3-ethylphenyl)benzenesulfonamide (building block available in the lab, 
0.150 g, 0.540 mmol), in a similar manner as described for preparation of 38a; (0.200 g, 
84%); m.p. 119-121 °C; 1H NMR (400 MHz, CDCl3) δ 1.09 (t, J = 7.6 Hz, 3H), 1.26 (t, J 
= 7.0 Hz, 3H), 1.30 (t, J = 7.0 Hz, 3H), 2.50 (q, J = 7.6 Hz, 2H), 4.19 (q, J = 7.0 Hz, 
2H), 4.24 (q, J = 7.0 Hz, 2H), 6.35 (s, 1H), 6.77 (dd, J = 1.2, 7.6 Hz, 1H), 6.83 (s, 1H), 
6.90 (d, J = 8.0 Hz, 1H), 7.04-7.10 (m, 3H), 7.67 (d, J = 8.8 Hz, 2H), 8.39 (d, J = 13.2 
Hz, 1H), 11.01 (d, J = 13.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 14.43, 14.58, 16.61, 
28.87, 60.79, 61.04, 96.44, 116.79, 119.06, 121.38, 125.30, 129.44, 134.62, 136.60, 
143.13, 150.46, 165.61, 168.83; νmax (solid)/(cm-1) 3420, 3338, 3210, 1638, 1496, 1307, 
1144, 1077; MS m/z (API-ES): found 447 (M+H)+ (100%), calculated for C22H26N2O6S 
446.1512, found 446.1523. 
 
Diethyl 2-((4-(N-methyl-N-phenylsulfamoyl)phenylamino)methylene)malonate (38c)  
N
S
N
H
OO
O
O
OO
 
This was prepared from diethyl ethoxymethylenemalonate (0.130 mL, 0.700 mmol) and 
4-amino-N-methyl-N-phenylbenzenesulfonamide (building block available in the lab, 
0.150 g, 0.600 mmol) in a similar manner as described for preparation of 38a; (0.070 g, 
30%); m.p. 103-104 °C; 1H NMR (400 MHz, CDCl3) δ 1.33 (t, J = 7.2 Hz, 3H), 1.39 (t, J 
= 7.2 Hz, 3H), 3.18 (s, 3H), 4.28 (q, J = 7.2 Hz, 2H), 4.34 (q, J = 7.2 Hz, 2H), 7.10 (dd, 
J = 1.2, 6.8 Hz, 2H), 7.15 (d, J = 8.6 Hz, 2H), 7.29-7.31 (m, 3H), 7.54 (d, J = 8.6 Hz, 
2H), 8.51 (d, J = 13.2 Hz, 1H), 11.12 (d, J = 13.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
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δ 14.41, 15.43, 60.65, 60.95, 72.50, 96.43, 116.56, 126.74, 127.63, 129.12, 130.11, 
131.97, 141.54, 143.08, 150.38, 163.83, 165.40, 168.78; νmax (solid)/(cm-1) 2988, 1688, 
1640, 1573, 1442, 1347, 1239, 1145; MS m/z (API-ES): found 433.1 (M+H)+ (100%), 
calculated for C21H24N2O6S 433.1428, found 433.1445. 
 
Diethyl 2-((4-(N-m-tolylsulfamoyl)phenylamino)methylene)malonate (38d)  
N
H
S
N
H
OO
O
O
OO
 
This was prepared from diethyl ethoxymethylenemalonate (0.130 mL, 0.630 mmol) and 
4-amino-N-m-tolylbenzenesulfonamide (building block available in the lab, 0.150 g, 
0.600 mmol) in a similar manner as described for preparation of 38a; (0.21 g, 82%); m.p. 
128-130 °C; 1H NMR (400 MHz, CDCl3) δ 1.32 (t, J = 7.2 Hz, 3H), 1.38 (t, J = 7.2 Hz, 
3H), 2.27 (s, 3H), 4.27 (q, J = 7.2 Hz, 2H), 4.32 (d, J = 7.2 Hz, 2H), 6.60 (s, 1H) 6.95 (d, 
J = 8.2 Hz, 2H), 7.03 (d, J = 8.2 Hz, 2H) , 7.12 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 8.8 Hz, 
1H), 8.43 (d, J = 13.2 Hz, 1H), 11.05 (d, J = 13.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
δ
 14.42, 14.58, 60.77, 61.04, 96.47, 116.80, 118.79, 122.53, 126.55, 134.63, 139.65, 
143.15, 150.42, 165.56, 168.84; νmax (solid)/(cm-1); MS m/z (API-ES):  433.1 (M+H)+ 
(100%), calculated for C21H24N2O6S 433.1428, found 433.1425. 
 
Diethyl 2-((4-(N-(3-methoxyphenyl)sulfamoyl)phenylamino)methylene)malonate 
(38e)  
N
H
S
N
H
OO
O
O
OO
O
 
This was prepared from diethyl ethoxymethylenemalonate (0.0800 mL, 0.700 mmol) and 
4-amino-N-(3-methoxyphenyl)benzenesulfonamide (building block available in the lab, 
0.100 g, 0.360 mmol) in a similar manner as described for preparation of 38a; (0.060 g, 
40%); m.p. 130-131 °C; 1H NMR (400 MHz, CDCl3) δ 1.32 (t, J = 7.2 Hz, 3H), 1.35 (t, J 
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= 7.2 Hz, 3H), 3.75 (s, 3H), 4.18 (q, J = 7.2 Hz, 2H), 4.37 (q, J = 7.2 Hz, 2H), 6.47 (d, J 
= 6.4 Hz, 1H), 6.52 (d, J = 6.4 Hz, 1H), 6.73 (d, J = 1.6 Hz, 2H), 7.12-7.14 (m, 3H), 7.75 
(d, J = 8.8 Hz, 2H), 8.45 (d, J = 13.2 Hz, 1H), 11.09 (d, J = 13.2 Hz, 1H); 13C NMR (101 
MHz, CDCl3) δ 14.42, 14.58, 55.56, 60.75, 61.04, 95.59, 107.64, 111.21, 113.79, 116.80, 
129.6, 130.36, 134.46, 137.68, 143.27, 150.33, 160.58, 165.48, 268.83; νmax (solid)/(cm-
1) 3420, 3417, 3342, 3213, 1595, 1492, 1414, 1307, 1180; 1144 (st); MS m/z (API-ES): 
449 (M+H)+ (100%), calculated for C21H24N2O7S 449.1377, found 449.1380. 
 
Diethyl 2-((4-(N-phenylsulfamoyl)phenylamino)methylene)malonate (38f) 
N
H
S
N
H
OO
O
O
OO
 
This was prepared from diethyl ethoxymethylenemalonate (0.130 mL, 0.630 mmol) and 
4-amino-N-phenylbenzenesulfonamide (building block available in the lab, 0.150 g, 
0.570 mmol) in a similar manner as described for preparation of 38a; (0.200 g, 78%); 
m.p. 154-155 °C; 1H NMR (400 MHz, CDCl3) δ 1.25 (t, J = 7.2 Hz, 3H), 1.27 (t, J = 7.2 
Hz, 3H), 4.19 (q, J = 7.2 Hz, 2H), 4.24 (q, J = 7.2 Hz, 2H), 6.98-7.06 (m, 5H), 7.16-7.19 
(m, 2H), 7.68 (d, J = 2.8 Hz, 2H), 8.38 (d, J = 13.2 Hz, 1H), 11.00 (d, J = 13.2 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 14.42, 14.58, 60.81, 61.04, 96.44, 116.83, 121.90, 125.68, 
129.58, 134.53, 143.15, 150.46, 165.66, 168.80; νmax (solid)/(cm-1) 3420, 3348, 3217, 
1635, 1591, 1492, 1418, 1311, 1147; MS m/z (API-ES):  419.1 (M+H)+ (100%), 
calculated for C20H22N2O6S 419.1271,  found 419.1269. 
 
Diethyl 2-((4-(N-p-tolylsulfamoyl)phenylamino)methylene)malonate (38g) 
N
H
S
N
H
OO
O
O
OO
 
This was prepared from diethyl ethoxymethylenemalonate (0.130 mL, 0.700 mmol) and 
4-amino-N-p-tolylbenzenesulfonamide (building block available in the lab, 0.150 g, 
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0.600 mmol) in a similar manner as described for preparation of 38a; (0.230 g, 88%); 
m.p. 179-181 °C; 1H NMR (400 MHz, CDCl3) δ 1.32 (t, J = 7.2 Hz, 3H), 1.38 (t, J = 7.2 
Hz, 3H), 2.28 (s, 3H), 4.26 (q, J = 7.2 Hz, 2H), 4.31 (q, J = 7.2 Hz, 2H), 6.91 (d, J = 8.4 
Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 8.47 
(d, J = 13.2 Hz, 1H), 11.09 (d, J = 13.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 14.42, 
14.58, 21.05, 60.78, 61.02, 96.39, 116.79, 122.63, 129.64, 130.12, 133.88, 135.77, 
143.06, 150.48, 165.63, 168.82; νmax (solid)/(cm-1) 3427, 3345, 3224, 1642, 1589, 1492, 
1414, 1315, 1144; MS m/z (API-ES): 433.1 (M+H)+ (100%), calculated for C21H24N2O6S 
433.1428, found 433.1424. 
 
Diethyl 2-((4-(N-(2-chlorophenyl)sulfamoyl)phenylamino)methylene)malonate (38h)  
N
H
S
N
H
OO
O
O
OO
Cl
 
This was prepared from diethyl ethoxymethylenemalonate (0.110 mL, 0.540 mmol) and 
4-amino-N-(2-chlorophenyl)benzenesulfonamide (building block available in the lab, 
0.150 g, 0.500 mmol) in a similar manner as described for preparation of 38a; (0.190 g, 
80%); m.p. 134-136 °C; 1H NMR (400 MHz, CD3OD) δ 1.31 (t, J = 7.2 Hz, 3H), 1.34 (t, 
J = 7.2 Hz, 3H), 4.22 (q, J = 7.2 Hz, 2H), 4.29 (q, J = 7.2 Hz, 2H), 7.14 (dt, J = 1.6, 6.0 
Hz, 1H), 7.24-7.30 (m, 2H), 7.34 (d, J = 9.2 Hz, 2H), 7.54 (dd, J = 1.4, 6.8 Hz, 1H), 7.73 
(d, J = 8.8 Hz, 2H), 8.54 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 14.63, 14.72, 60.42, 
60.91, 72.34, 96.48, 106.27, 117.97, 128.00, 128.38, 126.67, 134.23, 135.92, 143.72, 
150.15, 164.17, 164.28, 164.83, 165.38, 167.50; νmax (solid)/(cm-1) 3168, 2984, 1675, 
1590, 1569, 1478, 1438, 1343, 1162; MS m/z (API-ES): 453.0 (M+H)+ (100%), 
calculated for C20H21ClN2O6S 453.0882, found 453.0887. 
 
Diethyl 2-((4-(N-methyl-N-o-tolylsulfamoyl)phenylamino)methylene)malonate (38i) 
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N
S
N
H
OO
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This was prepared from diethyl ethoxymethylenemalonate (0.110 mL, 0.540 mmol) and 
4-amino-N-methyl-N-o-tolylbenzenesulfonamide (building block available in the lab, 
0.150 g, 0.600 mmol) in a similar manner as described for preparation of 38a; (0.150 g, 
61%); m.p. 136-137 °C; 1H NMR (400 MHz, CD3OD) δ 1.27 (t, J = 7.2 Hz, 3H), 1.35 (t, 
J = 7.2 Hz, 3H), 2.37 (s, 3H), 3.13 (s, 3H), 4.18 (q, J = 7.2 Hz, 2H), 4.21 (q, J = 7.2 Hz, 
2H), 6.63 (dd, J = 0.8, 6.8 Hz), 7.07 (dt, J = 0.4, 6.8 Hz), 7.21 (dt, J = 1.2, 6.8 Hz), 7.30 
(dd, J = 0.4, 7.2 Hz), 7.45 (dd, J = 2, 6.8 Hz), 7.69 (d, J = 6.8 Hz), 7.73 (s, 2H), 8.61 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ 14.61, 14.82, 14.91, 18.64, 60.47, 60.67, 61.48, 
96.63, 118.12, 127.33, 127.50, 128.91, 130.01, 138.77, 144.03, 150.12, 165.43, 
167.43; νmax (solid)/(cm-1) 3642, 2992, 1682, 1633, 1569, 1343, 1237, 1148; MS m/z 
(API-ES): 447.1 (M+H)+ (100%), calculated for C22H26N2O6S 446.1584, found 
446.1581. 
 
Ethyl 4-oxo-7-(N-o-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxylate (39a)  
N
H
S
N
H
OO O
O
O
 
o-Dichlorobenzene (10 mL) was added to diethyl 2-((4-(N-o-tolylsulfamoyl) 
phenylamino)methylene)malonate (38a) (1.500 g, 3.500 mmol) and heated at 250 °C for 
15 min in the microwave reactor. Hexane (10 mL) was added to the reaction mixture, 
which was filtered and the precipitate washed with hexane (20 mL) to afford 39a (1.17 g, 
84%) as an off-white solid; m.p. 270-271 °C; 1H NMR (400 MHz, CD3OD) δ 1.34 (t, J = 
7.2 Hz, 3H), 2.00 (s, 3H), 4.30 (q, J = 7.2 Hz, 2H), 7.05-7.12 (m, 4H), 7.63 (d, J = 8.8 
Hz, 1H), 7.90 (d, J = 2 Hz, 1H), 8.66 (d, J = 2.0 Hz, 1H), 8.69 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 14.45, 132.42, 134.46, 143.12, 165.55, 168.80, 14.59, 17.89, 60.75, 
61.02, 77.02, 77.34, 77.66, 96.45, 116.77, 125.27, 126.78, 127.10, 129.51, 131.12, 
135.24, 150.41; MS m/z (API-ES): 387 (M+H)+ (100%), calculated for C19H18N2O5S 
387.0970, found 387.0987. 
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Ethyl 7-(N-(3-ethylphenyl)sulfamoyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(39b) 
N
H
S
N
H
OO O
O
O
 
This was prepared from compound 38b (0.100 g, 0.220 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a (0.0700 g, 81%), m.p. 273-
274 °C; 1H NMR (400 MHz, CD3OD) δ 1.10 (t, J = 7.6 Hz, 3H), 1.36 (t, J = 7.2 Hz, 3H), 
2.51 (q, J = 7.6 Hz, 2H), 4.32 (q, J = 7.2 Hz, 2H), 6.89-6.92 (m, 3H), 7.08 (t, J = 7.6 Hz, 
1H), 7.63 (d, J = 8.8 Hz, 1H), 7.97 (dd, J = 2.0, 8.8 Hz, 1H), 8.66 (s, 1H), 8.72 (d, J = 
2.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 14.96, 38.63, 60.56, 111.89, 120.95, 126.78, 
127.12, 128.10, 132.42, 141.60, 146.61, 165.01, 173.41; νmax (solid)/(cm-1) 3423, 3345, 
3217, 1627, 1591, 1496, 1407, 1315, 1133 (st); MS m/z (API-ES):  401.1 (M+H)+ 
(100%), calculated for C20H20N2O5S 401.1165, found 401.1161. 
 
Ethyl 7-(N-methyl-N-phenylsulfamoyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(39c)  
N
S
N
H
OO O
O
O
 
This was prepared from compound 38c (0.100 g, 0.230 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a. (0.060 g, 70%); m.p. 266-
267 °C; 1H NMR (400 MHz, CDCl3) δ 1.24 (t, J = 7.2 Hz, 3H), 3.12 (s, 3H), 4.21 (q, J = 
7.2 Hz, 2H), 7.07-7.10 (m, 2H), 7.27-7.34 (m, 4H), 7.70 (dd, J = 2.4, 8.4 Hz, 1H), 7.75 
(d, J = 8.4 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 8.63 (d, J = 6.4 Hz, 1H), 11.07 (d, J = 13.2 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 14.96, 15.98, 28.68, 60.53, 111.76, 118.13, 
124.47, 126.11, 127.20, 129.76, 138.07, 142.07, 145.51, 146.52, 164.94, 173.41; νmax 
(solid)/(cm-1) (st); MS m/z (API-ES): 387.1 (M+H)+ (100%), calculated for C19H18N2O5S 
387.1009, found 387.1013. 
 
Ethyl 4-oxo-7-(N-m-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxylate (39d) 
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This was prepared from compound 38d (0.100 g, 0.220 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a. (0.0500 g, 57%); m.p. 265-
266 °C; 1H NMR (400 MHz, CD3OD) δ 1.36 (t, J = 7.2 Hz, 3H), 2.21 (s, 3H), 4.32 (d, J 
= 7.2 Hz, 2H), 6.79-6.98 (m, 3H), 7.04 (t, J = 8.0 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.99 
(dd, J = 0.8, 8.8 Hz, 1H), 8.66 (s, 1H), 8.72 (d, J = 1.6 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 14.96, 21.70, 60.53, 111.77, 117.75, 121.04, 125.65, 130.38, 136.05, 139.22, 
146.56, 164.96, 173.43; νmax (solid)/(cm-1) 1638 (st), 1591, 1496, 1403, 1307, 1186; 
1133; MS m/z (API-ES): 387.0 (M+H)+ (100%), calculated for C19H18N2O5S 387.1009, 
found 387.1009. 
 
Ethyl 7-(N-(3-methoxyphenyl)sulfamoyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(39e) 
N
H
S
N
H
OO O
O
O
O
 
This was prepared form compound 38e (0.0500 g, 0.110 mmol) and o-dichlorobenzene (1 
mL) in a similar manner as described for preparation of 39a. (0.0400 g, 90%); m.p. 268-
270 °C; 1H NMR (400 MHz, CD3OD) δ 1.37 (t, J = 7.2 Hz, 2H), 3.69 (s, 3H), 4.32 (q, J 
= 7.2 Hz, 2H), 6.57 (dd, J = 2.0, 6.8 Hz, 1H), 6.63 (dd, J = 2.0, 6.0 Hz, 1H), 6.72 (t, J = 
2.2 Hz, 1H), 7.06 (t, J = 8.0 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 8.01 (dd, J = 2.0, 8.8 Hz, 
1H), 8.66 (s, 1H), 8.74 (d, J = 1.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) d 14.96, 55.67, 
60.53, 106.40, 109.93, 111.81, 112.59, 121.08, 126.10, 127.21, 130.37, 130.77, 135.91, 
139.34, 146.55, 160.37, 164.93, 173.40; MS m/z (API-ES):  found 403.0 (M+H)+ 
(100%), calculated for C19H18N2O6S 403.0958, found 403.0964. 
 
Ethyl 4-oxo-7-(N-phenylsulfamoyl)-1,4-dihydroquinoline-3-carboxylate (39f) 
N
H
S
N
H
OO O
O
O
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This was prepared form compound 38f (0.100 g, 0.240 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a. (0.0800 g, 89%), m.p. 275-
276 °C; 1H NMR (400 MHz, CD3OD) δ 1.37 (t, J = 7.2 Hz, 3H), 4.32 (q, J = 7.2 Hz, 
2H), 6.98-7.25 (m, 3H), 7.46-7.54 (m, 1H), 7.62 (d, J = 8.7 Hz, 1H), 7.97 (d, J = 8.7 Hz, 
1H), 8.62-8.77 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 14.95, 60.52, 111.79, 120.90, 
121.02, 124.96, 129.50, 135.97, 142.09, 146.53, 165.94, 173.40; νmax (solid)/(cm-1) 1653, 
1603, 1441, 1240, 1184, 1140; MS m/z (API-ES): 373.0 (M+H)+ (100%), calculated for 
C18H16N2O5S 373.0852, found 373.0859. 
 
Ethyl 4-oxo-7-(N-p-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxylate (39g) 
N
H
S
N
H
OO O
O
O
 
This was prepared form compound 38g (0.100 g, 0.230 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a. (0.0800 g, 88%); m.p. 274-
276 °C; 1H NMR (400 MHz, CD3OD) δ 1.36 (t, J = 7.2 Hz, 3H), 2.15 (s, 3H), 4.32 (q, J 
= 7.2 Hz, 2H), 7.02 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 7.6 Hz, 2H), 7.18 (t, J = 7.6 Hz, 2H), 
7.63 (d, J = 8.7 Hz, 1H), 7.98 (dd, J = 2.2, 8.7 Hz, 1H), 8.66 (s, 1H), 8.73 (d, J = 2.0 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 14.93, 20.93, 60.51, 111.74, 120.96, 121.45, 126.08, 
129.45, 130.39, 135.41, 142.03, 146.54, 164.93, 173.47; νmax (solid)/(cm-1) 1767, 1721, 
1664, 1642, 1599, 1481, 1438, 1320, 1244, 1173; MS m/z (API-ES): 387.1 (M+H)+ 
(100%), calculated for C19H18N2O5S 387.1009, found 387.1005. 
 
Ethyl 7-(N-(2-chlorophenyl)sulfamoyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(39h) 
N
H
S
N
H
OO O
O
O
Cl
 
This was prepared form compound 38h (0.100 g, 0.200 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a. (0.0500 g, 60%); m.p. 274-
275 °C; 1H NMR (400 MHz, CD3OD) δ 1.36 (t, J = 7.1 Hz, 1H), 4.33 (d, J = 7.1 Hz, 
1H), 7.15 (t, J = 7.0 Hz, 1H), 7.24-7.29 (m, 2H), 7.57 (dd, J = 1.2, 8 Hz, 1H), 7.62 (d, J 
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= 8.5 Hz, 1H), 7.97 (dd, J = 2.2, 8.5 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.69 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 14.97, 60.54, 111.81, 120.94, 126.06, 128.65, 130.06, 131.38, 
142.14, 146.57, 164.99, 173.44; νmax (solid)/(cm-1) 1697, 1563, 1361, 1198, 1035; MS 
m/z (API-ES): 407.0 (M+H)+ (100%), calculated for C18H15ClN2O5S 407.0463, found 
407.0459. 
 
 
Ethyl 7-(N-methyl-N-o-tolylsulfamoyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(39i) 
N S
N
H
OO O
O
O
 
This was prepared form compound 38i (0.100 g, 0.220 mmol) and o-dichlorobenzene (2 
mL) in a similar manner as described for preparation of 39a. (0.0800 g, 88%); m.p. 298-
300 °C; 1H NMR (400 MHz, DMSO) δ 1.26 (t, J = 7.2 Hz, 3H), 2.30 (s, 3H), 3.07 (s, 
3H), 4.20 (q, J = 7.2 Hz, 2H), 6.56 (d, J = 7.2 Hz, 1H), 7.06 (t, J = 7.2 Hz, 1H), 7.23 (t, J 
= 7.2 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.88 (dd, J = 2.0, 8.8 
Hz, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.65 (d, J = 6.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
δ 14.97, 18.65, 60.56, 104.99, 111.87, 121.12, 126.79, 127.41, 129.04, 138.73, 142.36, 
146.64, 165.04, 173.51; νmax (solid)/(cm-1) 1697, 1650, 1559, 1541, 1506, 1456, 1361, 
1194; MS m/z (API-ES): found 401.1 (M+H)+ (100%), calculated for C20H20N2O5S 
401.1165, found 401.1175. 
 
4-Oxo-7-(N-o-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxylic acid (40)  
N
H
S
N
H
OO O
OH
O
 
Ethyl 4-oxo-7-(N-o-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxylate (39a) (0.200 g, 
0.500 mmol) was dissolved in EtOH (10 mL). Potassium hydroxide (10%, 10 mL) was 
added and heated to reflux for 1.5 hrs. EtOH was evaporated and the resulting mixture 
was acidified to pH 5.0 (HCl, 1.0 M) and the precipitate was filtered, the residue dried 
and washed with water to afford 40 (0.180 g, 98%); 1H NMR (400 MHz, CD3OD) δ 2.04 
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(s, 3H), 7.03-7.11 (m, 4H), 7.77 (d, J = 8.8 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 8.69 (d, J 
= 2 Hz, 1H), 8.86 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 16.98, 108.90, 120.51, 124.70, 
125.38, 126.40, 126.79, 126.96, 130.86, 131.29, 134.47, 134.68, 138.36, 141.80, 146.34, 
167.88, 178.81; MS m/z (API-ES): 357 (M-H)+ (100%), calculated for C17H14N2O5S 
359.0696, found 359.0694. 
 
N-Methyl-4-oxo-7-(N-o-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxamide (41) 
N
H
S
N
H
OO O
N
H
O
 
4-Oxo-7-(N-o-tolylsulfamoyl)-1,4-dihydroquinoline-3-carboxylic acid (40) (0.150 g, 
0.420 mmol) was refluxed with SOCl2 (2.00 mL) for 10 minutes. Excess SOCl2 was 
evaporated and 0.0500 g of the resulting mass was dissolved in DCM (1 mL). To the 
resulting mixture, pyridine (0.012 mL) and CH3NH2 (1.0 M in THF, 0.0700 mL, 0.14 
mmol) was added and stirred at rt for 1 hr. Pyridine-DCM mixture was evaporated and 
the resulting mass was column purified using EtoAc-Hexane (50:50, v/v) to give 41 
(0.00900 g, 23%) as an off-white solid, m.p. 280-282 °C; 1H NMR (400 MHz, CD3OD) δ 
2.04 (s, 3H), 2.97 (d, J = 3.5 Hz, 3H), 6.97-7.15 (m, 4H), 7.68 (d, J = 8.7 Hz, 1H), 7.94 
(dd, J = 2.0 Hz, 8.7 Hz, 1H), 8.68 (d, J = 2.0 Hz, 1H), 8.78 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 16.90, 24.80, 112.24, 119.76, 125.91, 126.01, 126.34, 126.88, 130.45, 130.81, 
134.65, 134.71, 137.46, 141.62, 144.56, 166.22, 176.71; MS m/z (API-ES): 372.1 
(M+H)+ (100%), calculated for C18H17N3O4S 372.1012, found 372.1006;  
 
2-Amino-5,5-bis(hydroxymethyl)thiazol-4(5H)-one (43)143 
N
S
O
OH
OH
H2N
 
Formaldehyde (37% solution in water, 6.00 mL, 78.0 mmol) was added to 
pseudothiohydantoin (2.00 g, 17.0 mmol). To the above mixture, triethylamine (0.300 
mL) was added in three portions over a period of 30 min and stirred at rt for 1.5 hrs. To 
this reaction mixture, ammonium carbonate (2.80 g, 29.0 mmol) was added and stirred at 
rt for 16 hrs. The reaction mass was filtered, and the filtrate was evaporated and dried to 
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afford 43 (2.76 g, quantitative) as a colorless solid. The crude product was taken to the 
next step without further purification; m.p 189-191 °C (lit.68 191-192 °C); 1H NMR (400 
MHz, D2O) δ 3.61 (d, J = 11.6 Hz, 2H), 3.72 (d, J = 11.6 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 64.12, 73.19, 76.47, 183.72, 190.49; MS m/z (API-ES): 401.1 (M+H)+ (100%). 
 
3-Ethyl-7,7-bis(hydroxymethyl)-3,4-dihydro-2H-thiazolo[3,2-a][1,3,5]triazin-6(7H)-
one (44)143 
N
S
O
OH
OHN
N
 
Formaldehyde (35% solution in water, 2.60 mL, 31.0 mmol) was added to 2-amino-5,5-
bis(hydroxymethyl)thiazol-4(5H)-one (43) (2.17 g, 12.3 mmol). To this mixture, 
ethylamine (70% solution in water, 0.790 mL, 12.3 mmol) and potassium carbonate 
(0.300 g, 3.00 mmol) was added and stirred at rt for 30 min. Water was evaporated from 
the reaction mixture and the crude reaction mass was purified by column chromatography 
using DCM-MeOH (75 : 25, v/v) to afford 44 (1.81 g, 60%) as a white solid; m.p 129-131 
°C (lit.68 131-133 °C); 1H NMR (400 MHz, CD3OD) δ 1.09 (t, J = 7.2 Hz, 3H), 2.65 (q, J 
= 7.2 Hz, 2H), 3.75 (d, J = 11.6 Hz, 2H), 3.88 (d, J = 11.6 Hz, 2H), 4.36 (s, 2H), 4.67 (s, 
2H); 13C NMR (101 MHz, CDCl3) δ 12.27, 45.19, 60.97, 63.58, 66.53, 73.25, 153.54, 
173.48; Anal. Calcd for C9H15N3SO3; C, 44.07; H, 6.16; N, 17.13; S, 13.07; Found: C, 
42.59; H, 5.89; N, 18.83; S, 9.52; MS m/z (API-ES):  246.0 (M+H)+ (100%). 
 
 
7.4 General procedure for the synthesis of tetrahydro-cyclopentane quinoline-4-
carboxylic acids 46a-b:  
Ytterbium triflate (0.100 mol eq) and magnesium sulfate (6.60 mol eq) were suspended in 
MeCN (0.800 mL) and cooled to 0 °C. To this solution, a mixture of the aniline (1 mol 
eq), glyoxylic acid monohydrate (1 mol eq) and freshly cracked cyclopentadiene (3 mol 
eq) in MeCN (0.800 mL) was added. The resulting mixture was stirred at rt for 16 hrs. 
Acetonitrile was evaporated and the crude mass was extracted with EtOAc (3 × 10 mL), 
dried (Na2SO4) and evaporated to give the crude product. Purification was performed as 
described below. 
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(3aRS,4SR,9bSR)-6-Methoxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-
carboxylic acid (46a)144 
N
H
OH
OO
H
H
 
This was prepared from o-anisidine (0.100 g, 0.800 mmol), glyoxylic acid monohydrate 
(0.0700 g, 0.800 mmol) and cyclopentadiene (0.150 g, 2.40 mmol) in a similar manner as 
described above. The reaction mass was extracted three times with DCM, dried (Na2SO4) 
and evaporated. Purification of the crude reaction mass was done by column 
chromatography using EtOAc-hexane (Rf = 0.2, 30:70 EtOAc-hexane, v/v) (greenish 
solid, 0.0700 g, 58%); m.p 186-188 °C; 1H NMR (400 MHz, CDCl3) δ 2.38-2.46 (m, 
1H), 2.54-2.61 (m, 1H), 3.33 (dq, J = 3.6, 8.8 Hz, 1H), 3.83 (s, 3H), 4.11 (d, J = 8.8 Hz, 
1H), 4.16 (d, J = 3.2 Hz, 1H), 5.68-5.67 (m, 1H), 5.76-5.79 (m, 1H), 6.60 (dd, J = 1.6, 
7.2 Hz, 1H), 6.73-6.74 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 32.71, 40.82, 46.48, 
55.66, 56.20, 107.46, 118.78, 120.72, 126.22, 130.18, 133.45, 134.16, 147.34, 178.19;  
Anal Calcd for C13H13NO3; C, 68.56; H, 6.16; N, 5.71; found; C, 68.13; H, 5.96; N, 
5.59; MS m/z (API-ES): 243.1 (M+H)+ (100%). 
 
(3aRS,4SR,9bSR)-6-Hydroxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-
carboxylic acid (46b)152 
N
H
OH
OOH
H
H
 
This was prepared from 2-aminophenol (0.360 g, 3.300 mmol), glyoxylic acid 
monohydrate (0.300 g, 3.30 mmol) and cyclopentadiene (0.800 mL, 3.200 mmol) in a 
similar manner as described above. The crude product was purified by washing with 
MeOH, (greenish solid, 0.250 g, 33%), m.p. 180-182 °C; 1H NMR (400 MHz, DMSO) δ 
2.31-2.48 (m, 2H), 3.13 (dq, J = 3.6, 5.6 Hz, 1H), 3.90 (d, J = 3.2 Hz, 1H), 3.98 (dd, J = 
0.8, 7.6 Hz, 1H), 4.42 (br s, 1H), 5.56-5.58 (m, 1H), 5.70-5.71 (m, 1H)m 6.42-6.48 (m, 
3H), 9.36 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 32.39, 40.66, 46.65, 56.47, 111.21, 
119.01, 119.43, 127.23, 129.07, 132.48, 144.86, 174.28; MS m/z (API-ES): 232.09 
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(M+H)+ (100%). 
 
N-(Furan-2-ylmethyl)-4-methoxyaniline (50a)147, 148 
O H
N
O
 
p-Anisidine (0.280 g, 2.26 mmol) was dissolved in EtOH (5 mL). To this mixture, 2-
furaldehyde (0.180 mL, 2.26 mmol) was added and heated at 130 °C for 15 min in the 
microwave reactor. To the resulting solution, MeOH (2 mL) was added. To this mixture, 
NaBH4 (2.5 mol eq) was added in portions till effervescence ceased. After stirring the 
reaction mixture at rt for 30 minutes, the solvent was evaporated and the aqueous layer 
was extracted with DCM (3 × 5 mL), dried (Na2SO4) and evaporated to give 50a, (brown 
oil, 0.42 g, 97%); The crude product was used as such to the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 3.75 (s, 3H), 4.27 (s, 2H), 6.22 (dd, J = 0.7, 
3.2 Hz, 1H), 6.32 (dd, J = 1.8, 3.2 Hz, 1H), 6.65 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 
2H), 7.36 (dd, J = 0.7, 1.8 Hz, 1H). 
 
N-(Furan-2-ylmethyl)-4-isopropylaniline (50b) 
O H
N
 
This was prepared from p-isopropylaniline (0.440 g, 3.12 mmol) and 2-furaldehyde 
(0.260 mL, 3.12 mmol) in a similar manner as described for the preparation of 50a, 
(brown oil, quantitative). The crude product was used as such to the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 1.22 (d, J = 6.8 Hz, 6H), 2.81 (heptet, 
J = 6.8 Hz, 1H), 4.30 (s, 2H), 6.24 (d, J = 3.2 Hz, 1H), 6.32 (dd, J = 1.8, 3.2 Hz, 1H), 
6.62 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 7.25 (s, 1H), 7.36 (br s, 1H). 
 
2,4-Difluoro-N-(furan-2-ylmethyl)aniline (50c) 
O H
N
F
F
 
This was prepared from 2,4-difluoroaniline (0.400 g, 3.12 mmol) and 2-furaldehyde 
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(0.260  mL, 3.12 mmol) in a similar manner as described for the preparation of 50a, 
(brown oil, 0.530 g, 82%). The crude product was taken as such to the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 4.32 (s, 2H), 6.23 (d, J = 3.2 Hz, 1H), 
6.32-6.33 (m, 1H), 6.68-6.80 (m, 3H), 7.37 (br s, 1H). 
 
4-Chloro-N-(furan-2-ylmethyl)aniline (50d) 
O H
N
Cl
 
This was prepared from p-chloroaniline (0.390 g, 3.12 mmol) and 2-furaldehyde (0.260 
mL, 3.12 mmol) in a similar manner as described for the preparation of 50a (brown oil, 
0.620 g, 96%). The crude product was used as such to the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 4.28 (s, 2H), 6.22 (d, J = 3.2 Hz, 1H), 6.31-
6.32 (m, 1H), 6.60 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 7.26 (s, 1H), 7.36 (br s, 
1H). 
 
4-Bromo-N-(furan-2-ylmethyl)aniline (50e) 
O H
N
Br
 
This was prepared from p-bromoaniline (0.530 g, 3.12 mmol) and 2-furaldehyde (0.260 
mL, 3.12 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 
0.790 g, quantitative). The crude product was used as such to the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 4.28 (s, 3H), 6.23 (d, J = 3.2 Hz, 1H), 
6.31-6.32 (m, 1H), 6.56 (d, J = 8.8 Hz, 2H), 7.26 (d, J = 8.8 Hz, 2H), 7.36 (br s, 1H). 
 
N-(Furan-2-ylmethyl)-4-(methylthio)aniline (50f) 
O H
N
S
 
This was prepared from 4-(thiomethyl)aniline (0.300 g, 2.15 mmol) and 2-furaldehyde 
(0.180 mL, 2.15 mmol) in a similar manner as described for the preparation of 50a, 
(brown oil, 0.470 g, quantitative). The crude product was used as such to the next step 
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without further purification. 1H NMR (400 MHz, CDCl3) δ 2.40 (s, 3H), 4.30 (s, 2H), 
6.22 (d, 3.2 Hz, 1H), 6.31 (dd, J = 1.6, 3.2 Hz, 1H), 6.61 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 
8.4 Hz, 2H), 7.36 (br s, 1H). 
 
4-Ethoxy-N-(furan-2-ylmethyl)aniline (50g) 
O H
N
O
 
This was prepared from 4-ethoxyaniline (0.430 g, 3.12 mmol) and 2-furaldehyde (0.260 
mL, 3.12 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 
0.870 g, quantitative). The crude product was used as such to the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 1.35 (t, J = 6.8 Hz, 3H), 3.73 (br s, 
1H), 3.94 (q, J = 6.8 Hz, 2H), 4.29 (d, J = 6.0 Hz, 2H), 6.20 (d, J = 3.2 Hz, 1H), 6.30 
(dd, J = 1.8, 3.2 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 7.35 (br s, 
1H). 
 
4-Ethyl-N-(furan-2-ylmethyl)aniline (50h) 
O H
N
 
This was prepared from 4-ethylaniline (0.300 g, 2.47 mmol) and 2-furaldehyde (0.200 
mL, 2.47 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 
0.500 g, quantitative). The crude product was taken as such to the next step without 
further purification. 1H NMR (400 MHz, CDCl3) δ 1.36 (t, J = 7.6 Hz, 3H), 3.94 (q, J = 
7.6 Hz, 2H), 4.29 (s, 2H), 6.22 (d, J = 3.2 Hz, 1H), 6.31 (dd, J = 1.6, 3.2 Hz, 1H), 6.61 
(d, J = 8.4 Hz, 2H), 7.01 (d, J = 8.4 Hz, 2H), 7.35 (br s, 1H). 
 
N-(Furan-2-ylmethyl)-2-methoxyaniline (50i) 
O H
N
O
 
This was prepared from o-anisidine (0.300 g, 2.40 mmol) and 2-furaldehyde (0.200 mL, 
2.40 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 
quantitative). The crude product was used as such to the next step without further 
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purification. 1H NMR (400 MHz, CDCl3) δ 3.84 (s, 3H), 4.34 (d, J = 6.0 Hz, 2H), 4.61 
(br s, 1H), 6.24 (d, J = 3.2 Hz, 1H), 6.29-6.34 (m, 1H), 6.67-6.73 (m, 2H), 6.77 (d, J = 
6.8 Hz, 1H), 6.84 (t, J = 7.6 Hz, 1H), 7.36 (br s, 1H). 
 
N-(Furan-2-ylmethyl)-3-methoxyaniline (50j) 
O H
N O
 
This was prepared from m-anisidine (0.300 g, 2.400 mmol) and 2-furaldehyde (0.200 mL, 
2.40 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 0.580 
g, quantitative). The crude product was used as such to the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 3.77 (s, 3H), 4.30 (s, 2H), 6.23 (d, J = 2.4 Hz, 
2H), 6.29- (m, 4H), 7.07-7.10 (m, 1H), 7.36 (br s, 1H). 
 
N-(Furan-2-ylmethyl)benzo[d][1,3]dioxol-5-amine (50k) 
O H
N
O
O
 
This was prepared from 3,4-methylenedioxyaniline (0.430 g, 3.120 mmol) and 2-
furaldehyde (0.260 mL, 3.120 mmol) in a similar manner as described for the preparation 
of 50a, (brown oil, 0.620 g, 92%). The crude product was used as such to the next step 
without further purification. 1H NMR (400 MHz, CDCl3) δ 3.81 (br s, 1H), 4.24 (s, 2H), 
5.85 (s, 2H), 6.09 (dd, J = 2.2, 8.2 Hz, 1H), 6.21 (d, J = 3.2 Hz, 1H), 6.30-6.32 (m, 2H), 
6.64 (d, J = 8.4 Hz, 1H), 7.35 (s, 1H). 
 
4-(Furan-2-ylmethylamino)benzamide (50l) 
O H
N
NH2
O
 
This was prepared from p-aminobenzamide (0.420 g, 3.12 mmol) and 2-furaldehyde 
(0.260 mL, 3.12 mmol) in a similar manner as described for the preparation of 50a, 
(brown oil, 0.300 g, 44%). The crude product was used as such to the next step without 
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further purification. 1H NMR (400 MHz, CDCl3) δ 4.30 (s, 2H), 6.18-6.28 (m, 2H), 6.57 
(d, J = 8.8 Hz, 1H), 7.30-7.33 (m, 1H), 7.59 (d, J = 8.8 Hz, 2H). 
 
N-(Furan-2-ylmethyl)-3,4-dimethoxyaniline (50m) 
O H
N O
O
 
This was prepared from 4-aminoveratrole (0.500 g, 3.12 mmol) and 2-furaldehyde (0.260 
mL, 3.12 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 
0.500 g, 76%). The crude product was used as such to the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 3.79 (s, 3H), 3.82 (s, 3H), 4.27 (s, 2H), 6.20 
(dd, J = 2.6, 8.0 Hz, 2H), 6.29-6.32 (m, 2H), 6.72 (d, J = 8.8 Hz, 1H), 7.35 (br s, 1H). 
 
N-(Furan-2-ylmethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-amine (50n) 
O H
N
O
O
 
This was prepared from 1,4-benzodioxan-6-amine (0.300 g, 1.98 mmol) and 2-
furaldehyde (0.260 mL, 1.98 mmol) in a similar manner as described for the preparation 
of 50a, (brown oil, 0.490 g, quantitative). The crude product was used as such to the next 
step without further purification. 1H NMR (400 MHz, CDCl3) δ 3.75 (br s, 1H), 4.17-4.19 
(m, 2H), 4.21-4.24 (m, 4H), 6.19-6.24 (m, 3H), 6.30 (dd, J = 1.8, 3.0 Hz, 1H), 6.69 (d, J 
= 8.4 Hz, 1H), 7.35 (br s, 1H). 
 
N-(Furan-2-ylmethyl)-4-methylaniline (50o) 
O H
N
 
This was prepared from p-toluidine (0.330 g, 3.12 mmol) and 2-furaldehyde (0.260 mL, 
3.12 mmol) in a similar manner as described for the preparation of 50a, (brown oil, 0.520 
g, 89%). The crude product was taken as such to the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 2.24 (s, 3H), 4.29 (s, 2H), 6.21 (dd, J = 3.2, 
7.2 Hz, 1H), 6.30 (dd, J = 2.0, 3.2 Hz, 1H), 6.59 (d, J = 8.0 Hz, 2H), 6.99 (d, J = 8.2 Hz, 
 103 
2H), 7.35 (br s, 1H). 
 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-
methoxy-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51a) 
 
N
OOH
O
O
O
 
N-(Furan-2-ylmethyl)-4-methoxyaniline (50a) (0.300 g, 1.47 mmol) was dissolved in 
toluene. To this mixture, maleic anhydride (0.140 g, 1.47 mmol) was added and the 
reaction mixture was stirred at rt for 3 days. Toluene was evaporated from the mixture to 
afford the Diels-Alder adduct as a brown solid (0.380 g, 87%). The crude product was 
used as such to the next step without further purification; 1H NMR (400 MHz, DMSO) δ 
2.55 (d, J = 9.1 Hz, 1H), 3.02 (d, J = 9.1 Hz, 1H), 3.73 (s, 3H), 3.99 (d, J = 11.5 Hz, 
1H), 4.50 (d, J = 11.5 Hz, 1H), 5.02 (d, J = 1.4 Hz, 1H), 6.24 (s, 1H), 6.47 (d, J = 5.6 
Hz, 1H), 6.62 (d, J = 5.6 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 7.54 (d, J = 9.0 Hz, 2H); MS 
m/z (API-ES): 324 (M+Na)+ (100%). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-
isopropyl-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51b) 
N
OOH
O
O
 
This was prepared from maleic anhydride (0.300 g, 3.12 mmol) and compound 50b 
(0.670 g, 3.12 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.270 g, 28%). The crude product was used as such to the next step without further 
purification; 1H NMR (400 MHz, DMSO) δ 1.18 (d, J = 6.8 Hz, 6H), 2.57 (d, J = 9.2 Hz, 
1H), 2.87 (heptet, J = 6.8 Hz, 1H), 3.04 (d, J = 9.2 Hz, 1H), 4.03 (d, J = 11.6 Hz, 1H), 
4.52 (d, J = 11.6 Hz, 1H), 5.02 (d, J = 1.6 Hz, 1H), 6.46 (dd, J = 1.6, 4.4 Hz, 1H), 6.63 
(d, J = 5.6 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.8 Hz, 2H); MS m/z (API-
ES): Calculated for C18H19NO4 314.1386, found 314.1390 (M+H)+ (100%), 336.1213 
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(M+Na)+. 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(2,4-
difluorophenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51c) 
N
OOH
O
F
O
F
 
This was prepared from maleic anhydride (0.180 g, 1.90 mmol) and compound 50c 
(0.400 g, 1.90 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.460 g, 79%). The crude product was used as such to the next step without further 
purification. 1H NMR (400 MHz, DMSO) δ 2.54 (d, J = 9.2 Hz, 1H), 2.98 (d, J = 9.2 Hz, 
1H), 3.91 (d, J = 11.4 Hz, 1H), 4.46 (d, J= 11.4 Hz, 1H), 5.03 (d, J = 1.6 Hz, 1H), 6.46 
(dd, J = 1.6, 5.6 Hz, 1H), 6.61 (d, 6.0 Hz, 1H), 7.13-7.14 (m, 1H), 7.34-7.47 (m, 2H); MS 
m/z (API-ES): 308 (M+H)+ (100%). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-chloro-
phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51d) 
N
OOH
O
Cl
O
 
This was prepared from maleic anhydride (0.180 g, 1.92 mmol) and compound 50d 
(0.400 g, 1.92 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.470 g, 80%). The crude product was used as such to the next step without further 
purification. 1H NMR (400 MHz, DMSO) δ 2.56 (d, J = 9.2 Hz, 1H), 3.06 (d, J = 9.2 Hz, 
1H), 3.14 (br s, 1H), 4.05 (d, J = 11.4 Hz, 1H), 4.50 (d, J = 11.4 Hz, 1H), 5.03 (s, 1H), 
6.46 (dd, J = 1.6, 5.6 Hz, 1H), 6.61 (d, J = 6.0 Hz, 1H), 7.41 (d, J = 9.0 Hz, 2H), 7.68 (d, 
J = 9.0 Hz, 2H); MS m/z (API-ES): Calculated for C15H12ClNO4 305.0528 found 
305.0531 (M+H)+. 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-bromo-
phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ) (51e) 
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N
OOH
O
Br
O
 
This was prepared from maleic anhydride (0.140 g, 1.47 mmol) and compound 50e 
(0.300 g, 1.47 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.380 g, 87%); 1H NMR (400 MHz, DMSO) δ 2.57 (d, J = 9.2 Hz, 1H), 3.05 (d, J 
= 8.8 Hz, 1H), 4.07 (d, J = 11.6 Hz, 1H), 4.52 (d, J = 11.6 Hz, 1H), 5.03 (s, 1H), 6.47 (d, 
J = 5.6 Hz, 1H), 6.61 (d, J = 5.6 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.4 Hz, 
2H); MS m/z (API-ES): Calculated for C15H12BrNO4 350.0023 found 350.0011 (M+H)+. 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-
thiomethyl-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51f) 
N
OOH
O
S
O
 
This was prepared from maleic anhydride (0.230 g, 1.80 mmol) and compound 50f 
(0.400 g, 1.80 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.630 g, 88%), 1H NMR (400 MHz, DMSO) δ 2.43 (s, 3H), 2.54 (d, J = 9.2 Hz, 
1H), 3.03 (d, J = 9.2 Hz, 1H), 4.00 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 11.6 Hz, 1H), 5.01 
(d, J = 1.6 Hz, 1H), 6.45 (dd, J = 1.6, 4.4 Hz, 1H), 6.60 (d, J = 5.6 Hz, 1H), 7.24 (d, J = 
9.0 Hz, 2H), 7.58 (d, J = 9.0 Hz, 2H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-ethoxy-
phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51g) 
N
OOH
O
O
O
 
This was prepared from maleic anhydride (0.160 g, 1.60 mmol) and compound 50g 
(0.350 g, 1.60 mmol) in a similar manner as described for the preparation of 51a. (Brown 
solid, 0.540 g, quantitative); 1H NMR (400 MHz, DMSO) δ 1.27 (t, J = 7.2 Hz, 3H), 2.53 
(d, J = 9.2 Hz, 1H), 3.00 (d, J = 9.2 Hz, 1H), 3.96 (q, J = 7.2 Hz, 2H), 4.47 (d, J = 11.6 
Hz, 1H), 6.45 (dd, J = 1.6, 5.6 Hz, 1H), 6.60 (d, J = 5.6 Hz, 1H), 6.89 (d, J = 9.0 Hz, 
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2H), 7.51 (d, J = 9.0 Hz, 2H), 12.22 (s, 1H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-ethyl-
phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51h) 
N
OOH
O
O
 
This was prepared from maleic anhydride (0.250 g, 2.50 mmol) and compound 50h 
(0.500 g, 2.50 mmol) in a similar manner as described for the preparation of 51a. (brown 
solid, 0.720 g, 97%); 1H NMR (400 MHz, DMSO) δ 1.11 (t, J = 7.6 Hz, 3H), 2.53-2.58 
(m, 3H), 3.01 (d, J = 8.8 Hz, 1H), 3.99 (d, J = 11.6 Hz, 1H), 4.48 (d, J = 11.6 Hz, 1H), 
5.01 (d, J = 1.6 Hz, 1H), 6.44 (dd, J = 1.2, 4.4 Hz, 1H), 6.60 (5.6 Hz, 1H), 7.17 (d, J = 
8.6 Hz, 2H), 7.52 (d, J = 8.6 Hz, 2H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(2-
methoxy-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51i) 
N
OOH
O
O O
 
This was prepared from maleic anhydride (0.240 g, 2.40 mmol) and compound 50i (0.500 
g, 2.40 mmol) in a similar manner as described for the preparation of 52a. The crude 
reaction mass was purified by column chromatography using EtOAc-Hexane (50:50, v/v) 
to give 27i (0.310 g, 44%) as a yellowish solid; 1H NMR (400 MHz, DMSO) δ 2.89 (d, J 
= 9.0 Hz, 1H), 3.07 (d, J = 9.0 Hz, 1H), 3.85 (s, 3H), 3.97 (d, J = 12.0 Hz, 1H), 4.55 (d, 
J = 12.0 Hz, 1H), 5.35 (d, 1H), 6.50 (dd, J = 1.6, 5.8 Hz, 1H), 6.55 (d, J = 5.8 Hz, 1H), 
6.97-6.99 (m, 2H), 7.25-7.31 (m, 2H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(3-
methoxy-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51j) 
N
OOH
O
O
O
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This was prepared from maleic anhydride (0.230 g, 2.40 mmol) and compound 50j 
(0.580 g, 2.40 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.110 g, 20%); 1H NMR (400 MHz, DMSO) δ 2.95 (d, J = 9.0 Hz, 1H), 3.06 (d, J 
= 9.0 Hz, 1H), 3.83 (s, 3H), 4.22 (d, J = 11.6 Hz, 1H), 4.46 (d, J = 11.6 Hz, 1H), 5.41 (s, 
1H), 6.36 (d, J = 12.8 Hz, 1H), 6.44 (d, J = 12.8 Hz, 1H), 6.74 (ddd, J = 2.4, 8.0, 16.0 
Hz, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.27-7.31 (m, 2H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(3,4-
methylenedioxy phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51k) 
N
OOH
O
O
O
O
 
This was prepared from maleic anhydride (0.230 g, 2.30 mmol) and compound 50k 
(0.500 g, 2.30 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.570 g, 78%); 1H NMR (400 MHz, DMSO) δ 2.53 (d, J = 9.2 Hz, 1H), 3.01 (d, J 
= 9.2 Hz, 1H), 3.97 (d, J = 11.2 Hz, 1H), 4.46 (d, J = 11.2 Hz, 1H), 5.01 (d, J = 1.2 Hz, 
1H), 6.00 (s, 2H), 6.45 (dd, J = 1.6, 5.6 Hz, 1H), 6.59 (d, J = 5.6 Hz, 1H), 6.89 (d, J = 
8.4 Hz, 1H), 6.96 (dd, J = 2.0, 8.4 Hz, 1H), 7.36 (d, J = 2.0 Hz, 1H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-
benzamido-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51l) 
N
OOH
O
O
O
NH2
 
This was prepared from maleic anhydride (0.140 g, 1.40 mmol) and compound 50l (0.300 
g, 1.40 mmol) in a similar manner as described for the preparation of 51a, (brown solid, 
0.0780 g, 17%); 1H NMR (400 MHz, DMSO) δ 2.58 (d, J = 9.2 Hz, 1H), 3.11 (d, J = 9.2 
Hz, 1H), 4.11 (d, J = 11.6 Hz, 1H), 4.26 (br s, 2H), 4.56 (d, J = 11.6 Hz, 1H), 5.04 (d, J 
= 1.6 Hz, 1H), 6.48 (dd, J = 1.6, 5.6 Hz, 1H), 6.62 (d, J = 5.6 Hz, 1H), 7.28 (Br s, 1H), 
7.75 (d, J= 8.8 Hz, 2H), 7.89 (d, J = 8.8 Hz, 2H), 7.91 (s, 1H). 
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(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(3,4- 
dimethoxy-phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51m) 
N
OOH
O
O
O
O
 
This was prepared from maleic anhydride (0.200 g, 2.16 mmol) and compound 50m 
(0.500 g, 2.16 mmol) in a similar manner as described for the preparation of 51a, (brown 
solid, 0.710 g, 98%); 1H NMR (400 MHz, DMSO) δ 2.55 (d, J = 9.2 Hz, 1H), 3.02 (d, J 
= 9.2 Hz, 1H), 3.71 (s, 6H), 4.00 (d, J = 11.2 Hz, 1H), 4.47 (d, J = 11.2 Hz, 1H), 5.01 (d, 
J = 1.8 Hz, 1H), 6.45 (dd, J = 1.8, 5.6 Hz, 1H), 6.59 (d, J = 5.6 Hz, 1H), 6.90 (d, J = 8.8 
Hz, 1H), 7.00 (dd, J = 2.4, 8.8 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(2,3-
dihydrobenzo[b][1,4]dioxin)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51n) 
N
OOH
O
O
O
O
 
This was prepared from maleic anhydride (0.0800 g, 0.870 mmol) and compound 50n 
(0.200 g, 0.870 mmol) in a similar manner as described for the preparation of 51a. 
(brown solid, 0.27 g, 95%); 1H NMR (400 MHz, DMSO) δ 2.55 (d, J = 9.2 Hz, 1H), 3.00 
(d, J = 9.2 Hz, 1H), 3.95 (d, J = 11.2 Hz, 1H), 4.19-4.23 (m, 4H), 4.44 (d, J = 11.2 Hz, 
1H), 5.01 (d, J = 1.8 Hz, 1H), 6.45 (dd, J = 1.8, 5.6 Hz, 1H), 6.59 (d, J = 5.6 Hz, 1H), 
6.81 (d, J = 8.8 Hz, 1H), 7.02 (dd, J = 2.6, 8.8 Hz, 1H), 7.22 (d, 2.6 Hz, 1H). 
 
(±)-3a,6-Epoxy-3aH-isoindole-7-carboxylic acid, 1,2,3,6,7,7a-hexahydro-2-(4-methyl-
phenyl)-1-oxo-, [3aR-(3aα,6α,7β,7aβ)] (51o) 
N
OOH
O
O
 
This was prepared from maleic anhydride (0.210 g, 2.13 mmol) and compound 50o 
(0.400 g, 2.13 mmol) in a similar manner as described for the preparation of 51a. (White 
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solid, 0.430 g, 70%); 1H NMR (400 MHz, DMSO) δ 2.26 (s, 3H), 2.54 (d, J = 9.0 Hz, 
1H), 3.03 (d, J = 9.0 Hz, 1H), 3.99 (d, J = 11.2 Hz, 1H), 4.48 (d, J = 11.2 Hz, 1H), 5.01 
(d, J = 1.6 Hz, 1H), 6.45 (dd, J = 1.6, 5.6 Hz, 1H), 6.61 (d, J = 5.6 Hz, 1H), 7.15 (d, J = 
8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H); MS API-ES (m/z) calculated for C16H15NO4 
286.1078, found 286.1078. 
 
2-(4-Methoxyphenyl)-3-oxoisoindoline-4-carboxylic acid (52a) 
NH
O NH
O
OH
HO
OHO
 
The acid (51a) (0.300 g, 0.990 mmol) was refluxed with phosphoric acid (85% solution, 
4 mL) for 1 hr. The resulting solution was poured into water, filtered and the residue 
washed with water to give 52a (0.130 g, 49%) as a brown solid; m.p 200-202 °C; 1H 
NMR (400 MHz, DMSO) δ 3.78 (s, 3H), 5.17 (s, 2H), 7.04 (d, J = 8.8 Hz, 2H), 7.71 (d, J 
= 8.8 Hz, 2H), 7.82 (t, J = 7.4 Hz, 1H), 7.92 (d, J = 7.4 Hz, 1H), 8.12 (d, J = 8.0 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 53.23, 56.01, 114.93, 123.89, 127.97, 129.51, 
131.18, 132.33, 133.28, 143.29, 158.05, 165.69, 168.40; MS m/z (API-ES): 284 (M+H)+ 
(100%) 306.07 (M+Na)+, calculated for C16H13NO4 282.0772, found 282.0792. 
 
2-(4-Isopropylphenyl)-3-oxoisoindoline-4-carboxylic acid (52b) 
N
CO2H O
 
This was prepared from compound 51b (0.200 g, 0.640 mmol) and H3PO4 (4 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.0700 g, 39%); m.p. 
204-206 °C; 1H NMR (400 MHz, DMSO) δ 1.21 (d, J = 6.8 Hz, 6H), 2.92 (heptet, J = 
6.8 Hz, 1H), 5.19 (s, 2H), 7.37 (d, J = 8.5 Hz, 2H), 7.74 (d, J = 8.6 Hz, 2H), 7.85 (t, J = 
7.6 Hz, 1H), 7.93 (d, J = 7.5 Hz, 1H), 8.11 (d, J = 7.5 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 24.50, 33.68, 52.88, 122.13, 127.55, 127.95, 129.75, 130.01, 132.15, 133.44, 
136.16, 143.38, 147.08, 165.83, 168.52; MS m/z (API-ES): 284.09 (M+H)+ (100%), 
calculated for C18H17NO3, 296.1281, found 296.1266. 
 110 
 
2-(2,4-Difluorophenyl)-3-oxoisoindoline-4-carboxylic acid (52c) 
N
CO2H O
F
F
 
This was prepared from compound 51c (0.200 g, 0.650 mmol) and H3PO4 (2.60 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.110 g, 61%), m.p. 
196-198 °C; 1H NMR (400 MHz, DMSO) δ 5.08 (s, 2H), 7.28 (t, J = 9.0 Hz, 1H), 7.52-
7.53 (m, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.94 (d, J = 7.3 Hz, 1H), 
8.08 (d, J = 7.4 Hz, 1H); 13C NMR (101 MHz, DMSO) δ 53.90, 105.85, 112.98, 121.83, 
124.25, 128.06, 128.47, 128.88, 130.07, 131.72, 132.89, 133.64, 142.94, 144.45, 156.50, 
159.13, 160.87, 163.45, 165.98, 168.90, MS m/z (API-ES): 290 (M+H)+ (100%), 
calculated for C15H9F2NO3 289.0550, found 289.0532. 
 
2-(4-Chlorophenyl)-3-oxoisoindoline-4-carboxylic acid (52d) 
N
CO2H O
Cl
 
This was prepared from compound 51d (0.200 g, 0.650 mmol) and H3PO4 (2.60 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.0820 g, 44%); m.p. 
227-229 °C; 1H NMR (400 MHz, DMSO) δ 5.18 (s, 2H), 7.56 (d, J = 8.8 Hz, 2H), 7.89 
(d, J = 9.0 Hz, 4H), 87.98-8.09 (m, 1H); 13C NMR (101 MHz, DMSO) δ 52.46, 123.25, 
127.61, 129.61, 129.73, 130.24, 131.50, 133.60, 137.60, 143.20, 166.21, 168.40; MS m/z 
(API-ES): 287 (M+H)+ (100%), calculated for C15H10NO3Cl 288.0422, found 288.0412. 
 
2-(4-Bromophenyl)-3-oxoisoindoline-4-carboxylic acid (52e) 
N
CO2H O
Br
 
This was prepared from compound 51e (0.200 g, 0.650 mmol) and H3PO4 (2.30 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.0780 g, 41%); m.p. 
230-232 °C; 1H NMR (400 MHz, DMSO) δ 5.18 (s, 2H), 7.68 (d, J = 8.9 Hz, 2H), 7.84 
(d, J = 8.1 Hz, 3H), 7.90 (d, J = 7.7 Hz, 1H), 7.98-8.15 (m, 1H); 13C NMR (101 MHz, 
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DMSO) δ 52.36, 118.62, 123.44, 127.59, 129.59, 130.22, 131.51, 132.63, 133.59, 138.01, 
143.14, 166.18, 168.39; MS m/z (API-ES): 330 (M+H)+ (100%), calculated for 
C15H10NO3Br 331.9917, found 331.9910. 
 
2-(4-Ethoxyphenyl)-3-oxoisoindoline-4-carboxylic acid (52f) 
N
CO2H O
O
 
This was prepared from compound 51g (0.300 g, 0.960 mmol) and H3PO4 (2.60 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.134 g, 47%); m.p. 
182-184 °C; 1H NMR (400 MHz, DMSO) δ 1.33 (t, J = 6.9 Hz, 3H), 4.05 (q, J = 6.9 Hz, 
2H), 5.17 (s, 2H), 7.04 (d, J = 9.7 Hz, 2H), 7.71 (d, J = 9.7 Hz, 2H), 7.88 (td, J = 15.2, 
7.4 Hz, 2H), 8.13 (d, J = 7.6 Hz, 1H); 13C NMR (101 MHz, DMSO) δ 15.26, 53.18, 
63.96, 115.34, 123.79, 127.96, 129.47, 131.03, 132.35, 133.26, 143.24, 157.31, 165.65, 
168.36; MS m/z (API-ES): 297 (M+H)+ (100%), calculated for C17H15NO4 296.0928, 
found 298.0938. 
 
2-(2-Methoxyphenyl)-3-oxoisoindoline-4-carboxylic acid (52g) 
N
CO2H O
O
 
This was prepared from compound 51i (0.300 g, 0.996 mmol) and H3PO4 (3.00 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.0500 g, 19%); m.p. 
207-208 °C; 1H NMR (400 MHz, DMSO) δ 4.23 (s, 3H), 5.44 (s, 2H), 7.49 (d, J = 7.6 
Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.86-7.93 (m, 2H), 8.29 (t, J = 7.6 Hz, 1H), 8.37 (d, J 
= 7.6 Hz, 1H), 8.59 (d, J = 7.6 Hz); 13C NMR (101 MHz, DMSO) δ 54.03, 56.52, 
113.30, 121.35, 125.39, 128.45, 128.63, 129.32, 129.55, 130.78, 132.45, 132.58, 133.48, 
144.48, 155.29, 165.58, 169.48, MS m/z (API-ES): 283 (M+H)+ (100%), calculated for 
C16H13NO4 282.0772, found 282.0784; 
 
2-(Benzo[d][1,3]dioxol-5-yl)-3-oxoisoindoline-4-carboxylic acid (52h) 
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N
CO2H O O
O
 
This was prepared from compound 51k (0.300 g, 0.960 mmol) and H3PO4 (3.00 mL) in a 
similar manner as described in the preparation of 52a, (brown solid, 0.0270 g, 30%); m.p. 
266-267 °C; 1H NMR (400 MHz, DMSO) δ 5.14 (s, 2H), 6.08 (s, 2H), 7.04 (d, J = 7.8 
Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.46 (s, 1H), 7.85 (d, J = 6.6 Hz, 1H), 7.94 (s, 1H), 
8.11 (d, J = 6.6 Hz, 1H); 13C NMR (101 MHz, DMSO) δ 53.53, 102.31, 104.50, 108.92, 
116.24, 127.87, 129.71, 129.88, 132.10, 132.34, 133.41, 143.29, 146.10, 148.24, 165.86, 
168.44; MS m/z (API-ES): 298 (M-H)- (100%), calculated for C16H11NO5 296.0564, 
found 296.0569. 
 
Methyl 2-(4-methoxyphenyl)-3-oxoisoindoline-4-carboxylate (53a) 
N
O
O
O O
 
Compound 52a (0.0150 g, 0.0500 mmol) was dissolved in MeOH (0.3 mL). To this 
solution, SOCl2 (0.200 mL) was added drop wise and heated at 140 °C for 2 min. 
Methanol was evaporated at reduced pressure to afford 53a (0.0120 g, quantitative) as a 
brown solid, m.p. 196-198 °C; 1H NMR (400 MHz, CD3OD) δ 3.88 (s, 3H), 4.13 (s, 3H), 
4.82 (s, 2H), 6.94 (d, J = 9.0 Hz, 2H), 7.56-7.65 (m, 3H), 7.71 (d, J = 9.0 Hz, 2H); 13C 
NMR (101 MHz, DMSO) δ 51.04, 52.05, 55.72, 114.54, 122.00, 124.93, 128.07, 130.61, 
131.10, 131.67, 132.46, 141.20, 157.06, 165.20, 168.04; MS m/z (API-ES): 297 (M+H)+ 
(100%), calculated for C17H15NO4 298.1074, found 298.1085. 
 
Ethyl 2-(4-methoxyphenyl)-3-oxoisoindoline-4-carboxylate (53b) 
N
O
O
O O
 
Compound 52a (0.0140 g, 0.0500 mmol) was dissolved in EtOH (0.30 mL). To this 
solution, SOCl2 (0.200 mL) was added drop wise and heated at 140 °C for 2 min. Ethanol 
was evaporated at reduced pressure to afford 53b (0.0120 g, quantitative) as a brown 
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solid; m.p >250 °C; 1H NMR (400 MHz, CD3OD) δ 1.42 (t, J = 7.2 Hz, 3H), 3.72 (s, 
3H), 4.49 (q, J = 7.2 Hz, 2H), 4.82 (s, 2H), 6.94 (d, J = 9.0 Hz, 2H), 7.58-7.60 (m, 3H), 
7.71 (d, J = 9.0 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 14.41, 51.04, 55.72, 62.18, 
114.55, 121.98, 124.74, 127.90, 130.53, 131.59, 131.64, 132.54, 141.17, 157.02, 162.44, 
167.58; MS m/z (API-ES): 297 (M+H)+ (100%), calculated for C18H17NO4 312.1230, 
found 312.1252. 
 
Sodium 2-(4-methoxyphenyl)-3-oxoisoindoline-4-carboxylate (54) 
N
O
O
-O ONa+
 
Compound 52a (0.100 g, 0.350 mmol) was dissolved in NaOEt (0.20 M, 1.75 mL). This 
mixture was stirred at rt for 16 hrs. Ethanol was evaporated and dried to give 54 (0.100 g, 
quantitative) as a brown solid, m.p. >300 °C; 1H NMR (400 MHz, DMSO) δ 3.76 (s, 3H), 
5.01 (s, 2H), 7.00 (d, J = 9.2 Hz, 2H), 7.65 (br s, 3H), 7.72 (d, J = 9.2 Hz, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ 52.53, 56.00, 114.87, 123.42, 126.03, 129.28, 130.50, 131.88, 
132.88, 133.47, 142.82, 157.61, 167.52, 167.95; MS m/z (API-ES): 284 (M+H)+ (100%), 
calculated for C16H13NO4 282.0772, found 228.0790. 
 
2-(4-Methoxyphenyl)isoindolin-1-one (56) 
N
O
O
 
Phthaldialdehyde 55 (0.400 g, 3.00 mmol) was dissolved in AcOH (8.60 mL). To this 
solution, p-anisidine (0.360 g, 3.00 mmol) was added and the reaction mixture was 
heated at 130 °C for 10 min. Water (2 mL) was added and the AcOH-water was 
evaporated under reduced pressure. The aqueous layer was extracted three times with 
DCM (5.00 mL), washed with HCl (1.0 M, 5 mL), dried (Na2SO4) and evaporated. The 
crude product was purified by column chromatography using EtOAc-hexane (1:3, v/v). 
The product obtained from column chromatography was further recrystallised from 
EtOAc-hexane (1:5, v/v) to give 56 (0.0660 g, 9.2%) as a colourless solid; m.p. 133-134 
°C; 1H NMR (400 MHz, CDCl3) δ 3.83 (s, 3H), 4.83 (s, 2H), 6.96 (d, J = 8.8 Hz, 2H), 
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7.48-7.52 (m, 2H), 7.57-7.60 (m, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.91 (d, J = 7.2 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 51.37, 55.71, 114.54, 121.68, 124.22, 128.51, 132.01, 
132.86, 140.35, 156.82, 167.44; MS m/z (API-ES): 239 (M+H)+ (100%), calculated for 
C15H13NO2 240.1019, found 240.1010; 
 
1-(4-Methoxyphenyl)pyrrolidin-2-one (59)149 
O
N
NH
O
 
2-Chloroethylisocyanate (0.0700 mL, 0.800 mmol) in THF (1 mL) was added to p-
anisidine (0.100 g, 0.800 mmol) and heated at 100 °C for 10 min in the microwave 
reactor.  The crude reaction mass was added dropwise to a solution of NaH (60% 
dispersion in paraffin oil, 0.0400 g, 0.960 mmol) in THF (0.2 mL). The reaction mixture 
was stirred at rt for 30 min. The aqueous layer was extracted with DCM (3 × 5 mL), dried 
(Na2SO4) and evaporated. The crude product was recrystallised from DCM (3 mL) to 
give 59 (0.0500 g, 35%) as brown crystals; m.p 214-215 °C; 1H NMR (400 MHz, 
DMSO) δ 3.60-3.85 (m, 4H), 6.69-6.94 (m, 2H), 7.41 (d, J = 7.6 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 37.34, 45.49, 55.85, 114.45, 119.37, 134.76, 154.91, 159.92; MS m/z 
(API-ES) 192 (M+H)+ (100%), calculated for C10H12N2O2 192.0893, found 192.0897. 
 
1-(4-Methoxyphenyl)pyrrolidin-2-one (61a)153 
O
N O
 
p-Anisidine (0.200 g, 1.60 mmol) was dissolved in CHCl3 (3 mL). To this solution, 
Na2HPO4 (0.46 g, 3.20 mmol) was added. After the aniline dissolved, 4-chloro butyryl 
chloride (0.180 mL, 1.60 mmol) was added and stirred at rt for 22 hrs. The crude reaction 
mass was filtered over cotton and the filtrate was evaporated to afford 4-chloro-N-(4-
methoxyphenyl)butanamide. The resulting crude product was added dropwise to a 
solution of NaH (0.0840 g, 2.11 mmol) in THF (2 mL). After the addition was over, the 
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product was extracted with DCM (3 × 5 mL), dried (Na2SO4) and evaporated to afford 
61a (0.600 g, 49%) as a reddish solid, m.p. 111-112 °C; 1H NMR (400 MHz, DMSO) δ 
2.09-2.17 (quintet, J = 7.2 Hz, 2H), 2.60 (t, J = 8.0 Hz, 2H), 3.79 (s, 3H), 3.84 (t, J = 7.2 
Hz, 2H), 7.16 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 21.64, 23.74, 36.27, 53.36, 124.65, 133.07, 138.64, 140.81, 179.40; MS (m/z) 
(API-ES) 191 (M+H)+ (100%), calculated for C11H13NO2 192.1019, found 192.1018. 
 
1-p-Tolylpyrrolidin-2-one (61b) 
N O
 
p-Toluidine (0.200 g, 1.86 mmol) was dissolved in CHCl3 (3 mL). To this solution, 
Na2HPO4 (0.530 g, 3.73 mmol) was added. After the aniline dissolved, 4-chlorobutyryl 
chloride (0.210 mL, 1.86 mmol) was added and stirred at rt for 22 hrs. The crude reaction 
mass was filtered over cotton and the filtrate was evaporated to afford 4-chloro-N-p-
tolylbutanamide. The resulting crude product was added drop wise to a solution of NaH 
(0.0840 g, 2.11 mmol) in THF (2 mL). After the addition was over, the product was 
extracted three times with DCM (5 mL), dried (Na2SO4) and evaporated to afford 61b 
(0.600 g, 49%) as a reddish solid, m.p. 82-84 °C; 1H NMR (400 MHz, CDCl3) δ 2.09 
(quintet, J = 7.4 Hz, 2H), 2.56 (t, J = 8.0 Hz, 2H), 3.80 (t, J = 7.4 Hz, 2H), 7.14 (d, J = 
8.8 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 21.68, 36.05, 
52.01, 58.66, 117.77, 126.61, 136.29, 161.33, 179.34; MS (m/z) (API-ES) 175 (M+H)+ 
(100%), calculated for C11H13NO 176.1070, found 176.1080. 
 
7.5 General procedure for the synthesis of substituted cyclohexanecarboxylic acids 
63a-h154  
cis-Cyclohexane dicarboxylic anhydride was dissolved in CHCl3 (1 mL). To this solution, 
the aniline (1 Mol eq) was added and stirred at rt for 30 min. The slurry was filtered and 
the filtrate washed with CHCl3 (3 mL) and dried to give the pure product. 
 
(1S,2R)-2-(4-Methoxyphenylcarbamoyl)cyclohexanecarboxylic acid (63a) 
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O
NH
OO OH
 
This was prepared from p-anisidine (0.0800 g, 0.650 mmol) in a similar manner as 
described above, (colorless solid, 0.150 g, 85%), m.p. 180-182 °C; 1H NMR (400 MHz, 
CD3OD) δ 1.44-1.49 (m, 2H), 1.79-1.83 (m, 2H), 2.74-2.76 (m, 2H), 2.92-2.93 (m, 2H), 
3.75 (s, 3H), 6.85 (d, J = 9.01 Hz, 2H), 7.36 (d, J = 9.01 Hz, 2H); 13C NMR (101 MHz, 
CD3OD) δ 23.14, 24.64, 25.96, 28.44, 42.70, 43.15, 55.78, 114.31, 121.35, 133.41, 
155.56, 172.79, 175.81; MS (m/z) (API-ES) 277 (M+H)+ (100%), calculated for 
C15H19NO4 278.1387, found 278.1391. 
 
(1S,2R)-2-(2,4-Difluorophenylcarbamoyl)cyclohexanecarboxylic acid (63b) 
F
NH
OO OH
F
 
This was prepared from 2,4-difluoroaniline (0.0800 g, 0.650 mmol) in a similar manner 
as described above, (colorless solid, 0.130 g, 69%), m.p. 140-142 °C; 1H NMR (400 
MHz, CD3OD) δ 1.44-1.49 (m, 2H), 1.79-1.83 (m, 2H), 2.74-2.76 (m, 2H), 2.92-2.93 (m, 
2H), 2.98 (q, J = 5.0 Hz, 1H), 3.15 (d, J = 5.0 Hz, 1H), 7.01-7.04 (m, 1H), 7.28 (dt, J = 
2.8, 8.0 Hz, 1H), 7.61-7.68 (m, 1H), 9.47 (s, 1H); 13C NMR (101 MHz, CD3OD) δ 23.07, 
24.59, 25.94, 28.29, 42.70, 104.65 (dd, J = 2.0, 24.2 Hz), 111.50 (dd, J = 4.0, 18.18 Hz), 
123.60 (dd, J = 4.0, 8.0 Hz), 126.87 (d, J = 9.0), 153.65, 156.11, 157.83, 160.25, 173.60, 
175.70; MS (m/z) (API-ES) 283 (M+H)+ (100%), calculated for C14H15F2NO3 284.1093, 
found 284.1096. 
 
(1S,2R)-2-(4-Chlorophenylcarbamoyl)cyclohexanecarboxylic acid (63c) 
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Cl
NH
OO OH
 
This was prepared from 4-chloroaniline (0.0820 g, 0.650 mmol) in a similar manner as 
described above, (colorless solid, 0.170 g, 93%), m.p. 190-192 °C; 1H NMR (400 MHz, 
CD3OD) δ 1.44-1.49 (m, 2H), 1.79-1.83 (m, 2H), 2.74-2.76 (m, 2H), 2.92-2.93 (m, 2H), 
2.90 (q, J = 5.0 Hz, 1H), 3.15 (d, J = 5.0 Hz, 1H), 7.28 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 
8.8 Hz, 2H), 9.83 (s, 1H); 13C NMR (101 MHz, CD3OD) δ 23.03, 24.65, 25.89, 28.30, 
42.69, 43.25, 121.30, 126.95, 129.05, 139.17, 173.46, 175.73; MS (m/z) (API-ES) 281 
(M+H)+ (100%), calculated for C14H16NO3Cl 282.0891, found 282.0897. 
 
(1S,2R)-2-(4-Bromophenylcarbamoyl)cyclohexanecarboxylic acid (63d) 
Br
NH
OO OH
 
This was prepared from 4-bromoaniline (0.110 g, 0.650 mmol) in a similar manner as 
described above, (Colorless solid, 0.160 g, 74%), m.p. 196-198 °C; 1H NMR (400 MHz, 
CD3OD) δ 1.44-1.49 (m, 2H), 1.79-1.83 (m, 2H), 2.74-2.76 (m, 2H), 2.92-2.93 (m, 2H), 
2.90 (q, J = 5.0 Hz, 1H), 3.15 (d, J = 5.0 Hz, 1H), 7.43 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 
8.8 Hz, 2H), 9.83 (s, 1H); 13C NMR (101 MHz, CD3OD) δ 23.03, 24.66, 25.88, 28.29, 
31.33, 42.67, 43.26, 114.90, 121.70, 131.98, 139.59, 173.49, 175.73; MS (m/z) (API-ES) 
325 (M+H)+ (100%), calculated for C14H16BrNO3 326.0386, found 326.0387. 
 
(1S,2R)-2-(p-Tolylcarbamoyl)cyclohexanecarboxylic acid (63e) 
NH
OO OH
 
This was prepared form p-toluidine (0.070 g, 0.650 mmol) in a similar manner as 
described above, (colorless solid, 0.150 g, 87%), m.p. 186-188 °C; 1H NMR (400 MHz, 
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CD3OD) δ 1.44-1.49 (m, 2H), 1.79-1.82 (m, 2H), 2.21 (s, 3H), 2.73-2.76 (m, 2H), 2.91-
2.92 (m, 2H), 2.90 (q, J = 5.0 Hz, 1H), 3.15 (d, J = 5.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 2H), 
7.43 (d, J = 8.4 Hz, 2H), 9.58 (s, 1H); 13C NMR (101 MHz, CD3OD) δ 21.06, 23.11, 
24.68, 25.93, 28.47, 42.71, 43.23, 119.85, 129.53, 132.21, 137.74, 173.06, 175.81; MS 
(m/z) (API-ES) 261 (M+H)+ (100%), calculated for C15H19NO3 262.1438, found 
262.1439. 
 
(1S,2R)-2-(4-Isopropylphenylcarbamoyl)cyclohexanecarboxylic acid (63f) 
NH
OO OH
 
This was prepared from 4-isopropylaniline (0.0870 g, 0.650 mmol) in a similar manner as 
described above, (colorless solid, 0.160 g, 83%), m.p. 176-178 °C; 1H NMR (400 MHz, 
CD3OD) δ 1.15 (d, J = 7.2 Hz, 6H), 1.45-1.46 (m, 2H), 1.78-1.80 (m, 2H), 2.73-2.74 (m, 
2H), 2.78-2.80 (m, 1H), 2.91-2.93 (m, 2H), 7.11 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 
2H); 13C NMR (101 MHz, CD3OD) δ 23.09, 24.66, 25.92, 28.46, 33.53, 42.70, 43.19, 
119.88, 126.84, 138.02, 143.43, 173.06, 175.78; MS (m/z) (API-ES) 289 (M+H)+ 
(100%), calculated for C17H23NO3 290.1751, found 290.1754. 
 
(1S,2R)-2-(4-(Trifluoromethyl)phenylcarbamoyl)cyclohexanecarboxylic acid (63g) 
CF3
NH
OO OH
 
This was prepared from 4-trifluoromethylaniline (0.080 mL, 0.650 mmol) in a similar 
manner as described above, (colorless solid, 0.200 g, 98%), m.p. 176-182 °C; 1H NMR 
(400 MHz, CD3OD) δ 1.43-1.45 (m, 2H), 1.79-1.82 (m, 2H), 2.73-2.75 (m, 2H), 2.91-
2.93 (m, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H); 13C NMR (101 MHz, 
CD3OD) δ 22.96, 24.63, 25.86, 28.20, 39.71 (t, J = 21.2 Hz), 40.60 (d, J = 65.6 Hz), 
79.81, 119.53, 123.00 (m), 123.95, 129.13, 143.81, 173.98, 175.71; MS (m/z) (API-ES) 
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315 (M+H)+ (100%), calculated for C15H16F3NO3 316.1155, found 316.1165. 
 
(1S,2R)-2-(4-(Ethoxycarbonyl)phenylcarbamoyl)cyclohexanecarboxylic acid (63h) 
NH
OO OH
O O
 
This was prepared form 4-(aminoethyl) benzoate (0.110 g, 0.650 mmol) in a similar 
manner as described above, (colorless solid, 0.170 g, 84%), m.p. 158-160 °C; 1H NMR 
(400 MHz, CD3OD) δ 1.30 (t, J = 7.2 Hz, 3H), 1.44-1.46 (m, 2H), 1.78-1.80 (m, 2H), 
2.73-2.75 (m, 2H), 2.91-2.93 (m, 2H), 4.28 (q, J = 7.2 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 
7.87 (d, J = 8.8 Hz, 2H); 13C NMR (101 MHz, CD3OD) δ 14.87, 22.96, 24.67, 25.82, 
28.26, 42.66, 43.32, 61.02, 119.01, 124.39, 130.76, 144.62, 166.03, 173.94, 175.71; MS 
(m/z) (API-ES) 319 (M+H)+ (100%), calculated for C17H21NO5 320.1493, found 
320.1497. 
 
7.6 General procedure for the synthesis of substituted oxobutanoic acids 65a-g155 
The aniline was dissolved in CHCl3 (2 mL). To this solution, succinic anhydride (1 eq) 
was added and stirred at rt for 30 minutes. After 30 min, the reaction mixture was 
filtered, the residue washed with CHCl3 and dried to give the pure product.  
 
4-(4-Methoxyphenylamino)-4-oxobutanoic acid (65a)  
HN
O
OH
O
O
 
This was prepared from p-anisidine (0.120 g, 1.00 mmol) in a similar manner as 
described above. The product was collected as a colorless solid (0.180 g, 81%), m.p. 162-
164 °C; 1H NMR (400 MHz, CD3OD) δ 2.63 (dd, J = 3.6, 5.6 Hz, 4H), 3.76 (s, 3H), 6.84 
(d, J = 8.8 Hz, 2H), 7.39 (d, J = 8.8 Hz, 2H); 13C NMR (101 MHz, CD3OD) δ 28.96, 
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31.02, 54.66, 113.72, 121.82, 121.93, 131.65, 156.62, 171.41, 175.20; MS (m/z) (API-
ES) 223 (M+H)+ (100%), calculated for C11H13NO4 222.0772, found 222.0776. 
 
4-(2,4-Difluorophenylamino)-4-oxobutanoic acid (65b) 
HN
F
OH
O
O
F
 
This was prepared from 2,4-difluoroaniline (0.130 g, 1.00 mmol) in a similar manner as 
described above. The product was collected as a colorless solid (0.240 g, quantitative), 
m.p. 158-160 °C; 1H NMR (400 MHz, CD3OD) δ 2.65 (d, J = 5.8 Hz, 2H), 2.68 (d, J = 
5.8 Hz, 2H), 6.90-6.94 (m, 1H), 6.98 (dt, J = 2.8, 9.6 Hz, 1H), 7.77-7.83 (m, 1H); 13C 
NMR (101 MHz, CD3OD) δ 28.75, 30.63, 103.57 (dd, J = 2.3, 24.2 Hz, 1C), 110.60 (dd, 
J = 3.8, 18.4 Hz, 1C); 122.30 (dd, J = 3.8, 8.2 Hz, 1C), 125.97 (dd, J = 2.6, 6.8 Hz, 1C), 
153.71 (d, J = 12.1 Hz, 1C), 156.18 (d, J = 12.0 Hz, 1C), 158.662 (d, J = 11.4 Hz, 1C), 
161.06 (d, J = 11.4 Hz, 1C); MS (m/z) (API-ES) 229 (M+H)+ (100%), calculated for 
C10H9F2NO3 228.0478, found 228.0493. 
 
4-(4-Chlorophenylamino)-4-oxobutanoic acid (65c) 
HN
Cl
OH
O
O
 
This was prepared using 4-chloroaniline (0.127 g, 1.00 mmol) in a similar manner as 
described above. The product was collected as a colorless solid (0.210 g, 92%), m.p. 168-
170 °C; 1H NMR (400 MHz, CD3OD) δ 2.65 (s, 4H), 7.27 (d, J = 8.4 Hz, 2H), 7.53 (d J 
= 8.4 Hz, 2H); 13C NMR (101 MHz, CD3OD) δ 28.72, 31.12, 121.19, 121.29, 128.52, 
128.57, 137.59, 171.66, 175.11; MS (m/z) (API-ES) 227 (M+H)+ (100%), calculated for 
C10H10ClNO3 226.0276, found 226.0278. 
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4-(4-Bromophenylamino)-4-oxobutanoic acid (65d) 
HN
Br
OH
O
O
 
This was prepared from 4-bromoaniline (0.170 g, 1.00 mmol) in a similar manner as 
described above. The product was collected as a colorless solid (0.260 g, 97%), m.p. 194-
196 °C; 1H NMR (400 MHz, CD3OD) δ 2.65 (s, 4H), 7.42 (d, J = 9.0 Hz), 7.50 (d, J = 
9.0 Hz); 13C NMR (101 MHz, CD3OD) δ 28.71, 31.15, 116.05, 121.51, 121.61, 131.54, 
138.05, 171.67, 175.13; MS (m/z) (API-ES) 270 (M+H)+ (100%), calculated for 
C10H10BrNO3 269.9771, found 269.9771. 
 
4-Oxo-4-(p-tolylamino)butanoic acid (65e) 
HN
OH
O
O
 
This was prepared form p-toluidine (0.100 g, 1.00 mmol) in a similar manner as 
described above. The product was collected as a colorless solid (0.190 g, 91%), m.p. 180-
182 °C; 1H NMR (400 MHz, CD3OD) δ 2.28 (s, 3H), 2.60 (s, 4H), 7.09 (d, J = 8.4 Hz, 
2H), 7.39 (d, J = 8.4 Hz, 2H); 13C NMR (101 MHz, CD3OD) δ 19.74, 28.89, 31.12, 
120.12, 129.03, 135.58, 136.07, 171.50, 175.18; MS (m/z) (API-ES) 207 (M+H)+ 
(100%), calculated for C11H13NO3 206.0823, found 206.0830. 
 
4-(4-Isopropylphenylamino)-4-oxobutanoic acid (65f)  
HN
OH
O
O
 
This was prepared from 4-isopropylaniline (0.142 g, 1.00 mmol) in a similar manner as 
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described above. The product was collected as a colorless solid (0.230 g, 98%), m.p. 156-
158 °C; 1H NMR (400 MHz, CD3OD) δ 1.22 (d, J = 6.8 Hz, 6H), 2.64 (s, 4H), 2.82 
(heptet, J = 6.8 Hz, 1H), 7.15 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H); 13C NMR 
(101 MHz, CD3OD) δ 23.32, 28.90, 31.12, 33.67, 120.20, 126.40, 136.35, 144.74, 
171.52, 175.17; MS (m/z) (API-ES) 235 (M+H)+ (100%), calculated for C13H17NO3 
234.36, found 234.1136. 
 
4-(4-(Ethoxycarbonyl)phenylamino)-4-oxobutanoic acid (65g)  
HN
OH
O
O
OO
 
This was prepared from ethyl 4-aminobenzoate (0.165 g, 1.00 mmol) in a similar manner 
as described above. The product was collected as a colorless solid (0.210 g, 82%), m.p. 
159-161 °C; 1H NMR (400 MHz, CD3OD) δ 1.37 (t, J = 7.2 Hz, 3H), 2.66 (t, J = 3.6 Hz, 
4H), 4.30 (q, J = 7.2 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 8.4 Hz, 2H); 13C 
NMR (101 MHz, CD3OD) δ 13.47, 28.67, 31.29, 60.79, 118.80, 118.89, 125.20, 130.29, 
143.31, 166.55, 171.91, 175.13; MS (m/z) (API-ES) 265 (M+H)+ (100%), calculated for 
C13H15NO5 264.0878, found 264.0881. 
 
Methyl 2-methyl-6-nitrobenzoate (67) 
NO2
O
O
 
2-Methyl 6-nitro benzoic acid (0.500 g, 3.00 mmol) was dissolved in acetone (10 mL). 
To the resulting solution, K2CO3 (2.00 g, 15.4 mmol) and iodomethane (0.900 mL, 15.4 
mmol) was added and refluxed for 15 hrs. The reaction mass was filtered after cooling to 
rt and extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to afford 67 
(0.530 g, 90%) as a yellow solid. The crude product was taken to the next step without 
further purification; m.p 50-51 °C; 1H NMR (400 MHz, CDCl3) δ 2.41 (s, 2H), 3.96 (s, 
3H), 7.50 (t, J = 8.0 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H). 
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Methyl 2-(bromomethyl)-6-nitrobenzoate (68)156 
NO2
O
O
Br
 
Methyl 2-methyl-6-nitrobenzoate 67 (0.500 g, 2.56 mmol) was dissolved in CCl4 (5 mL). 
to this solution, NBS (0.431 g, 2.82 mmol) and catalytic amount of AIBN were added 
and refluxed for 40 hrs. The crude mass was extracted with DCM (3 × 5 mL), dried 
(Na2SO4) and evaporated to afford 68 (0.270 g, 39%) as a yellow solid in 39% yield. The 
crude product was taken to the next step without further purification; m.p 50-51 °C; 1H 
NMR (400 MHz, CDCl3) δ 3.97 (s, 3H), 4.56 (s, 2H), 7.58 (t, J = 8.0 Hz, 1H), 7.76 (d, J 
= 8.0 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H). 
 
2-(4-Methoxyphenyl)-7-nitroisoindolin-1-one (69) 
NO2
N O
O
 
Methyl 2-(bromomethyl)-6-nitrobenzoate 68 (0.0500 g, 0.180 mmol) was dissolved in 
DMF (0.1 mL). To this solution, p-anisidine (0.0220 g, 0.180 mmol) was added heated at 
150 °C for 15 min in the microwave reactor. After the completion of the reaction, DMF 
was evaporated from the reaction mixture and the crude product was recrystallized from 
DCM to afford 69 (0.02 g, 44%) as a yellow crystalline solid; m.p 226-228 °C; 1H NMR 
(400 MHz, DMSO) δ ppm 3.83 (s, 3H), 4.89 (s, 2H), 6.96 (d, J = 9.2 Hz, 2H), 7.70-7.75 
(m, 5H); 13C NMR (101 MHz, DMSO) δ 50.67, 55.73, 114.62, 122.00, 123.16, 124.38, 
126.48, 130.16, 131.18, 131.89, 132.57, 142.71, 157.37; MS (m/z) (API-ES) 285 (M+H)+ 
(100%), calculated for C15H12N2O4 285.0870, found 285.0877. 
 
7.7 General procedure for the synthesis of urea derivatives 78a-e: 
2-Isocyanatobenzoic acid (1 mol eq) was dissolved in THF (4 mL). To this solution, the 
aniline (1 mol eq) was added and heated at 100 °C for 10 min in the microwave reactor. 
The THF in the resulting mixture was evaporated to dryness to get the product.   
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2-(3-(2-(Methoxycarbonyl)phenyl)ureido)benzoic acid (77a) 
NH
O
OH
O NH
O
O
 
This was prepared from 2-aminobenzoic acid (0.300 g, 2.20 mmol) and 2-
isocyanatobenzoic acid (0.380 g, 2.20 mmol) in a similar manner as described above. The 
product was collected as a colorless solid (0.600 g, 88%); This was taken to the next step 
without further purification. 1H NMR (400 MHz, CD3OD) δ 490 (s, 3H), 7.06-7.10 (m, 
2H), 7.52-7.57 (m, 2H), 8.01 (dd, J = 1.2, 8.0 Hz, 2H), 8.05 (dd, J = 1.2, 8.0 Hz, 2H), 
8.37 (dd, J = 0.4, 8.8, 2H), 8.41 (dd, J = 0.6, 8.4 Hz, 2H). 
 
3-(3-(2-(Methoxycarbonyl)phenyl)ureido)benzoic acid (77b) 
NH
O NH
O
O
COOH
 
This was prepared from 3-aminobenzoic acid (0.300 g, 2.20 mmol) and 2-
isocyanatobenzoic acid (0.380 g, 2.20 mmol) in a similar manner as described above. The 
product was collected as a colorless solid (0.670 g, 97%); This was taken to the next step 
without further purification. 1H NMR (400 MHz, CD3OD) δ 3.94 (s, 3H), 7.04 (dt, J = 
1.2, 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.51 (dt, J = 1.2, 8.0 Hz, 1H), 7.68 (td, J = 1.2, 
8.0 Hz, 1H), 7.74-7.77 (m, 1H), 8.03 (dd, J = 1.6, 8.0 Hz, 1H), 8.15 (t, J = 1.6 Hz, 1H), 
8.36 (dd, J = 0.8, 8.8 Hz, 1H). 
 
4-(3-(2-(Methoxycarbonyl)phenyl)ureido)benzoic acid (77c) 
NH
O NH
O
O
HOOC
 
This was prepared from 4-aminobenzoic acid (0.300 g, 2.20 mmol) and 2-
isocyanatobenzoic acid (0.380 g, 2.20 mmol) in a similar manner as described above. The 
product was collected as a colorless solid (0.390 g, 57%); This was taken to the next step 
without further purification. 1H NMR (400 MHz, CD3OD) δ 3.94 (s, 3H), 7.05 (dt, J = 
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1.2, 7.8 Hz, 1H), 7.52 (dt, J = 1.8, 9.2 Hz, 1H), 7.61 (d, J = 8.6 Hz, 2H), 7.94 (d, J = 8.6 
Hz, 2H), 8.01 (dd, J = 1.6, 8.0 Hz, 1H), 8.36 (dd, J = 1.2, 8.6 Hz). 
 
2-Hydroxy-4-(3-(2-(methoxycarbonyl)phenyl)ureido)benzoic acid (77d) 
NH
O NH
O
O
OH
HOOC
 
This was prepared from 4-aminosalicylic acid (0.300 g, 2.20 mmol) and 2-
isocyanatobenzoic acid (0.350 g, 2.20 mmol) in a similar manner as described above. The 
product was collected as a colorless solid (0.640 g, 98%); This was taken to the next step 
without further purification. 1H NMR (400 MHz, CD3OD) δ 3.94 (s, 3H), 6.97 (dd, J = 
2.0, 4.8 Hz, 1H), 7.05 (t, J = 8.0 Hz, 1H), 7.24 (d, J = 2.0 Hz, 1H), 7.52 (dt, J = 1.6, 8.8 
Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 8.01 (dd, J = 1.6, 8.2 Hz, 1H), 8.35 (d, J = 8.2 Hz, 
1H). 
 
2-Hydroxy-5-(3-(2-(methoxycarbonyl)phenyl)ureido)benzoic acid (77e) 
NH
O NH
O
O
COOH
HO
 
This was prepared from 3-aminosalicylic acid (0.300 g, 2.20 mmol) and 2-
isocyanatobenzoic acid (0.350 g, 2.20 mmol) in a similar manner as described above. The 
product was collected as a colorless solid (0.300 g, 46%); This was taken to the next step 
without further purification. 1H NMR (400 MHz, CD3OD) δ 3.90 (s, 3H), 6.88 (d, J = 9.2 
Hz, 1H0, 7.02 (t, J = 7.6 Hz, 1H), 7.50-7.55 (m, 2H), 7.96 (d, J = 2.8 Hz, 1H), 7.99 (dd, 
J = 1.2, 8.0 Hz, 1H), 8.34 (d, J = 8.0 Hz, 1H), 10.30 (s, 1H). 
 
2,2'-Carbonylbis(azanediyl)dibenzoic acid (78a) 
NH
O
OH
O NH
O
OH
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2-(3-(2-(Methoxycarbonyl)phenyl)ureido)benzoic acid (77a) (0.100 g, 0.0300 mmol) was 
dissolved in MeOH (3 mL). To this solution, NaOH (1M, 1 mL) was added and heated at 
60 °C for 10 min in the microwave reactor. The resulting solution was acidified to pH 3.0 
(HCl, 1.0 M), filtered, the residue washed with water and dried to give 78a as a white 
solid (0.0600 g, 73%), m.p. > 300 °C; 1H NMR (400 MHz, CD3OD) δ 7.18-7.32 (m, 2H), 
7.39 (d, J = 7.8 Hz, 1H), 7.53-7.80 (m, 3H), 8.04 (d, J = 7.9 Hz, 1H), 8.20 (d, J = 7.8 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 114.91, 114.94, 115.85, 115.92, 123.21, 128.24, 
131.68, 135.95, 140.40, 140.54, 150.69, 150.78, 162.94, 162.96, 166.46; MS m/z (API-
ES): 283 (M-17) (100%), calculated for C15H12N2O5 300.0980, found 300.0986. 
 
2-(3-(3-Carboxyphenyl)ureido)benzoic acid (78b) 
NH
O NH
O
OH
OHO
 
This was prepared from compound 77b (0.100 g, 0.0300 mmol) in a similar manner in a 
similar manner as described in the preparation of 78a. The product was obtained as an 
off-white solid, (0.0600 g, 73%), m.p. >300 °C; 1H NMR (400 MHz, CD3OD) δ 7.24-
7.30 (m, 2H), 7.56 (qd, J = 1.2, 0.4 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.73 (d, J = 1.6 Hz, 
1H), 7.95 (t, J = 1.6Hz, 1H), 8.08 (dd, J = 1.2, 6.4 Hz, 1H), 8.13 (td, J = 1.6, 4.8 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 115.04, 115.95, 123.19, 128.24, 129.68, 129.80, 
130.86, 132.30, 132.30, 134.40, 135.90, 136.71, 140.53, 150.82, 162.91, 167.41; MS m/z 
(API-ES): 283 (M-17) (100%), calculated for C15H12N2O4 300.0980, found 300.0982. 
 
2-(3-(4-Carboxyphenyl)ureido)benzoic acid (78c) 
NH
O NH
O
OHO
OH
 
This was prepared from compound 77c (0.100 g, 0.0300 mmol) in a similar manner in a 
similar manner as described in the preparation of 78a. The product was obtained as an 
off-white solid, (0.0750 g, 79%), m.p. > 300 °C; 1H NMR (400 MHz, CD3OD) δ 7.19-
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7.35 (m, 2H), 7.44 (d, J = 8.6 Hz, 2H), 7.65-7.78 (m, 1H), 8.01-8.23 (m, 3H); 13C NMR 
(101 MHz, CDCl3) δ 114.95, 115.97, 123.25, 128.23, 130.17, 130.47, 131.25, 135.97, 
140.46, 140.51, 150.61, 162.74, 167.52; MS m/z (API-ES): 283 (M-17) (100%), 
calculated for C15H12N2O4 300.0980, found 300.0983. 
 
4-(3-(2-Carboxyphenyl)ureido)-2-hydroxybenzoic acid (78d) 
NH
O NH
O
OH
HO
OHO
 
This was prepared from compound 77d (0.100 g, 0.0300 mmol) in a similar manner in a 
similar manner as described in the preparation of 78a. The product was obtained as a 
grayish solid, (0.0840 g, 88%), m.p. 298-300 °C; 1H NMR (400 MHz, CD3OD) δ 6.87 
(dd, J = 2, 6.4 Hz, 1H), 6.94 (d, J = 1.6 Hz, 1H), 7.22-7.29 (m, 2H), 7.73 (dd, J = 1.2, 
7.2 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 8.07 (dd, J = 0.8, 7.2 Hz); 13C NMR (101 MHz, 
CDCl3) δ 113.54, 114.94, 115.94, 118.83, 121.00, 123.22, 128.22, 131.15, 135.94, 
140.49, 142.69, 150.42, 162.00, 162.56, 172.13; MS m/z (API-ES): found 299 (M-17) 
(100%), calculated for C15H12N2O6 316.0945, found 316.0928. 
 
5-(3-(2-Carboxyphenyl)ureido)-2-hydroxybenzoic acid (78e) 
NH
O NH
O
OHO
OH OH
 
This was prepared from compound 77e in a similar manner as described in the 
preparation for 78a. The product was collected as an orange solid, (0.0570 g, 60%), m.p. 
298-300 °C; 1H NMR (400 MHz, CD3OD) δ 6.94 (d, J = 8.77 Hz, 1H), 7.08-7.33 (m, 
3H), 7.54-7.74 (m, 2H), 7.97 (d, J = 8.01 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
δ 113.84, 115.02, 115.88, 118.10, 123.12, 127.42, 128.24, 131.43, 135.80, 137.05, 
140.47, 151.01, 161.36, 172.07; MS m/z (API-ES): found 299 (M-17) (100%), calculated 
for C15H12N2O6 316.0945, found 316.0933. 
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2,3-Dioxoindoline-5-sulfonyl chloride (80)105 
N
H
O
O
S
OO
Cl
 
5-Isatin sulfonic acid sodium salt dihydrate (10.0 g, 35.1 mmol) was dissolved in 
tetramethylene sulfone (50 mL). To this solution, POCl3 (16.0 ml, 177.0 mmol) was 
added and the reaction mixture was heated at 60 °C for 3 hrs. After 3 hrs, the reaction 
mixture was cooled to 0 °C and water (150 mL) was added. The greenish yellow residue 
was filtered, re-dissolved in EtOAc (75 mL) and filtered. Hexane (100 mL) was added to 
the filtrate, the yellow solid was filtered, the residue washed with hexane to give 80 (5.97 
g, 56%) as yellow solid; m.p 197-198 °C (lit. 200-202 °C); 1H NMR (400 MHz, DMSO) 
δ 6.82 (d, J = 8.8 Hz, 1H), 7.55 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 11.08 (s, 1H). 
 
5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81a) 
N
H
O
O
S
OO
N
N
F
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(4-fluorophenyl)piperazine (0.0770 g, 0.430 mmol) was added. 
To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C 
for 10 min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, 
extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81a (0.130 g, 
88%) as a yellow solid. The crude product was used as such for the formation of 82a 
without further purification; 1H NMR (400 MHz, DMSO) δ 3.00 (br s, 4H), 3.13 (br s, 
4H). 6.89 (dd, J = 4.4, 9.0 Hz, 2H), 7.00 (t, J = 9.0 Hz, 2H), 7.10 (d, J = 8.4 Hz, 1H), 
7.70 (d, J = 2.0 Hz, 1H), 7.91 (dd, J = 1.6, 8.4 Hz); MS m/z (API-ES) 388 (M+H)+, 
calculated for C18H16FN3O4S 388.0773, found 388.0793. 
 
3-Imino-N-(4-morpholinophenyl)-2-oxoindoline-5-sulfonamide (81b) 
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N
H
O
O
S
OO
HN
N
O
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, N-(4-morpholinophenyl)-2,3-dioxoindoline-5-sulfonamide (0.0760 
g, 0.430 mmol) was added. To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) 
was added and heated at 60 °C for 10 min. in the microwave reactor. Water (4 mL) was 
added to the reaction mixture, extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and 
evaporated to give 81b (0.240 g, 88%) as a yellow solid. The crude product was used as 
such for the formation of 82b without further purification. 
 
N-(2-Morpholinoethyl)-2,3-dioxoindoline-5-sulfonamide (81c) 
N
H
O
O
S
OO
HN
N
O
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 2-morpholinoethanamine (0.0560 g, 0.430 mmol) was added. To 
the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C for 
10 min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, 
extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81c (0.107 g, 
95%) as a reddish solid. The crude product was used as such for the formation of 82c 
without further purification. 
 
2,3-Dioxo-N-(1H-tetrazol-5-yl)indoline-5-sulfonamide (81d) 
N
H
O
O
S
OO
HN
N
N N
NH
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1H-tetrazol-5-amine (0.040 g, 0.430 mmol) was added. To the 
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resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C for 10 
min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, extracted 
with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81d (0.092 g, 98%) as a 
yellow solid. The crude product was used as such for the formation of 82d without 
further purification. 
 
N-(Isoxazol-3-yl)-2,3-dioxoindoline-5-sulfonamide (81e) 
N
H
O
O
S
OO
HN
O
N
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.050 g, 0.160 mmol) was dissolved in THF (3 
mL). To this solution, isoxazol-3-amine (0.0140 g, 0.180 mmol) was added. To the 
resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C for 10 
min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, extracted 
with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81e (0.21 g, 22%) as a 
yellow solid. The crude product was used as such for the formation of 82e without further 
purification. 
 
5-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81f) 
N
H
O
O
S
OO
N
N
O
O
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(benzo[d][1,3]dioxol-5-ylmethyl)piperazine (0.0900 g, 0.430 
mmol) was added. To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added 
and heated at 60 °C for 10 min. in the microwave reactor. Water (4 mL) was added to the 
reaction mixture, extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to 
give 81f (0.141 g, quantitative) as a yellow solid. The crude product was used as such for 
the formation of 82f without further purification. 
 
5-(4-(3-Chlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81g) 
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N
H
O
O
S
OO
N
N
Cl
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(3-chlorophenyl)piperazine (0.0760 g, 0.430 mmol) was added. 
To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C 
for 10 min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, 
extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81g (0.0320 g, 
53%) as a yellow solid. The crude product was used as such for the formation of 82g 
without further purification. 
 
5-(4-(3-(Trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81h) 
N
H
O
O
S
OO
N
N
CF3
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(3-(trifluoromethyl)phenyl)piperazine (0.114 g, 0.430 mmol) 
was added. To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and 
heated at 60 °C for 10 min. in the microwave reactor. Water (4 mL) was added to the 
reaction mixture, extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to 
give 81h (0.145 g, quantitative) as a yellow solid. The crude product was used as such for 
the formation of 82h without further purification. 
 
5-(4-(3,4-Dichlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81i) 
N
H
O
O
S
OO
N
N
Cl Cl
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
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mL). To this solution, 1-(3,4-dichlorophenyl)piperazine (0.0760 g, 0.430 mmol) was 
added. To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated 
at 60 °C for 10 min. in the microwave reactor. Water (4 mL) was added to the reaction 
mixture, extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81i 
(0.0310 g, 51%) as a yellow solid. The crude product was used as such for the formation 
of 82i without further purification. 
 
5-(4-(2,3-Dichlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81j) 
N
H
O
O
S
OO
N
N
Cl
Cl
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(2,3-dichlorophenyl)piperazine (0.0760 g, 0.430 mmol) was 
added. To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated 
at 60 °C for 10 min. in the microwave reactor. Water (4 mL) was added to the reaction 
mixture, extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81j 
(0.010 g, 30%) as a yellow solid. The crude product was used as such for the formation of 
82j without further purification. 
 
5-(4-(3-Methoxyphenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81k) 
N
H
O
O
S
OO
N
N
O
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(3-methoxyphenyl)piperazine (0.0760 g, 0.430 mmol) was 
added. To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated 
at 60 °C for 10 min. in the microwave reactor. Water (4 mL) was added to the reaction 
mixture, extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81k 
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(0.0480 g, 80%) as a yellow solid. The crude product was used as such for the formation 
of 82k without further purification. 
 
5-(4-(3-Chlorobenzyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81l) 
N
H
O
O
S
OO
N
N
Cl
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-(3-chlorobenzyl)piperazine (0.0900 g, 0.420 mmol) was added. 
To the resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C 
for 10 min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, 
extracted with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81l (0.138 g, 
quantitative) as a yellow solid. The crude product was used as such for the formation of 
82l without further purification. 
 
5-(4-cyclohexylpiperazin-1-ylsulfonyl)indoline-2,3-dione (81m) 
N
H
O
O
S
OO
N
N
 
2,3-Dioxoindoline-5-sulfonyl chloride (0.100 g, 0.330 mmol) was dissolved in THF (3 
mL). To this solution, 1-cyclohexylpiperazine (0.0700 g, 0.415 mmol) was added. To the 
resulting mixture, DIPEA (0.100 mL, 0.660 mmol) was added and heated at 60 °C for 10 
min. in the microwave reactor. Water (4 mL) was added to the reaction mixture, extracted 
with EtOAc (3 × 5 mL), dried (Na2SO4) and evaporated to give 81m (0.123 g, 
quantitative) as a yellow solid. The crude product was used as such for the formation of 
82m without further purification. 
 
(Z)-4-(2-(5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82a) 
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N
H
N
O
S
OO
N
NH
O
OH
N
F
 
5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81a) (0.100 g, 0.220 
mmol) was dissolved in EtOH (5 mL). To this solution 4-hydrazinobenzoic acid (0.0400 
g, 0.250 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82a 
(0.044 g, 34%) as a yellow solid, m.p. 290 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 3.00-3.04 (m, 4H), 3.14-3.16 (m, 4H), 6.92-6.93 (m, 2H), 7.01 (t, J = 7.2, 9.2 
Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.67 (dd, J = 1.6, 8.0 Hz, 
1H), 7.87 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 8.8 Hz, 2H), 11.57 (s, 1H), 12.80 (s, 1H); 13C 
NMR (101 MHz, DMSO) δ 46.47, 49.54, 111.70, 114.97, 115.97, 116.19, 118.77, 
122.26, 125.88, 128.40, 128.73, 129.61, 131.72, 144.56, 146.48, 163.62, 167.55; MS m/z 
(ESI-ve) 522 (M-H)- (100%), calculated for C25H22FN5O5S 522.1253, found 522.1253. 
 
(Z)-4-(2-(5-(N-(4-Morpholinophenyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) 
benzoic acid (82b) 
N
H
N
O
S
OO NH
O
OH
HN
N
O
 
3-Imino-N-(4-morpholinophenyl)-2-oxoindoline-5-sulfonamide (81b) (0.100 g, 0.220 
mmol) was dissolved in EtOH (5 mL). To this solution 4-hydrazinobenzoic acid (0.040 g, 
0.250 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
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heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82b 
(0.0380 g, 29%) as a yellow solid, m.p. >300 °C; 1H NMR (400 MHz, DMSO) δ 2.95 (t, 
J = 4.8 Hz, 4H), 3.63 (t, J = 4.8 Hz, 4H), 6.79 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 
2H), 6.98 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 1.6 Hz, 2H), 7.92 (d, 
J = 8.8 Hz, 2H), 9.71 (s, 1H), 11.44 (s, 1H), 12.74 (s, 1H); 13C NMR (101 MHz, DMSO) 
δ 49.84, 66.36, 114.80, 117.11, 118.00, 121.92, 123.42, 123.45, 125.79, 128.86, 131.77, 
133.75, 143.93, 146.52, 163.58, 167.54; MS m/z (ESI-ve) 520 (M-H)- (100%), calculated 
for C25H23N5O6S 520.1296, found 520.1301. 
 
(Z)-4-(2-(5-(N-(2-Morpholinoethyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) 
benzoic acid (82c) 
N
H
N
O
S
OO
HN
NH
O
OH
N
O
 
N-(2-Morpholinoethyl)-2,3-dioxoindoline-5-sulfonamide (81c) (0.100 g, 0.220 mmol) 
was dissolved in EtOH (5 mL). To this solution 4-hydrazinobenzoic acid (0.040 g, 0.250 
mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and heated 
at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow precipitate 
was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82c (0.023 g, 
17%) as a yellow solid, m.p. 243-245 °C; 1H NMR (400 MHz, DMSO) δ 3.11 (m, 4H), 
3.17 (br s, 2H), 3.35 (d, J = 4.2 Hz, 2H), 3.64 (t, J = 8.0 Hz, 2H), 3.93 (d, J = 12.0 Hz, 
2H), 7.10 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 4.4 Hz, 2H), 7.72 (d, J = 8.4 Hz, 1H), 7.93 (d, 
J = 8.8 Hz, 2H), 7.97 (s, 1H), 11.52 (s, 1H), 12.85 (s, 1H); 13C NMR (101 MHz, DMSO) 
δ 51.92, 55.09, 55.86, 63.76, 111.52, 114.85, 118.04, 122.19, 125.82, 128.72, 128.87, 
131.75, 133.56, 144.09, 146.55, 163.65, 167.54; MS m/z (ESI+ve) 474 (M+H)+ (100%), 
calculated for C21H23N5O6S 474.1441, found 474.1454. 
 
 136 
(Z)-4-(2-(5-(N-1H-Tetrazol-5-ylsulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) 
benzoic acid (82d) 
N
H
N
O
S
OO
HN
NH
O
OH
N
N N
NH
 
2,3-Dioxo-N-(1H-tetrazol-5-yl)indoline-5-sulfonamide (81d) (0.0610 g, 0.160 mmol) was 
dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid (0.027 g, 0.180 
mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and heated 
at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow precipitate 
was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82d (0.00800 
g, 10%) as a yellow solid, m.p. 270 °C, decomposed; 1H NMR (400 MHz, DMSO) δ 7.05 
(d, J = 8.4 Hz, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.81 (dd, J = 1.6, 8.4 Hz, 1H), 8.04 (d, J = 
8.8 Hz, 2H), 8.16 (d, J = 1.6 Hz, 1H); 13C NMR (101 MHz, DMSO) δ 111.58, 114.88, 
118.20, 122.05, 125.83, 128.72, 128.75, 128.86, 131.79, 144.56, 146.49, 146.51, 156.82, 
163.63, 167.54, 167.56, 179.10; MS m/z (API-ES) 427 (M-H)- (100%), calculated for 
C16H12N8O5S 427.0578, found 427.0594. 
 
(Z)-4-(2-(5-(N-Isoxazol-3-ylsulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic 
acid (82e) 
N
H
N
O
S
OO
HN
NH
O
OH
O
N
 
N-(Isoxazol-3-yl)-2,3-dioxoindoline-5-sulfonamide (81e) (0.0700 g, 0.190 mmol) was 
dissolved in EtOH (1 mL). To this solution 4-hydrazinobenzoic acid (0.0330 g, 0.219 
mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and heated 
at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow precipitate 
was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82e (0.021 g, 
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22%) as a yellow solid, m.p. 295 °C, decomposed; 1H NMR (400 MHz, DMSO) δ 6.44 
(s, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.73 (dd, J = 1.6 Hz, 8.0 Hz, 
1H), 7.93 (d, J = 8.8 Hz, 2H), 7.99 (d, J = 1.6 Hz, 1H), 8.71 (s, 1H), 11.53 (s, 1H), 12.76 
(s, 1H); 13C NMR (101 MHz, DMSO) δ 98.99, 111.46, 114.89, 118.05, 122.16, 125.84, 
128.71, 128.84, 131.78, 133.17, 144.53, 146.49, 157.71, 161.62, 161.67, 163.61, 167.56; 
MS m/z (API-ES) 426 (M-H)- (100%), calculated for C18H13N5O6S 426.0513, found 
426.0511. 
 
(Z)-4-(2-(5-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-ylsulfonyl)-2-oxoindolin-
3-ylidene)hydrazinyl)benzoic acid (82f) 
N
H
N
O
S
OO
N
NH
O
OH
N
O
O
 
5-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81f) 
(0.141 g, 0.330 mmol) was dissolved in EtOH (5 mL). To this solution 4-
hydrazinobenzoic acid (0.0500 g, 0.410 mmol) was added. To the resulting mixture, HCl 
(1.0 M, 2 drops) was added and heated at 120 °C for 15 min in the microwave reactor. 
After the reaction, the yellow precipitate was filtered, the residue washed with MeOH (3 
× 3 mL) and dried to give 82f (0.0930 g, 46%) as a yellow solid, m.p. >300 °C; 1H NMR 
(400 MHz, DMSO) δ 2.64 (br s, 2H), 3.12 (be s, 2H), 3.75 (br s, 2H), 4.20 (br s, 2H), 
6.01 (be s, 2H), 6.91 (d, J = 12.0 Hz, 2H), 7.03 (s, 1H), 7.15 (d, J = 8.0 Hz, 1H), 7.61 (d, 
J = 8.8 Hz, 2H), 7.84 (s, 1H), 7.92 (8.8 Hz, 2H), 11.62 (s, 1H), 12.81 (s, 1H); 13C NMR 
(101 MHz, DMSO) δ 101.98, 102.08, 102.20, 108.96, 112.88, 122.28, 125.89, 128.25, 
128.50, 131.70, 139.12, 144.71, 146.42, 148.02, 148.75, 163.54, 167.55; MS m/z 
(ESI+ve) 564 (M+H)+ (100%), calculated for C27H25N5O7S 564.1548, found 564.1547. 
 
(Z)-4-(2-(5-(4-(3-Chlorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82g) 
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H
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5-(4-(3-Chlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81g) (0.0700 g, 0.170 
mmol) was dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid (0.0250 
g, 0.160 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82g 
(0.044 g, 34%) as a yellow solid, m.p. 285 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 2.99 (br s, 4H), 3.25 (br s, 4H), 6.78 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 10.8 Hz, 
1H), 6.90 (sm 1H), 7.13 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.0 
Hz, 1H), 7.87 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 11.55 (s, 1H), 12.80 (s, 1H); 13C NMR 
(101 MHz, DMSO) δ 46.40, 53.43, 111.65, 111.72, 114.97, 115.92, 119.47, 125.84, 
128.22, 128.29, 128.70, 131.72, 144.50, 144.53, 146.47, 152.22, 163.63, 167.56; MS m/z 
(ESI-ve) 538 (M-H)- (100%), calculated for C25H22FN5O5S 538.0957, found 538.0960. 
 
(Z)-4-(2-(2-Oxo-5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indolin-3-
ylidene)hydrazinyl)benzoic acid (82h) 
N
H
N
O
S
OO
N
NH
O
OH
N
CF3
 
5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81h) (0.0725 
g, 0.165 mmol) was dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid 
(0.02500 g, 0.118 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was 
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added and heated at 120 °C for 15 min in the microwave reactor. After the reaction, the 
yellow precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to 
give 82h (0.072 g, 65%) as a yellow solid, m.p. >300 °C; 1H NMR (400 MHz, DMSO) δ 
3.02 (br s, 4H), 3.28 (br s, 4H), 7.04 (d, J = 8.8 Hz, 1H), 7.14-7.16 (m, 3H), 7.37 (t, J = 
8.8 Hz, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.65 (dd, J = 4.2 Hz, 8.0 Hz, 1H), 7.87 (d, J = 4.2 
Hz, 1H), 7.92 (d, J= 8.8 Hz, 2H), 11.56 (s, 1H), 12.80 (s, 1H); 13C NMR (101 MHz, 
DMSO) δ 46.47, 49.54, 111.70, 114.97, 115.97, 116.19, 118.77, 122.26, 125.88, 128.40, 
128.73, 129.61, 131.72, 144.56, 146.48, 163.62, 167.55; MS m/z (ESI-ve) 572 (M-H)- 
(100%), calculated for C26H22F3N5O5S 572.1221, found 572.1239. 
 
(Z)-4-(2-(5-(4-(3,4-Dichlorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82i) 
N
H
N
O
S
OO
N
N
Cl Cl
NH
O
OH
 
5-(4-(3,4-Dichlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81i) (0.0700 g, 
0.150 mmol) was dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid 
(0.020 g, 0.125 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was 
added and heated at 120 °C for 15 min in the microwave reactor. After the reaction, the 
yellow precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to 
give 82i (0.032 g, 36%) as a yellow solid, m.p. 280 °C, decomposed; 1H NMR (400 
MHz, DMSO) δ 2.99 (br s, 4H), 3.29 (br s, 4H), 6.85 (dd, J = 2.8 Hz, 9.2 Hz, 1H), 7.08 
(d, J = 2.8 Hz, 1H), 7.13 (d J = 8.0 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.59 (d, J = 8.8 
Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.86 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H); 13C NMR (101 
MHz, DMSO) δ 46.29, 47.81, 111.66, 114.94, 116.58, 117.56, 118.77, 121.01, 121.23, 
122.28, 126.01, 128.27, 128.66, 129.62, 131.20, 131.72, 132.15, 144.54, 146.41, 150.68, 
163.60, 167.60; MS m/z (ESI-ve) 572 (M-H)- (100%), calculated for C25H22FN5O5S 
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572.0567, found 572.0534. 
 
(Z)-4-(2-(5-(4-(2,3-Dichlorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82j) 
N
H
N
O
S
OO
N
NH
O
OH
N
Cl
Cl
 
5-(4-(2,3-Dichlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81j) (0.0700 g, 
0.150 mmol) was dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid 
(0.020 g, 0.125 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was 
added and heated at 120 °C for 15 min in the microwave reactor. After the reaction, the 
yellow precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to 
give 82j (0.00900 g, 11%) as a yellow solid, m.p. 250 °C, decomposed; 1H NMR (400 
MHz, DMSO) δ 3.06 (br s, 8H), 7.14-7.18 (m, 2H), 7.29-7.30 (m, 2H), 7.59 (d, J = 8.8 
Hz, 2H), 7.66 (d, J = 10.0 Hz, 1H), 7.88 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 11.57 (s, 1H), 
12.81 (s, 1H); 13C NMR (101 MHz, DMSO) δ 50.86, 62.33, 114.98, 118.83, 120.70, 
122.30, 125.83, 128.46, 128.76, 129.29, 131.72, 131.80, 133.23, 144.56, 146.48, 151.02, 
161.54, 163.65, 167.57; MS m/z (ESI-ve) 572 (M-H)- (100%), calculated for 
C25H21Cl2N5O5S 572.0567, found 572.0552. 
 
(Z)-4-(2-(5-(4-(3-methoxyphenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82k) 
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5-(4-(3-Methoxyphenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81k) (0.0700 g, 0.170 
mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid (0.0250 
g, 0.160 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82k 
(0.039 g, 41%) as a yellow solid, m.p. 275 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 2.99 (br s, 4H), 3.26 (be s, 4H), 3.64 (s, 3H), 6.33 (d, 8.4 Hz, 1H), 6.40 (s, 1H), 
6.44 (d, J = 8.4 Hz, 1H), 7.03 (t, J = 8.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 
8.8 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 4.2 Hz, 1H), 7.92 (d, J = 8.4 Hz, 2H), 
11.55 (s, 1H), 12.80 (s, 1H); 13C NMR (101 MHz, DMSO) δ 46.51, 48.50, 55.41, 102.97, 
105.54, 109.23, 114.94, 118.78, 122.24, 125.83, 128.28, 128.72, 131.72, 144.52, 152.24, 
152.30, 160.79, 167.57, 180.36; MS m/z (ESI-ve) 534 (M-H)- (100%), calculated for 
C26H25N5O6S 534.1452, found 534.1459. 
 
(Z)-4-(2-(5-(4-(3-chlorobenzyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82l) 
N
H
N
O
S
OO
N
N
Cl
NH
O
OH
 
5-(4-(3-Chlorobenzyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81l) (0.0700 g, 0.170 
mmol) was dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid (0.0250 
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g, 0.160 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82l 
(0.031 g, 34%) as a yellow solid, m.p. 260 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 2.70 (br s, 2H), 3.14 (br s, 4H), 3.76 (br s, 2H), 4.30 (br s, 2H), 7.15 (d, J = 8.0 
Hz, 1H), 7.43 (br s, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.63 (dd, J = 2.0 Hz, 8.0 Hz, 2H), 7.85 
(s, 1H), 7.91 (d, 8.4 Hz, 2H), 11.62 (s, 1H), 12.81 (s, 1H); 13C NMR (101 MHz, DMSO) 
δ
 40.70, 50.46, 58.36, 111.87, 114.98, 118.68, 122.27, 125.90, 128.46, 130.16, 131.24, 
133.94, 144.70, 146.39, 163.54, 167.56; MS m/z (ESI-ve) 553 (M-H)- (100%), calculated 
for C26H24ClN5O5S 552.1114, found, 552.1134. 
 
 (Z)-4-(2-(5-(4-cyclohexylpiperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene)hydrazinyl) 
benzoic acid (82m) 
N
H
N
O
S
OO
N
NH
O
OH
N
 
5-(4-cyclohexylpiperazin-1-ylsulfonyl)indoline-2,3-dione (81m) (0.0900 g, 0.209 mmol) 
was dissolved in EtOH (2 mL). To this solution 4-hydrazinobenzoic acid (0.0400 g, 0.250 
mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and heated 
at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow precipitate 
was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82m (0.0750 g, 
64%) as a yellow solid, m.p. >300 °C; 1H NMR (400 MHz, DMSO) δ 1.17-1.24 (m, 4H), 
1.55 (d, J = 8.0 Hz, 1H), 1.74 (br s, 2H), 1.94 (br s, 2H), 2.67 (br s, 2H), 3.14-3.16 (m, 
4H), 3.46 (d, J = 12.0 Hz, 2H), 3.76 (d, J = 12.0 Hz, 2H), 7.18 (d, J = 8.4 Hz, 1H), 7.61 
(d, 8.4 Hz, 2H), 7.67 (d, J = 8.4, 1H), 7.90 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 11.63 (s, 
1H), 12.82 (s, 1H); 13C NMR (101 MHz, DMSO) δ 25.05, 25.29, 26.63, 40.54, 47.61, 
59.18, 111.83, 111.89, 115.00, 118.81, 122.28, 125.90, 127.98, 128.49, 131.70, 142.18, 
144.74, 146.43, 148.21, 163.53, 167.56; MS m/z (ESI-ve) 510 (M-H)-, calculated for 
 143 
C25H29N5O5S 510.1817, found 510.1827. 
 
(Z)-3-(2-(5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82n) 
N
H
N
O
S
OO
N
NH
N
F
O
OH
 
5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81a) (0.100 g, 0.220 
mmol) was dissolved in EtOH (5 mL). To this solution 3-hydrazinobenzoic acid (0.0400 
g, 0.250 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82n 
(0.0135 g, quantitative) as a yellow solid, m.p. 270 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 3.01 (br s, 4H), 3.14 (br s, 4H), 6.89-6.91 (m, 2H), 6.99 (t, J = 8.4 Hz, 2H), 
7.15 (d, J = 8.4 Hz, 1H), 7.50 (t, J = 8.4 Hz, 1H), 7.63-7.65 (m, 2H), 7.77 (d, J = , 1H), 
7.82 (s, 1H), 8.03 (s, 1H), 11.54 (s, 1H), 12.81 (s, 1H); 13C NMR (101 MHz, DMSO) δ 
45.80, 50.95, 111.66, 115.71, 116.65, 118.37, 120.71, 124.94, 128.02, 132.74, 143.09, 
143.18, 144.27, 157.70, 157.94, 160.08, 163.63, 167.62, 167.67; MS m/z (ESI-ve) 522 
(M-H)- (100%), calculated for C25H22FN5O5S 522.1253, found 522.1256. 
 
(Z)-3-(2-(5-(N-(4-Morpholinophenyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) 
benzoic acid (82o) 
N
H
N
O
S
OO NH
HN
N
O
O
OH
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3-Imino-N-(4-morpholinophenyl)-2-oxoindoline-5-sulfonamide (81b) (0.100 g, 0.220 
mmol) was dissolved in EtOH (5 mL). To this solution 3-hydrazinobenzoic acid (0.040 g, 
0.250 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82o 
(0.0500 g, 37%) as a yellow solid, m.p. 230 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 3.66 (s, 4H), 3.63 (s, 4H), 6.79 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 9.2 Hz, 2H), 
6.97 (d, J = 8.4 Hz, 1H), 7.48-7.51 (m, 2H), 7.62 (d, J = 4.2 Hz, 1H), 7.66 (dd, J = 4.2 
Hz, 1H), 7.84 (d, J = 4.2 Hz, 1H), 8.05 (s, 1H), 9.71 (s, 1H), 11.49 (s, 1H), 12.78 (s, 1H); 
13C NMR (101 MHz, DMSO) δ 47.05, 58.56, 104.98, 111.21, 115.39, 117.63, 119.84, 
122.43, 127.60, 128.36, 131.81, 132.73, 133.32, 143.25, 143.77, 144.63, 163.55, 167.70; 
MS m/z (ESI-ve) 522 (M-H)- (100%), calculated for C25H22FN5O5S 522.1250, found 
522.1223. 
 
(Z)-3-(2-(5-(N-(2-Morpholinoethyl)sulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl) 
benzoic acid (82p) 
N
H
N
O
S
OO
HN
NH
N
O
O
OH
 
N-(2-Morpholinoethyl)-2,3-dioxoindoline-5-sulfonamide (81c) (0.100 g, 0.220 mmol) 
was dissolved in EtOH (5 mL). To this solution 3-hydrazinobenzoic acid (0.040 g, 0.250 
mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and heated 
at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow precipitate 
was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82p (0.057 g, 
43%) as a yellow solid, m.p. 255 °C, decomposed; 1H NMR (400 MHz, DMSO) δ 1.24 
(t, J = 6.4 Hz, 3H), 3.08 (q, J = 6.4 Hz, 2H), 3.61 (br s, 4H), 3.92 (br s, 4H), 7.10 (d, J = 
8.4 Hz, 1H), 7.47-7.51 (m, 2H), 7.63 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.94 
(s, 1H), 11.51 (s, 1H), 12.79 (s, 1H); 13C NMR (101 MHz, DMSO) δ 40.34, 52.06, 55.95, 
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63.99, 111.34, 115.25, 117.63, 120.88, 124.84, 128.40, 133.35, 140.74, 143.26, 143.58, 
163.69, 167.70; MS m/z (ESI-ve) 472 (M-H)- (100%), calculated for C21H23N5O6S 
472.1296, found 472.1314. 
 
 (Z)-3-(2-(5-(N-Isoxazol-3-ylsulfamoyl)-2-oxoindolin-3-ylidene)hydrazinyl)benzoic 
acid (82q) 
N
H
N
O
S
OO
HN
NH
O
N
O
OH
 
5-(4-(4-Fluorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81e) (0.0 g, 0.220 
mmol) was dissolved in EtOH (1 mL). To this solution 3-hydrazinobenzoic acid (0.0370 
g, 0.240 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82q 
(0.043 g, 47%) as a yellow solid, m.p. 280 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 6.44 (d, J = 1.6 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 
7.62 (d, J = 7.6 Hz, 1H), 7.70 (t, J = 8.4 Hz, 2H), 7.96 (s, 1H), 8.06 (s, 1H), 8.70 (d, J = 
1.6 Hz, 1H), 11.57 (s, 1H), 12.81 (s, 1H); 13C NMR (101 MHz, DMSO) δ 98.99, 104.99, 
111.26, 115.47, 117.69, 122.34, 124.88, 127.63, 130.43, 131.57, 133.02, 143.23, 144.17, 
161.60, 163.64, 167.70; MS m/z (ESI-ve) 426 (100%), calculated for C16H12N8O5S 
427.0579, found 427.0562. 
 
 (Z)-3-(2-(5-(4-(3-Chlorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82r) 
N
H
N
O
S
OO
N
NH
N
Cl
O
OH
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5-(4-(3-Chlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81g) (0.0700 g, 0.170 
mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid (0.0250 
g, 0.160 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82r 
(0.0200 g, 22%) as a yellow solid, m.p. 280 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 2.99 (br s, 4H), 3.25 (br s, 4H), 6.75 (d, J = 7.6 Hz, 1H), 6.82 (d, J = 7.6 Hz, 
1H), 6.89 (s, 1H), 7.13 (d, J = 8.0 Hz, 2H), 7.47 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 8.4 Hz, 
2H), 7.75 (d, J = 8.8 Hz, 1H), 7.81 (s, 1H), 8.02 (s, 1H), 11.52 (s, 1H), 12.81 (s, 1H); 13C 
NMR (101 MHz, DMSO) δ 46.41, 47.96, 104.99, 115.73, 122.41, 127.52, 128.13, 
131.14, 134.44, 143.22, 144.18, 152.24, 163.65, 167.69; MS m/z (ESI-ve) 537 (M-H)- 
(100%), calculated for C25H22ClN5O5S 538.0957, found 538.0955. 
 
(Z)-3-(2-(2-Oxo-5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indolin-3-
ylidene)hydrazinyl)benzoic acid (82s) 
N
H
N
O
S
OO
N
N
CF3
NH
O
OH
 
5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81h) (0.147 g, 
0.330 mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid 
(0.0500 g, 0.360 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was 
added and heated at 120 °C for 15 min in the microwave reactor. After the reaction, the 
yellow precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to 
give 82s (0.0860 g, 39%) as a yellow solid, m.p. 295 °C, decomposed; 1H NMR (400 
MHz, DMSO) δ 3.02 (br s, 4H), 3.31 (br s, 4H), 7.04 (d, J = 7.6 Hz, 1H), 7.14-7.16 (m, 
3H), 7.37 (t, J = 8.0 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.62 (t, J = 4.2 Hz, 2H), 7.75 (d, J 
= 8.0 Hz, 1H), 7.82 (d, J = 4.2 Hz, 1H), 8.02 (s, 1H), 11.57 (s, 1H), 12.80 (s, 1H); 13C 
NMR (101 MHz, DMSO) δ 46.48, 47.93, 111.57, 112.40, 115.72, 118.37, 120.03, 
 147 
123.62, 126.33, 127.83, 132.75, 143.21, 151.29, 163.66, 167.69; MS m/z (ESI-ve) 572 
(M-H)- (100%), calculated for C26H22F3N5O5S 572.1221, found 572.1236. 
 
(Z)-3-(2-(5-(4-(3,4-Dichlorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82t) 
N
H
N
O
S
OO
N
N
Cl Cl
NH
O
OH
 
5-(4-(3,4-Dichlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81i) (0.0700 g, 
0.140 mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid 
(0.020 g, 0.150 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was 
added and heated at 120 °C for 15 min in the microwave reactor. After the reaction, the 
yellow precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to 
give 82t (0.031 g, 35%) as a yellow solid, m.p. 280 °C, decomposed; 1H NMR (400 
MHz, DMSO) δ 2.99 (br s, 4H), 3.26 (br s, 4H), 6.85 (dd, J = 2.8 Hz, 8.8 Hz, 1H), 7.08 
(d, J = 4.2 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.34 (d, J = 9.2 Hz, 1H), 7.47 (t, J = 9.2 
Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H), 8.02 (s, 1H), 
11.52 (s, 1H), 12.80 (s, 1H); 13C NMR (101 MHz, DMSO) δ 46.28, 47.80, 111.63, 
115.71, 116.54, 118.33, 119.75, 121.00, 122.41, 127.50, 128.10, 131.11, 131.77, 132.74, 
143.19, 144.17, 150.66; MS m/z (ESI-ve) 572 (M-H)- (100%), calculated for 
C25H21Cl2N5O5S 572.0567, found 572.0534. 
 
(Z)-3-(2-(5-(4-(2,3-Dichlorophenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82u) 
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N
H
N
O
S
OO
N
NH
N
Cl
Cl
O
OH
 
5-(4-(2,3-Dichlorophenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81j) (0.0700 g, 
0.140 mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid 
(0.020 g, 0.150 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was 
added and heated at 120 °C for 15 min in the microwave reactor. After the reaction, the 
yellow precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to 
give 82u (0.0100 g, 11%) as a yellow solid, m.p. 280 °C, decomposed; 1H NMR (400 
MHz, DMSO) δ 3.05 (br s, 8H), 7.13-7.18 (m, 2H), 7.29 (d, J = 4.2 Hz, 1H), 7.30 (s, 
1H), 7.49 (t, J = 8.0 Hz, 1H), 7.62-7.67 (m, 2H), 7.76 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 
4.2 Hz, 1H), 8.03 (s, 1H), 11.54 (s, 1H), 12.82 (s, 1H); 13C NMR (101 MHz, DMSO) δ 
46.41, 47.96, 104.99, 115.73, 122.41, 127.52, 128.13, 131.14, 134.44, 143.22, 144.18, 
152.24, 163.65, 167.69; MS m/z (ESI-ve) 572 (M-H)- (100%), calculated for 
C25H21Cl2N5O5S 572.0567, found 572.0556. 
 
(Z)-3-(2-(5-(4-(3-Methoxyphenyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82v) 
N
H
N
O
S
OO
N
N
O
NH
O
OH
 
5-(4-(3-Methoxyphenyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81k) (0.0700 g, 0.170 
mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid (0.0250 
g, 0.160 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
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precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82v 
(0.048 g, 51%) as a yellow solid, m.p. 253 °C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 3.00 (br s, 4H), 3.20 (br s, 4H), 3.64 (s, 3H), 6.34 (d, J = 8.0 Hz, 1H), 6.40 (s, 
1H), 6.44 (d, 8.8 Hz, 1H), 7.03 (t, J = 8.4 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 
8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 8.0 Hz, 1H), 7.82 (s, 1H), 8.02 (s, 1H), 
11.5 (s, 1H), 12.81 (s, 1H); 13C NMR (101 MHz, DMSO) δ 45.85, 50.05, 55.87, 104.41, 
108.42, 111.64, 115.71, 117.03, 119.74, 122.39, 124.90, 132.74, 143.18, 149.92, 160.76, 
163.63, 167.83; MS m/z (ESI-ve) 534 (M-H)- (100%), calculated for C26H25N5O6S 
534.1452, found 534.1460. 
 
(Z)-3-(2-(5-(4-(3-Chlorobenzyl)piperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) 
hydrazinyl)benzoic acid (82w) 
N
H
N
O
S
OO
N
NH
N
Cl
O
OH
 
5-(4-(3-Chlorobenzyl)piperazin-1-ylsulfonyl)indoline-2,3-dione (81l) (0.100 g, 0.210 
mmol) was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid (0.0400 
g, 0.230 mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and 
heated at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow 
precipitate was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82w 
(0.0640 g, 49%) as a yellow solid, m.p. 260°C, decomposed; 1H NMR (400 MHz, 
DMSO) δ 2.70 (br s, 2H), 3.14 (br s, 4H), 3.76 (br s, 2H), 4.30 (br s, 2H), 7.15 (d, J = 8.4 
Hz, 1H), 7.43 (br s, 2H), 7.47 (t, J = 8.0 Hz, 2H), 7.61-7.64 (m, 2H), 7.75 (d, J = 9.2 Hz, 
2H), 7.79 (s, 1H), 8.02 (s, 1H), 11.59 (s, 1H), 12.82 (s, 1H); 13C NMR (101 MHz, 
DMSO) δ 40.35, 50.42, 58.25, 111.75, 115.77, 119.77, 124.99, 128.09, 129.12, 130.13, 
130.56, 131.24, 132.75, 133.94, 135.29, 143.15, 144.36, 154.20, 163.58, 167.60; MS m/z 
(ESI-ve) 553 (M-H)- (100%), calculated for C26H24ClN5O5S 552.1114, found 552.1136. 
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(Z)-3-(2-(5-(4-cyclohexylpiperazin-1-ylsulfonyl)-2-oxoindolin-3-ylidene) hydrazinyl) 
benzoic acid (82x) 
N
H
N
O
S
OO
N
NH
N
O
OH
 
5-(4-Cyclohexylpiperazin-1-ylsulfonyl)indoline-2,3-dione (81m) (0.0900 g, 0.209 mmol) 
was dissolved in EtOH (2 mL). To this solution 3-hydrazinobenzoic acid (0.0400 g, 0.250 
mmol) was added. To the resulting mixture, HCl (1.0 M, 2 drops) was added and heated 
at 120 °C for 15 min in the microwave reactor. After the reaction, the yellow precipitate 
was filtered, the residue washed with MeOH (3 × 3 mL) and dried to give 82x (0.0600 g, 
49%) as a yellow solid, m.p. > 300 °C; 1H NMR (400 MHz, DMSO) δ 1.17-1.24 (m, 4H), 
1.55 (d, J = 8.0 Hz, 1H), 1.74 (br s, 2H), 1.94 (br s, 2H), 2.67 (br s, 2H), 3.14-3.16 (m, 
4H), 3.46 (d, J = 12.0 Hz, 2H), 3.76 (d, J = 12.0 Hz, 2H), 7.16 (d, J = 8.0 Hz, 1H), 7.50 
(t, 8.0 Hz Hz, 1H), 7.63 (d, J = 7.6 Hz, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.82 (br s, 1H), 
8.03 (s, 1H); 13C NMR (101 MHz, DMSO) δ 25.05, 25.29, 26.63, 40.54, 47.61, 64.77, 
111.83, 115.68, 116.19, 118.77, 122.33, 125.88, 128.40, 128.73, 127.94, 132.94, 143.14, 
146.48, 163.65, 167.74; MS m/z (ESI-ve) 510 (M-H)- (100%), calculated for 
C25H29N5O5S 510.1817, found 510.1830. 
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Appendix 1 
 
Crystal data and structure refinement for compound 41 
 
Empirical formula  C18H17N3O5S 
Formula weight  387.41 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Fdd2 
Unit cell dimensions a = 65.08(2) Å α= 90°. 
 b = 7.743(2) Å β= 90°. 
 c = 13.990(5) Å γ = 90°. 
Volume 7049(4) Å3 
Z 16 
Density (calculated) 1.460 Mg/m3 
Absorption coefficient 0.220 mm-1 
F(000) 3232 
Crystal size 0.40 x 0.30 x 0.15 mm3 
Theta range for data collection 1.25 to 24.99°. 
Index ranges -68<=h<=76, -8<=k<=8, -13<=l<=16 
Reflections collected 6875 
Independent reflections 2575 [R(int) = 0.0338] 
Completeness to theta = 24.99° 98.3 %  
Absorption correction SADABS 
Max. and min. transmission 1.000 and 0.412 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2575 / 1 / 246 
Goodness-of-fit on F2 0.915 
Final R indices [I>2sigma(I)] R1 = 0.0539, wR2 = 0.1519 
R indices (all data) R1 = 0.0591, wR2 = 0.1604 
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Absolute structure parameter -0.04(14) 
Largest diff. peak and hole 0.439 and -0.844 e.Å-3 
 
Crystal data and structure refinement for compound 44 
 
Empirical formula  C9H15N3O3S 
Formula weight  245.30 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.7622(10) Å α= 67.425(2)°. 
 b = 9.2133(14) Å β= 78.946(3)°. 
 c = 10.1660(16) Å γ = 74.897(2)°. 
Volume 561.64(15) Å3 
Z 2 
Density (calculated) 1.451 Mg/m3 
Absorption coefficient 0.285 mm-1 
F(000) 260 
Crystal size 0.20 x 0.18 x 0.14 mm3 
Theta range for data collection 2.18 to 25.12°. 
Index ranges -7<=h<=8, -10<=k<=11, -8<=l<=12 
Reflections collected 2837 
Independent reflections 1951 [R(int) = 0.0117] 
Completeness to theta = 25.12° 98.0 %  
Absorption correction SADABS 
Max. and min. transmission 1.000 and 0.765 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1951 / 0 / 147 
Goodness-of-fit on F2 0.880 
Final R indices [I>2sigma(I)] R1 = 0.0339, wR2 = 0.0894 
R indices (all data) R1 = 0.0359, wR2 = 0.0914 
Largest diff. peak and hole 0.377 and -0.273 e.Å-3 
Crystal data and structure refinement for compound 46a 
 
Empirical formula  C14H15NO3 
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Formula weight  245.27 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 16.035(3) Å α= 90°. 
 b = 30.243(5) Å β= 93.420(4)°. 
 c = 4.9189(9) Å γ = 90°. 
Volume 2381.2(7) Å3 
Z 8 
Density (calculated) 1.368 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 1040 
Crystal size 0.30 x 0.25 x 0.20 mm3 
Theta range for data collection 1.44 to 25.04°. 
Index ranges -15<=h<=14, -35<=k<=26, -3<=l<=5 
Reflections collected 5543 
Independent reflections 3588 [R(int) = 0.0228] 
Completeness to theta = 25.04° 85.5 %  
Absorption correction SADABS 
Max. and min. transmission 1.000 and 0.642 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3588 / 0 / 345 
Goodness-of-fit on F2 1.123 
Final R indices [I>2sigma(I)] R1 = 0.0613, wR2 = 0.1352 
R indices (all data) R1 = 0.0770, wR2 = 0.1428 
Largest diff. peak and hole 0.470 and -0.421 e.Å-3 
 
 
